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Abstract
In recent years, agent-based modelling (ABM) has been increasingly used to elucidate complex
adaptive systems. An ABM is a structural computational system that consists of a collection
of abstract objects (agents) embedded in a virtual environment that interact based on a set of
prescribed rules. While traditional approaches such as dierential equation-based compartmental
models span a vast literature, they often impose restrictive assumptions such as homogeneity
and determinism that limit their application to real settings. ABM overcomes these limitations
through a bottom-up approach in which macro dynamics emerge from micro level phenomena.
During the past decade, there has been a surge of interest in the use of ABM in human health and
disease dynamics. While this is rapidly growing, its application to other relevant areas such as
health economics is still in infancy, and frameworks that could systematically apply ABM are still
lacking. In this thesis, we develop a general framework for cost-eectiveness analysis in which
ABM is designed to project the system dynamics. We argue that ABM improves the empirical
reliability of policy-oriented simulation models and that it presents an ideal tool to address the
complexity of disease processes, project the impact of interventions and inform their optimal
implementation. We use this framework in an epidemiological context to quantify the economic
impact of vaccination strategies for prevention of infectious diseases.
We present two case studies for a human-to-human infection transmission (i.e., Haemophilus
inuenzae) and a vector-borne disease (i.e., Zika). In each case, we detail the construction of ABM
and its utilization to conduct Bayesian cost-eectiveness analysis of potential vaccine candidates.
In addition to uncovering important characteristics of these diseases in epidemic dynamics, we
present their rst cost-eectiveness analysis and implications for vaccination strategies in dierent
populations settings.
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Glossary
in silico Modelling Modelling of biological processes performed via computer simulations.
Agent-Based Modelling A type of computational model for simulating the actions and interac-
tions of autonomous agents.
Asymptomatic (or Carriage) A disease manifestation when the infected host does not show
any clinical symptoms, but is infectious and can transmit the disease to others.
Attack Rate The proportion of population infected over the course of an epidemic.
Basic reproduction number Commonly denoted by R0, it is dened as the average number
of secondary cases which a single infectious case produces in a completely susceptible
population.
Bootstrap A technique used for statistical inference by repeatedly sampling a dataset with
replacement.
Eective Reproductive Number Denoted byRe, it estimates the average number of secondary
cases caused by a single infectious case in a population when control measures are applied.
Generation Interval Refers to the time duration between the infection of an infected person
and the infection of his or her infector.
Herd Immunity The proportion of the population that is immune against the disease.
Latent Period Dened as the time duration between disease transmission and the onset of
infectiousness (i.e., when the infected host becomes infectious and can trasmit the disease).
This term is sometimes interchanged with exposed..
Survival Rate The percentage of people in a study or treatment group who are still alive for a
given period of time after diagnosis or treatment for a disease.
Symptomatic A disease manifestation when the infected host shows clinical symptoms.
xii
Chapter 1
Introduction
Innovations such as the exponential increase in computing power, and the evolution of information
and database technologies during the preceding two decades have opened up novel vistas for the
collection of complex, voluminous, and heterogeneous data that can be synthesized to address a
variety of real-life challenges, such as population health. Methodologically, since mathematical
and statistical models that are capable of encapsulating such data are often theoretically intractable,
computational models have become an integral part of scientic research, and have led to dramatic
changes in approaches to addressing societal issues. Such models have already had signicant
impacts on public policy at the global scale, and in particular for the development of intervention
strategies to combat emerging disease outbreaks. However, the systematic application of compu-
tational models in understanding the underlying processes of system dynamics (e.g., network of
human interactions and disease transmission mechanisms) is relatively new; the integration of
these systems into the public policy and decision-making processes is even more novel. In this
thesis, we aim to enhance this integration and develop a general framework for evidence-based
health economic analysis, by employing a computational modelling approach that has evolved
to deal with data that are more heterogeneous, less coarse (based at a community or individual
level), and more complex (joint spatial, temporal and behavioural interactions). This evolution is
typied by the “Agent-Based Modelling" (ABM) paradigm, in which the collection of autonomous
decision-making entities (i.e., agents) and their interactions unveil the dynamics and emergent
properties of the entire system. In the context of population health and infectious disease dynamics,
the exibility of ABM permits an eective representation of individual interaction with their own
characteristics, which may impact their future decisions and outcomes. The framework developed
here provides a methodology to perform cost-eectiveness analysis of public health interventions
more systematically, while accounting for critical properties that are often overlooked in existing
methods, yet essential for outcomes prediction and translating knowledge and evidence to action.
Traditionally, aggregate or cohort models such as continuous dynamical systems, decision trees,
and Markov models have been used to provide the integration of disease transmission dynam-
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ics and cost-eectiveness analysis. While such models are easy to implement and have been
generally successful, their use is often limited due to a number of limitations such as linearity
and homogeneity. To overcome these limitations, we apply ABM computational systems that
can capture the system heterogeneity from micro to macro levels, while utilizing the available
data and information that drive the model outcomes. In principle, ABM can theoretically encap-
sulate an arbitrary level of heterogeneities that can be observed experimentally, provided we
understand the underlying mechanisms of the individual components of phenomena. However, in
practice this exibility comes with a complexity and thus demands stringent simulation design
requirements than conventional models, especially with respect to outcome reproducibility. We
address these requirements in developing our framework to ensure its sound application to cost-
eectiveness analysis that remains an important component of decision-making process in public
health planning and program delivery.
In this framework, we show that ABM presents an ideal tool to address the complexity of disease
processes, project the impact of interventions, and inform their optimal implementation. We use
this framework in an epidemiological context to quantify the economic impact for vaccination
strategies for prevention of infectious diseases. We begin by providing a succinct and rigorous
description of an ABM computational system in Chapter 2, including construction details and a
formal mathematical structure. This is followed by an overview of cost-eectiveness analysis in
Chapter 3, where we also highlight the potential aws of current methodologies. We then apply
the framework to present two case studies for a human-to-human infection transmission model
and a vector-borne disease model in which ABM is used to generate system dynamics, considering
potential vaccine candidates. In Chapter 4, we study the dynamics of severe community-acquired
acute infections caused by Haemophilus inuenzae serotype ‘a’ (Hia), with alarming incidence
rates in North America, particularly among Indigenous populations. The severity and outcomes
of Hia infections are reminiscent to those of invasive Hib disease in the pre-vaccine era, including
pneumonia, septicaemia, and meningitis. The remarkable success of Hib conjugate vaccine
suggests that the development of an Hia vaccine could be a viable prevention measure to reduce the
incidence of invasive Hia disease as well as prevent the spread of disease in the general population.
Recent research eorts have established the pre-clinical proof of concept for a glycoconjugate
vaccine against Hia. However, quantications of the long-term epidemiologic and economic
impacts of vaccination are needed to inform decision on investment in Hia vaccine development
and immunization programs.
In Chapter 5 and Chapter 6, we utilize a multi-agent ABM to uncover important characteristics
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of Zika virus epidemics and transmission dynamics. Given the public health concern about
its potential to cause severe outcomes and long-term sequelae, including microcephaly with
brain abnormalities and neurological disorders in infants, and Guillain–Barré syndrome (GBS) in
adults, the development of a preventive measure is the key to combat this vector-borne disease.
Currently, a number of Zika vaccine platforms are being investigated, some of which have entered
clinical trials. Understanding the impact of this vaccine and its cost-eectiveness, especially in the
presence of Zika asymptomatic infection, can help inform vaccination strategies and prioritization
in countries where the primary vector carrier, Aedes aegypti, is endemic.
The outcomes of ABM in both case studies are integrated with a Bayesian cost-eectiveness
analysis to investigate the benets of vaccination and their economic impact. We close this
thesis in Chapter 7 with a discussion on the implication of our results. We believe that this
research will have a signicant impact on the relevant healthcare systems (including Canadian) by
generating scientic, evidence-based results that inform the optimal use of health resources and
improve population health, and therefore contribute to reducing health and economic burdens of
preventable diseases. Although our ABM framework is useful for the exploration of uncertainties,
heterogeneities, and their impact on public health decisions, we omit a number of important
factors in vaccine cost-eectiveness analysis, including research and development costs of vaccine,
potential adverse eects of vaccine that may incur additional costs for patient management,
and emerging technologies for vaccine development. These factors may alter parameters and
assumptions underlying health economics of vaccination, and should be evaluated before policy
implementation. We are committed to continuously rene our models to consider these factors.
3
Chapter 2
Agent Based Modelling
2.1 Introduction to Agent-Based Modelling
The seminal works of the American economist Thomas Schelling (1971) [1] showed that compu-
tational and simulation approaches can be applied to understanding the universal principles of
any complex adaptive systems1 provided the system can be reconstructed in silico environment
by programming the constituent components of the complex system. In Schelling’s approach2,
he directly manipulated abstract computer entities representing actors and updated them itera-
tively. This led to a whole new eld of research on socio-economic systems in which the natural
unit of decomposition is the individual rather than the observable or equations, often termed
individual-based modelling. Together with the rapid development of computational theory and
the collection of vast amounts of data, this eld has led to the evolution of Agent-Based Modelling
(ABM) computational systems.
Today, methodologies studying complex adaptive systems in a qualitative sense have shifted
to systematically investigate them by ABM through a disaggregation of the systems into their
individual components that have their own characteristics and behaviours and by capturing the
interdependencies between the individual components3 [13, 14, 15]. An ABM computational
system is a structural, dynamical system that consists of a collection of abstract objects (i.e.,
1While there is no single denition of a complex adaptive system, it is generally accepted that a complex adaptive
system is one that has many individual parts working together in order to generate the macro dynamics of the system.
Complex adaptive systems are common in both nature and society. For example, the immune system is a highly
advanced biological system comprised of a complex network of individual cells and chemicals working together to
produce non-linear eect, feedback loops, and other micro and macro-dynamics.
2In Schelling’s demonstration that residential segregation can occur at a systemic level, the economist implicitly
introduce the idea of a local neighbourhood which is a central element in the construction of agent-based models,
seen later in this chapter.
3ABM computational systems have been applied to a range of disciplines including economics [2, 3, 4], ecology
[5], healthcare [6], sociology [7], geography [8], nance [9], and even niche disciplines such as military strategies [10,
11, 12].
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agents) embedded in an in-silico (i.e., computer) environment and interact together through a set of
prescribed rules. This type of model is often implemented computationally by using deterministic
input-output functions, typically coded in a structured or object-oriented programming language.
The agents in ABM represents the individual components of the complex system under study.
Each agent individually perceives its situation, makes decisions, and performs actions according
to specic rules. These rules can be simple or complex, deterministic or stochastic, and xed
or adaptive. Thus an ABM encodes in a computer program a set of rules that describe the
behaviour of agents as the system evolves in time. While often the formal set of rules are simple,
large scale agent-based models can incorporate neural networks, genetic algorithms, and other
machine learning techniques for realistic agent behaviour and adaptation [16]. Since each agent is
modelled individually, there is no central controlling agency nor explicit language that describes
the global dynamics of the system. As a consequence, ABM allows for an investigation into the
universal properties of a complex system, including: heterogeneity since agents can be modelled
individually, adaptation since the model is dynamic, space and scale since an arbitrary number of
agents can be embedded in this virtual environment, and non-linearity since the model can track
individual agents separately. This methodology has three main advantages: (i) it allows to capture
global complex patterns and dynamics as a result of interactions between local, heterogeneous
individual agents; (ii) it allows the construction of models in the absence of knowledge about global
interdependencies of the complex system; and (iii) it provides the exibility required to study the
system’s complexity in comparison to traditional equation-based aggregate-level mathematical
modelling. These three points are discussed below.
Emergent global dynamics in ABM
Traditional models of complex systems are typically formulated in the general language of math-
ematics. Examples include dynamical systems such as the Lotka-Volterra equations, describing
predator-prey interactions [17] and the Susceptible-Exposed-Infected-Recovered models of epidemic
propagation [18]. While the utility of such models have been exemplied in a vast literature, a
signicant limitation of these models is the treatment of all or groups of individual components
as largely homogeneous entities, i.e., a representative entities. For example, in dierential equation
models of disease transmission, all individuals in a population are equipped with the same charac-
teristics and parameters. On the other hand, an ABM enables the generation of complex patterns
and dynamics “in a bottom-up approach" in which a single unied homogeneous model is replaced
with a population of individual models, each of which is an autonomous decision-maker (i.e., the
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agent). This population heterogeneity includes not just the variation in individual agents, but also
the interactions and network topology. Running such a model simply amounts to instantiating an
agent population with initial conditions and iteratively letting the agents interact by executing
the rules that dene them. Of course, if the model is stochastic, then multiple realizations are
necessary in order to capture the randomness. That is all that is necessary in order to solve
an agent-based model. As a result, although the global (or macro-level) dynamics of a process
are not explicitly programmed in the model, enigmatic global dynamics including xed points,
cycles, dynamic patterns, and long transients emerge from the local interactions among agents.
These emergent dynamics can have properties that are decoupled from those of the individual
components. The emphasis on modelling the heterogeneity of agents and the emergence of global
behaviour from local interactions is an important distinguishing feature of ABM.
Absence of global interdependencies
The essential characterization of any complex system is that they are invariably qualitative
in nature. That is, in many cases we do not know the full mathematical description of the
complex system under study, but only the behaviour of the constituent components of the system.
Agent-based models are particularly suited to complex systems in which the dynamics of its
constituent components are more understood than the overall dynamics of the system. They
are ideal for modelling systems in which individual component behaviour is non-linear and
heterogeneous, which dierential equations are unequipped to handle4, and where individual
behaviour includes learning and adaptation, including temporal and spatial correlations, and
non-Markovian behaviour. In this sense, contrary to what the term agent suggests, the concept
of an agent enables us to represent any physical object that can be programmed, provided we
have a clear understanding of the object. Agents can represent particles, cells, individuals, groups,
organizations, or spatial entities such as buildings and roads. Consequently ABM can, in principle,
incorporate any complex behaviour that can be observed experimentally, provided we have a
qualitative understanding of the underlying mechanisms and components. Of course, in practice
agent-based models are limited by nite computational resources, time investment, and incomplete
knowledge and therefore will inevitably require a balance between the desired complexity of a
system and available resources.
4It is true that dierential equations can be used to model arbitrary levels of heterogeneity, but the complexity of
the equations and their subsequent analysis increases exponentially as the complexity of the individual behaviour
increases. At some point dierential equation models becomes intractable.
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Flexibility of ABM in comparison to equation-based models
A common objection to agent-based models is that they are not (theoretically) as rigorous as
mathematical and analytical models. That is, they do not oer a set of equations together with
an algebraic solution that can be easily interpreted and analysed. Analytical or equation-based
models, for example dierential-equation based dynamical systems, provide a formal framework
for the organization and analysis of knowledge and theoretical results. Such models are equipped
with an established set of rigorous tools for analysis, for example bifurcation, sensitivity, and
stability analyses. This allows an analytical model to be easily communicated because they are
fully described and unambiguous by mathematical equations and formulas. On the other hand,
ABM often will not make use of any explicit mathematical equations but exploits computational
simulations, implemented in a programming language, to elucidate the complex system under-
pinning the model. However, the idea that the lack of formal mathematical tools prevents any
sort of formal analysis of agent-based models is misguided. Indeed computational ABM, by virtue
of being computer programs, can and do utilize a well-dened set of functions which relate
inputs to outputs, in either a deterministic or stochastic fashion, and unambiguously dene the
global dynamics and any eventual equilibria of the system [19, 20, 21, 22, 23]. For example, in
Laubenbacher et al. [22], the proposed mathematical representation of an agent-based model is a
time-discrete dynamical system over a nite state set. In this framework, the state of the model is
fully specied by a vector taking values over a nite eld K. A transition function transforms
a given state into another state based on rules of the complex system underpinning the model.
The model dynamics are generated by repeated iteration of this function. Another approach is
taken by Veliz-Cuba, Jarrah, and Laubenbacher [23] where they derive a polynomial dynamical
system where the input-output functions are dened by polynomials, which makes it amenable to
powerful symbolic computational capabilities. That is, the computation of equilibria and analysis
of the model reduces to symbolically solving a system of polynomial equations. Agent-based
models are also, from a formal point of view, Markov chains [24, 25, 26, 27, 28], Banisch, Lima,
and Araújo [25] and Gintis [27] and provide a rigorous mathematical basis of ABM by linking the
micro-description of the system to the complex global behaviours in the form of a Markov chain.
They establish how the corresponding global dynamics of an agent-based model are obtained by a
projection construction and the model’s long-term properties are given by the ergodic theorem
for Markov processes. Analysing an agent-based model as a Markov chain can make apparent
transient dynamics, asymptotic behaviour, and stochasticity that were otherwise not evident.
More generally, ABMs can be naturally classied as hidden or latent variable models that relates a
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set of observable variables to a set of latent variables [28]. In addition to formal mathematical
frameworks, Grimm et al. [29] establishes a protocol for an ABM specication. They develop the
so called ODD (Overview, Design concepts, Details) protocol which describes a standard template
for the model analysis, reproducibility, and transition functions [29].
Another common objection to ABM is that a single realization of the model is just a special case,
and that no formal statements on the results of the model can be stated. This is partially addressed
by the works of Newell and Simon who established the computer programs as suciency theorems
approach. When an ABM, call it A, produces result R, it establishes a suciency theorem which
is the formal statement R if A [19, 30]. In other words, each run of an ABM is a logical theorem
that reads: the output of an agent-based model follows with logical necessity from applying to the
input the formal rule-set that denes the model. Nevertheless, despite the fact that each run of
such a model yields a suciency theorem, a single run does not establish the robustness of such
theorems. That is, when A yields the result R, how much change in A is necessary in order for R
to no longer be derived. This problem is, however, easily treated by multiple realizations of the
agent-based model, often by Monte Carlo techniques with each realization systematically varying
initial conditions, parameters, and random number streams.
Despite these objections, there are several advantages of ABM approach over conventional
equation-based mathematical models. Axtell [30] describes three distinct uses of ABM: (1) nu-
merical computation of analytical models, (2) validation and robustness of analytical models,
and (3) a substitute for analytical models that are intractable. Often complex equation-based
models cannot be fully solved in order to gain insight into the system. When the solutions are not
available symbolically, a set of solutions can be obtained numerically by solving the equations.
ABMs can then provide a suitable validation of the numerical solutions. If the equation-based
model is stochastic, the primary method of obtaining numerical solutions consists of Monte Carlo
simulations. When the symbolic solution is explicitly specied, it would seem that there is no
specic role for agent-based modelling. However, since the output of ABM tend to be more visual
and pattern-oriented, such models can still be very eective in elucidating complex systems to
individuals that have no formal mathematical knowledge.
2.2 Structure and Components
A typical agent-based model has three fundamental components:
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1. A set of agents which represent the components of the system that is being modelled. Since
every ABM is a computer program, agents are often implemented as virtual computational
objects5. The concept of an agent as being a computational object makes it clear that this
basic unit is abstract. The agent is made concrete by translating sucient properties of the
real-world component into a suitable formalization in the programming language.
2. An in silico environment that allows agents to change their spatial and relational associations.
In most complex systems, the concept of physical space or spatial network is signicant to
the global dynamics. This concept is dicult to model in traditional analytic models, except
in highly stylized ways. However, in ABM it is rather easy to have the agent interactions
mediated by a virtual space.
3. A set of rules which dene the level of connectedness and modes of interaction between
agents. Each agent can be assigned a unique set of rules or a single one that can be applied
to all (or a group of) agents.
To integrate these three components, an ABM requires a computational framework or a simulator
engine (see §2.3). This simulator framework is responsible for driving the ABM by repeatedly (i.e.,
by iteration) executing the rules that dene the agents’ behaviours and interactions. This iterative
process often operates over a time-step or discrete event simulation structures. In the course
of these iterations, the simulator framework also calculates the aggregate results of the model
which can be re-injected back into the evolving behaviour of the agents. Thus, the construction
and simulation of an ABM as a whole is through a bottom-up approach from these constituent
components that work together to generate the global dynamics. The structure of a typical
agent-based model is shown in Figure 2.1. A mathematical description of ABM as a fully recursive
system is presented in §2.4, expanding on the formalism described in [21].
Agent Structure and Properties
Since an ABM is an abstraction of a real-world phenomenon, an agent ideally represents a
component of the complex system that is being modelled. When using this approach, we need to
systematically recognize which components of the system can be translated into agents. Next, we
need to decide on the level of abstraction and the details that are to be included for each agent.
5In computer science, an object is a data structure consisting of variables, functions, or methods, and is a value in
memory which is referenced by an identier. There is a large degree of similarity between a computational agent and
the concept of an object (or structure) in a programming language. In fact, an ABM can be seen as a set of object
classes that share the same properties and the same rules i.e., functions.
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Rules Agents Environment
Figure 2.1: The general structure of an ABM computational system. Figure shows agents equipped with a
set of properties, connected through a lattice environment system. Figure shows the interaction between a
susceptible and infected individual as a result of movement across the lattice
An acceptable compromise between realism and simplicity is required. If the level of abstraction
is too low, the model may fail to faithfully capture the system dynamics. On the other hand, it is
neither feasible nor always desirable to model all the complexity and agents’ heterogeneity. A
one-to-one mapping of the real-world component to an agent is likely unnecessary, impossible,
and/or computationally overwhelming. We will need to have valid hypothesis on the underlying
processes or fundamental mechanisms that needs to be explained. Ideally, the level of abstraction is
justied by utilizing empirical data as well as expert opinions. Doran [31] suggests two principles
that should be followed for implementing a set of rules: (i) agents should be as abstract as possible
subject to the requirement that any rule attributed to them must either be reliably set from
empirical observation or be subject to experimental observation, and (ii) assumptions based on
pre-conceptions are avoided. Several other authors [15, 19, 29, 32, 33, 34, 35] have also identied
similar key characteristics:
• Self-contained and autonomous. Autonomy implies that there is no central authority
that controls the agents’ behaviour. On the contrary, an agent can be thought of a model in
itself, capable of processing information and making decisions. They are free to interact
with other agents and move in the virtual environment they reside in.
• Heterogeneity. Each agent represents a unique component of the complex system. For
example, an agent representing a human in some population model can have age, sex, and
location as dynamic attributes.
• Active. Agents can be: goal-oriented [34] where agents try to achieve a goal but not
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necessarily maximize utility, perception-decision-action where they interact with each other
and their environment and only perform actions when triggered to do so by some external
stimulus [34, 36], or bounded rational [37] in which agents are generally assumed to be
rational optimisers with complete access to information and bounded analytical ability
(through heterogeneity).
• Internal state. Agents have an internal state (i.e., data represented by variables) and can
communicate this state to the model by message-passing or signal protocols.
The next step is to implement a formal set of functions (the rule-set) which dene the perception-
decision-action cycle (PDA) for every agent [34, 36]. An agent-based model systematically and
iteratively gives each agent the change to perform a PDA cycle. Formally speaking, let Λ denote
an ABM and let xa represent the represent the internal state of some agent a. xa is essentially a
list of quantitative variables and internal parameters associated with the agent’s current situation,
i.e. a vector taking values over some nite eld K (often K = Rn) that describes the state of the
agent at a given time. Let X = {xa}a∈Λ denote the collection of all internal states, so that x ∈ X
denotes the global state of the model. Then the PDA cycle of an agent a is a set of functions6:
• Dene Perception()a : X −→ P which computes a percept p ∈ P using the global state
of the model x. Intuitively, the function processes the global state of the model including
the environment, and returns data such as the coordinates of nearby agents or objects or
possible locations for a roaming agent. Thus, elements of P are often an multi-dimensional
vectors (or tuples) consisting of quantitative and categorical information.
• Dene Decision()a : P → D which is a core function executing the rules that denes
the agent’s behaviour given their perception. Decision functions are can be arbitrarily
complex, encapsulating the bulk of the model’s logic, ranging from simplistic fuzzy rules to
complex behaviours modelled by neural networks, logic systems, articial intelligence, or a
hybrid/multi-layer system and are often imputed by using empirical data and expert opinion.
Elements of D be in the form of discrete messages7 or signals being passed between agents.
In response to a message an agent may change their internal state, modify the environment,
or respond back with another message, but should not be able to modify the internal state
of other agents.
6Notation and names of the functions were adapted from Drogoul, Michel, and Ferber [36].
7The technical details of implementing message-passing in computational abstract objects is a technical study of
computer-science. It is beyond the scope of this thesis and details are omitted.
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Figure 2.2: A visual representation of a Perception-Action-Decision cycle which formally implements the
rule-set which drives an agent’s behaviors and interactions.
• Finally, the action function Action()a : D ×X → X computes the new internal state
x of the agent by acting on a decision d ∈ D, updates the global state of the model, and
advances the virtual time by the relevant unit.
The Virtual Environment
The second fundamental component of an agent-based model is the in-silico environment, which
models the physical space of the real-world system. The environment denes the spatial associa-
tions of an agent and the conditions for the PDA cycle to carry out, i.e. the state of the environment
is part of the input to the Perception function of every agent. The environment may also
include passive objects such as roads and buildings or resources such as wealth and healthcare.
As agents move in the environment, their location can be tracked by a dynamic variable. Agents
may also be spatially implicit, that is their location within the environment is irrelevant.
Modelling the environment is often via a discrete topology of discretized, connected, and
bounded space units. The topology of the environment denes possible interactions and re-
lationships between agents. There are two main types of a spatial environments:
1. The most common type is a discretized environment consisting of a nite grid of cells in
one or more dimensions with integer coordinates, which provides a simple representation
of physical space, e.g. GIS based environments. This type of environment provides an easy
mechanism for agents to interact with others who share similar coordinates or reside in
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neighbouring cells. The simplest form of spatial environments are described by cellular
automata models where the environment consists of a square lattice, divided uniformly
into ‘cells’. However, in cellular automata, the cells are interpreted as agents and there is
no distinction between the agents and the cells that create the lattice environment. ABMs
extend this topology by decoupling the agents from their cells. Agents can then move
from one cell to another and interact with dierent parts of the grid, resulting in a set of
neighbours that constantly change as the simulation proceeds.
2. The second type is a ‘relational environment’ in which a link between two agents denes
a network topology. Relational environments are often dened by graph- or node-based
constructions and there is no distinction between agents and the nodes of the network.
Both directed and undirected graphs can be supported and can be static or dynamic [15]. In
static networks, links are xed and do not change. In dynamic networks, links and nodes
are determined endogenously according to the mechanisms programmed in the model.
Figure 2.3 shows examples of dierent environment topologies. Agents typically interact with a
subset of all other agents, denoted as the agent’s neighbourhood. In complex and large-scale agent-
based models, spatial and relational environments can be intertwined to oer a more granular
approach. The environment may further have its own set of properties relevant to the real-world
complex systems; for example, in modelling disease-transmission at the age-group level, it might
be relevant to identify sections of the environment as school, residential and business. It may
respond to messages from agents (deterministic environment), or changes with time (dynamic
environment), and can even generate or delete agents.
Figure 2.3: Dierent environment topologies for agent interactions and movement. From left to right:
Cellular Automata (von Neumann neighbourhood), network relational topology, Geographic Information
System (GIS), and free-roaming with neighbourhoods.
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Rules of Interactions Between Agents
Recall that the Decision and Action functions of every agent implement the rules that
will aect their internal state and interactions with other agents in a dynamically changing
environment. The rules are typically derived from published literature, expert opinion, or empirical
data. For example, in modelling inuenza dynamics via an ABM, the intrinsic incubation period
of the disease is between three to ve days, derived from observational data. At the point of
infection, the latency period for each agent (if transmission occurred) is sampled from the relevant
distribution. In general, rules are based upon simple if-else statements with agents carrying out an
action once the specied condition has been met. More recently, there has been work incorporating
machine-learning techniques and articial intelligence within ABMs to better represent human
behaviour. Due to these adaptive rules, ABMs are non-linear with multiple feedback-loop dynamics
and can therefore have vastly dierent behaviours for each run.
2.3 Model Implementation
Every ABM implements a simulator engine that species the operating procedures of the agents,
drives the PDA cycle, and describes the model evolution in time from an initial condition. The
simulator is often implemented in a programming language and sound principles of computer
science should be applied whenever possible. For example, writing independent modules (which
represent distinct components of the complex system) makes maintenance, debugging, and code
re-use easier when considering future changes to the model. Good programming principles also
leads to reproducibility of the model across various platforms and operating systems.
2.3.1 Monte Carlo Simulations
ABMs are stochastic in nature and account for randomness found in real-life phenomena. This
stochasticity is known as rst-order uncertainty and relates to the natural randomness in agent
behaviours, interactions, and the progression of the model. First-order uncertainty is often
addressed by the use of a random number generator through a deterministic program code;
however, in digital computers random numbers are not really random. They are generated by
an algorithm that produces a sequence of numbers that is seemingly random. These numbers
are referred to as pseudo-random and the algorithm is called a pseudo-random number generator
(PRNG). Each sequence produced by any PRNG is uniquely identied by its seed s, a number
which provides the initial value to the generator. The seed is usually supplied by an environmental
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variable such as the computer clock, which can virtually guarantee that it is dierent for every
simulation run. In other words, PRNGs produce numbers based on a deterministic formula which
is seeded with some initial number. This allows for computer, and particularly agent-based models
to simulate stochastic variables but also oer reproducible results. Several probability distributions
have been established in computer-science literature8, although most random number generators
produce uniform randomness. First-order uncertainty can be reduced by running the model
several times, commonly known as Monte Carlo simulations. The sucient number of Monte
Carlo simulations depends on the parameters, time horizon, and the structure of the model, and
common ABMs can employ several hundred to several thousand independent runs.
The behavior of any ABM is further sensitive to the model parameters and on the initial conditions,
often called second-order uncertainty. That is, while rst-order uncertainty relates to stochasticity
in model structure, second-order uncertainty corresponds to estimation of parameters since
true values and distributions are often unknown. In order to address second-order uncertainty,
underlying distributions of parameters should be utilized whenever available. Typically, however,
second-order uncertainty is evaluated by formal sensitivity analysis methods such as Probabilistic
Sensitivity Analysis using Latin Hypercube Sampling techniques.
2.3.2 Temporal Evolution
In most ABMs, modelling the temporal evolution of the environment is crucial. The model
components (e.g. environment) may not only react to the agent inputs but also evolve according to
endogenous factors including time. Time evolution can be modelled using three main approaches:
(1) continuous time in which the model can compute the system state for any time input, (2) discrete
time in which time evolves in discrete, but xed intervals, and (3) discrete event in which time
instantaneously jumps from one event to the next. Within each time step, specic events occur
(e.g., movement of agents across the environment or transmission and progression of disease) or
agents update their internal state based on interactions and endogenous factors. The decision to
use continuous time or discrete time depends on the application domain. Applications of ABM in
this thesis are based on the discrete time approach.
Discrete Time In discrete-time mode, the simulator advances the virtual clock by a given
interval ∆t. The time interval ∆t will typically have a natural real-world unit associated with it,
8In virtually all agent-based models, the Mersenne Twister is an example of a pseudo-random number generator
that produces a uniformly distributed random number stream, at least until the number of random draws approaches
the algorithm’s period of 219937 − 1.
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Figure 2.4: In an ABM simulation agents are updated sequentially at any time. The order in which each
agent is updated may change the results obtained for the system state since the environment evolves for
each action.
such as seconds, hours, days, or years depending on the complex system underpinning the model.
At each ∆t, the simulator engine picks agents sequentially (in some given order) and executes
their PDA cycle iteratively. However, there is a signicant limitation of this technique. The order
in which the agents are selected (and their PDAs executed) may change the result obtained for
the system, since the system state evolves with each action. It is entirely possible that a dierent
ordering may result in very dierent global dynamics. Figure 2.4 illustrates this issue with three
agents. Possible solutions to this limitation include selecting shuing the order of agents at every
time interval or have all agents simulate concurrently by operating on temporary variables, so that
the perceived state is the same for all agents. For example, in an agent-based model that tracks
the HIV patterns over long-time periods, the natural time unit is a year. A model for seasonal
inuenza epidemics, the natural time unit has a day resolution.
Discrete Event A discrete-event simulation considers time as discrete increments with variable
magnitudes corresponding to events occurring in the model [38]. Every jump in time marks a
change of state in the system. Between consecutive events, the system is idle and no change in the
system is assumed to occur. A discrete-event model is programmed to maintain a list of events
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(a ‘queue’) corresponding to the events that will occur. The program iterates over the queue,
executing the event at the head of the queue. Once the event executed, it is removed from the
queue, and the next event is scheduled appropriately (and sometimes dynamically). In comparison
to the discrete-time approach, this is a more exible paradigm. For instance, because discrete-
event simulations do not have to simulate every time-step, they are typically run faster than the
corresponding discrete-time simulations9. Moreover, a discrete-event can be made equivalent to a
discrete-time approach via a linearly spaced sequence of events.
2.3.3 Validation and Calibration
Model validation concerns with identifying the degree of consistency between the agent-based
model and the underlying system it represents. It comprises of two stages: (i) Input validation
that refers to the realism of the assumptions used to build the model, and (ii) output validation
which measures the plausibility of the model outcomes relative to the observations of a real-world
phenomenon. Output-validation relies on a process called calibration, which systematically renes
the model parameters so that the output data closely resemble those observed in the phenomenon.
A proposed formal framework by Marks [39] characterises a model as useful if it can exhibit at
least some real-world observations; as accurate if the simulated data matches historically observed
real-world data; and as complete if the simulated data matches all of the observed patterns of the
real-world phenomenon. Based on this framework the goal of validation and calibration is to
construct a model that is accurate, but also complete if possible.
Input Validation Input validation concerns the structural assumptions of the model relative to
the theory it is based on. Structural assumptions include choices of the rules and behaviours that
dene an agent’s PDA cycle, the environment, and pattern of interactions. For instance, agents
can be utility maximizing or employ bounded rationality. A more complete and accurate set of
assumptions correspond to a higher number of parameters and variables in the model. Parameter-
rich models are often dicult to calibrate, may suer from over-tting, end up in dimension hell
and might even become computationally infeasible. In order to cope with the impossibility of
a complete and accurate model, it is often the case that input validation is evaluated against
some stylized facts, i.e., focusing on a limited number of variables which are most relevant to
the complex system. For example, the basic reproduction number (commonly denoted byR0) in
9If the time to some next event is very small, simulations can take a long time to run. In these cases discrete-time
should be used.
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epidemiology is a stylized fact summarizing succinctly the impact of a communicable disease. In
this sense, one does not need to know the individual trajectories of disease transmission but can
develop a functioning model based onR0 only.
Input-validation also often requires program validation which refers to the validation of the
simulator engine. That is, the validation of the computer codes which implement the various
components of the agent-based model. Computer codes do not automatically generate errors
when a bug is encountered or if something is incorrectly implemented. On the contrary, many
programs will continue to produce results, independently of how bad the code is. Careful attention
is therefore needed to capture bugs and other artefacts and is recommended that one follows
principles from computer-science, including modularity and unit-testing [34]. These tests can
be performed for each functional component of the system during the model development cycle,
in which simple scenarios are created to verifying that all modules of the model are working in
concert when executed together.
Output Validation This process systematically determines a set of model parameters and input
values which maximize the tness of the model with the observed data, i.e., nding parameter
values, assumptions and structural components that make the model t the data well. A well
calibrated and validated model can be used to make predictions, and can provide inference on
microscopic states, which may not be inferred from standard time series or statistical methods. On
the other hand, a model where the parameters have not been properly calibrated is not particularly
useful for inference and may even fail to describe the dynamics of the real-world complex system.
Calibration of agent-based models can be inherently dicult due to large parameter spaces, long
simulation run-times, stochasticity of the structural model, and sometimes lack of empirical data.
At present, ABMs are limited to some ad-hoc, qualitative calibration of the relevant parameters.
That is, comparing instances of a model with dierent values of parameters and choosing the ones
that best t the data. It is worth noting that calibration and validation does not necessarily imply
that the model reaches to a single optimal choice for the parameters. Indeed, often condence
intervals are generated in which the true value of the parameters lie. In a Bayesian approach to
calibration, parameters are equipped with a prior probability distribution reecting the uncertainty
about the parameter values based on prior knowledge. In either case, this eectively means using
observed empirical data to inform parameters such that the model predicts the past and present
observations well. It is clear, however, that this ad-hoc approach is limited by the quality of the
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empirical data available10. The high degrees of freedom in an ABM further exacerbates the issue of
data quality. When restrained by lack or limited amount of data, Fagiolo, Windrum, and Moneta
[40] suggests the use of stylized facts, i.e., dening a restricted set of criteria on which the model
is evaluated, to circumvent the problems of data availability and quality. With these stylized
facts, the ad-hoc approach continues by calculating statistics of the simulated data. These are
then compared through a suitable summary measure of the model quality, conditional on the
parameters values. A common choice for such a measure is the squared dierence distance metric
d(datasimulated, dataobserved) = (datasimulated−dataobserved)2, which increasingly penalizes parameters
that make simulated data more distant from observed data. The summary measure, in general, is
chosen with respect to the context of the model and can be, for example, specic data points, cross-
sectional averages, regression analysis, and averages over realizations. If the simulated dynamics
bear resemblance to the real-world observations, then the model is a possible explanation of the
underlying complex system. This naïve way of calibration and validation is often computationally
demanding. Indeed, for any given point in the parameter space, a large number of Monte Carlo
simulations must be run to generate a distribution for the statistics of interest. Even though we
have described a systematic algorithm, calibration is still based on observed qualitative similarities
between model outputs and real-world data. Nevertheless, the preceding two decades have seen
an increasingly number of studies attempting calibration and estimation of agent-based models
by way of optimization techniques and statistical methods [41, 42, 43]. These methods include
simulated minimum distance, Bayesian estimation, Markov Chain Monte Carlo (MCMC), Sequential
Monte Carlo (SMC), and particle lters which are all closely related to each other. However, in
validating the structural components of the model, a well-established method of degeneracy tests
can always be performed to evaluate the outcomes using extreme value analysis by selectively
disabling portions of the model or selecting plausible values for input parameters from estimated
ranges [44].
It is imperative that qualitatively derived parameters are subject to sensitivity analysis. This
is because a high goodness of t does not necessarily imply a highly predictive or explanatory
power [35, Chapter 5]. In this setting, sensitivity analysis amounts to running the Monte Carlo
simulations with modied parameters and initial conditions, at least within the range of some
condence interval, to determine the robustness of the simulation results. Often this analysis is
implemented in three stages: (i) individual parameter sensitivity: examines model sensitivity to
each parameter individually by executing simulations while varying each parameter systematically
10It is important to note that the rise of internet-of-things, cheap sensors and individual-level data collection tools
have recently led to a much greater availability of data, almost instantly from a variety of sources and platforms.
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across its full range and measuring the outcomes; (ii) parameter interactions sensitivity: identies
sensitivity of model outcomes to a number of important parameter pairs with respect to the
frequency and strength of their interactions; and (iii) robustness of results: evaluates the eect of
parameter uncertainty and sensitivity on the entire parameter space.
2.4 A Mathematical Formalism of Agent-Based Models
2.4.1 Partial Recursive Functions
Since an ABM is a collection of independent models (§2.1), all of which are computer programs (i.e.
computable by a Turing machine), there exists a corresponding unique partial recursive function11
[19, 21]. Therefore, in principle, one can provide a representation an ABM as an explicit set of
mathematical formulas (i.e. recursive functions). A system of equations is recursive (rather than
simultaneous) if the output depends on one or more of its past outputs; or in other words, the
values for all state variables can be determined sequentially rather than simultaneously. If, in
addition, the probability distribution of the next state only depends on the current state (and not
the entire history), the system is memoryless and is called a Markov Chain. In fact, it is always
possible to characterize an ABM as a Markov process [26] by redening the state space, a concept
we have not yet dened. Thus, all ABMs are Markov chains.
To begin, consider an ABM Λ with m agents which evolves over some time, which can be
continuous or discrete. We are interested in the state of the model observed at discrete times
t1, t2, . . ., with tk < tk+1. Even if the underlying model runs in continuous time, the model state
can be sampled at discrete observation times tk. At any time t, an agent i ∈ Λ is associated
with the variable x(i,t), which take values in some nite eld F12. Assuming the variables can be
codied in a nite set of possibilities and are quantitative in nature (i.e., real numbers or integers),
then x(i,t) corresponds to n-dimensional vector i.e., x(i,t) ∈ Rn. The variable x(i,t) represents the
state of an agent. For example, an agent could be described by the vector (age, sex, location), so
the set of variables is a triple with a mixture of numerical and codied entries. The complete
system state (i.e. the global state) at time t is the collection Xt = [x(1,t) x(2,t) . . .x(m,t)] which is
an n×m matrix of all individual states. The evolution of the agent’s state variable through time
11Recursive theory is still very young, having developed only in the early twentieth century with the study of
computable functions and Turing Degrees.
12For example, in the case of Boolean networks the choice of the underlying eld is the Galois eld F = {0, 1}.
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is specic by the dierence equation
x(i,t+1) = fi(x(i,t),Xt, αi) (2.1)
where fi is an agent-specic update function (or transition function) which implements the agent’s
PDA cycle, αi is a vector of agent-specic parameters (some of which could be stochastic) and
Xt is the global state of the model. . The set of update equations fi, one for each agent i denes
the data-generating process (DGP) of the model. These functions are typically complicated,
possibly involving discontinuities, fuzzy logic rules, and if-else statements. In the case that each
fi is a polynomial, the resulting model is called a polynomial dynamical system and is amenable to
the computational tools and theoretical results of computer algebra, an area that utilizes powerful
symbolic computation capabilities [23]. The time evolution of the overall model is thus specied
as a stochastic dierential or dierence equation,
Xt+1 = F (Xt,α) + ξt (2.2)
where α a vector of agent-specic parameters, and ξt ∈ Rn×m is a matrix containing all stochastic
elements at time t. Since the DGP functions fi need not be linear and stochasticity is often
implemented in each fi, the agent-based model is better represented by a more general map F
Xk+1 = F(Xk,α, ξk) (2.3)
where ξt is a stochastic random matrix. The initial conditions of the system at t0 are (X0, ξ0).
Equation (2.3) is called the transition equation of the system. A closer look at (2.3) reveals the
Markov chain representation of agent-based models, though in practice these expressions may be
extremely complex and dicult to interpret. Indeed, in most cases, the explicit set of functions
fi and F, are not tractable. In analytical models, the transition function (2.3) often have a closed
form, a simple structure, and are linear (or can be linearized), and are kept free of heterogeneity
(or at a minimum). Any aggregation can be performed on variables by taking expectations over
the stochastic elements. However, in ABM the specication of (2.3) have little or no restrictions.
Since the state space of the model can grow large (possibly with innite states), the transition
equation often does not have an analytical representation.
Once we have specied the data generating process, we are then interested in some aggregate or
macro feature of our model. Let yt be a set of aggregate statistics at time t, and let h be a statistic
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function (i.e., some projection function from X to y) over the system state
yt = h(x(1,t), x(2,t), . . . ,x(m,t)) = h(Xt) (2.4)
Regardless of the complexity and specication of each fi, the solution (i.e., shape and form) to
(2.4) for each time t can always be found by backwards iteration, which traces yk back to the
initial conditions. That is,
y0 = h(X0)
y1 = h(X1) = h(F(X0,α, ξ0))
y2 = h(X2) = h(F(X1,α, ξ1)) = h(F(F(X0, α, ξ0),α, ξ1))
...
yk = h(F(. . .F(F(X0,α, ξ0), . . .)))
This backwards iteration uniquely relates the value of yt to the initial conditions, however
explicating this relationship is complicated because of the stochastic ξt terms. Since the DGP
functions (Equation (2.3)) and the statistic function h need not be linear, these random terms cannot
be averaged out by expectations. Therefore, the relationship between the initial conditions (X0, ξ0)
and the statistic y is only realized by Monte Carlo analysis13. Using Monte Carlo simulations of
the agent-based model for dierent initial states and values of parameters, one could obtain a
distribution for y. Recall that Monte Carlo techniques for simulations relies on a pseudo-random
number generator (§2.3.1) which is an inherently deterministic algorithm given the initial value
of the seed s. Thus, any stochasticity implemented in the model by virtue of a PRNG has a
deterministic nature, which allows to further pin down the formalism of an ABM. In particular, the
stochastic term ξk is a deterministic function of the seed s and can be considered, conveniently,
part of the initial conditions. Letting Z0 = {X0, s}, Equation (2.3) is reduced to
Xk+1 = F(Z0, α) (2.5)
It follows that the statistic y is given by
Xt = F(F(. . .F(X0, α, s))) = F
t(Z0, α)
yt = h(F
t(Z0, α)) ≡ gk(Z0, α)
(2.6)
13Suppose the output Y of a stochastic model is completely determined by h(X) where h is a deterministic function
and X is a random variable, but can not be computed analytically. In a Monte Carlo simulation, many realizations of
X = x are made and y = h(x) are computed. In this way Y is built up progressively.
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Equation (2.6) is called the input-output transformation (IOT) function and drives the results of the
ABM. When the seed s is xed, the IOT is a deterministic mapping of inputs (initial values and
parameters of the system) onto outputs14. While this is a convenient mathematical representation,
from a practical point of view the explicit form of the IOT function is unknown and the empirical
distribution of the underlying stochastic process is often obtained by Monte Carlo simulations,
by selecting dierent random seeds together with the initial values and parameters. However,
since an ABM places little restrictions on the specication of Equation (2.1), careful attention is
needed to keep it simple (while controlling the complexity) and within the bounds of available
computation resources. Nevertheless, we have provided a convenient formalism for agent-based
modelling to bridge the gap in the alleged dierences in terms of mathematical rigour between
pure analytical models and computer simulations. This formalization is abstract enough to apply
statistical rigour in performing quantitative analysis of the emergent properties of an agent-based
model, in particular to assess stationarity and ergodicity.
2.4.2 Stationarity and Ergodicity
Stationarity and ergodicity are intuitive concepts describing the long-term properties of a process
or model. Stationarity of a process, in general, implies that every observation comes from the
same probability distribution and that every observation carries information about the properties
of the data-generating process. A variety of well-established techniques exist for understanding
stationarity of traditional models. For example, the Dickey-Fuller tests (unit root tests in which
the presence of a stochastic trend is equivalent to check the null-hypothesis in non-stationary)
and KPSS (checking the null-hypothesis in stationary) can be used to test the stationarity of
a time series [45]. However, any conclusion derived from using parametric tests is valid only
if the underlying assumptions are valid. In the framework of agent-based models where the
implementation of the data-generating process may not yield an analytical form, one needs to
confront with a priori unknown stochastic properties of the model, assumptions and applicability
of parametric tests that may be too restrictive or erroneous. Therefore, non-parametric tests are
in general more suited for agent-based models as they do not require any assumptions on the IOT
function of the model15.
Recall that the autonomous and heterogeneous nature of an agent can evolve the system in incon-
14The IOT function need not be one-to-one. Indeed, dierent inputs might lead to the same output.
15Although parametric tests are superior than non-parametric tests, their superiority stems from the assumptions
about the stochastic process generating the observations. On the other hand, the limited power of non-parametric
tests can be overcome by increasing the number of Monte Carlo simulations.
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sistent ways and global dynamics are generated by repeatedly running the model under dierent
initial conditions and parameters. Any equilibria obtained in agent-based models are always
idiosyncratic with respect to the agents, in the sense that in distinct Monte Carlo simulations,
the evolution of every agent may vary substantially. Therefore, equilibria in agent-based models
can only be dened at the aggregate level and in statistical terms after the global dynamics have
emerged. When the agent-based model is relatively simple so that for any values of the parameters
the model is stationary and ergodic, it is generally possible to characterise its equilibria. On the
other hand, non-stationarity and non-ergodicity hinders the capability of fully describing the
long-term dynamics of the model. By stationarity in this section, we mean weak stationarity (also
known as covariance stationarity).
Denition 1. A stochastic process {wt} is weakly stationary if the rst moment of wt is independent
of t, that is, E(wt) = µ and if Cov[wt, wt+h] exists, is nite and depends only on h and not on t.
Recall the IOT function derived earlier {yk}∞k=0 dened by yk = gk(Z0, α), which relates the
initial state of the system Z0 = (X0, s) to the aggregate output of the model yk. We call {yk}∞k=0
the associated time-series of the agent-based model. Intuitively speaking, a time-series from some
stochastic process is stationary if the statistical properties (mean, variance, etc) remain constant
over time. In other words, the time-series has no distinguished points in time. An example of a
stationary process is shown is Figure 2.5.
Denition 2. A statistical equilibrium in an agent-based model is reached in a given time window
(t−, t+) if the associated time-series {yk}∞k=0 is (weakly) stationary. The statistical equilibrium is
denoted by µ∗ = g∗(Z0) and is given by
µ∗(Z0, α) = E[yt | t ∈ (t−, t+)] (2.7)
with respect to the process {yt}, and initial conditions Z0. An equilibrium is said to be an absorbing
(or steady-state) if yk is stationary in (t−, t+ + τ), τ →∞. An equilibrium is said to be a transient
if yk is stationary in (t−, t+), but no longer stationary in (t−, t+ + τ), τ > 0.
A model may display both transient and absorbing equilibria, but the latter shows that once the
system is in this state, it can no longer move out. On the other hand, a model may oscillate between
two or more transient equilibria (possibly followed by an absorbing equilibria). It follows that for
any given initial conditions and parameters, there can be at most one absorbing equilibrium. It is
entirely possible that a model displays no absorbing equilibrium for a given statistic of interest. If
a model is stationary and converges to the same equilibria µ∗(Z0, α) = µ∗(α) irrespective of the
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Figure 2.5: Stationarity and ergodicity are independent concepts, and one does not imply the other. A typical
example of a stationary, but non-ergodic, process is drawing a number y1 from some distribution which
remains constant for the rest of the series, i.e. yt = y1 for all t (solid curve). An example of a non-stationary
but ergodic process is yt = yt−1 +N(0, 1) (dotted curve).
initial conditions Z0, the process yk is said to be ergodic. Ergodicity is sometimes dened [46] as
lim
n→∞
1
n
n∑
k=1
Cov(yt, yt−k) = 0 (2.8)
which describes a property that concerns with the memory of a process. An ergodic process is
characterized by weak memory (low persistence), and events far away from each other can be
considered as almost independent because the eects of stochasticity fades with time. That is, a
time series {yk}∞k=0 is ergodic if it exhibits the same type of qualitative behaviour. If an equilibrium
is reached, it will be the same for all simulation runs, irrespective of the initial conditions, and
the absorbing equilibrium will be unique. Dierent initial values (X0, s) would not change the
equilibrium value µ∗, but might change the reaching timing. Moreover, if yk is ergodic, the
observation of a unique time series provides sucient information to infer the shape and form of
the IOT function (2.6). That is, if the model is ergodic the properties can be analysed by using
a long time-series produced by a single run of the model. If the model is non-ergodic then a
set of Monte Carlo simulations (each produced by the same IOT but with dierent seeds) are
necessary to describe, in distributional terms, the properties of the model. Non-ergodic models,
on the other hand, are sensitive to their initial conditions, including the random seed. A model
that is stationary but not ergodic can obtain multiple absorbing equilibria depending on the initial
conditions. Furthermore, since transient equilibria are dened for a nite duration of time, these
equilibria will also dier when computed for dierent initial conditions. Ergodicity is a powerful
concept in agent-based models. If an ergodic model, one that is in a statistical equilibrium, receives
a shock that moves it out of its statistical equilibrium, the system returns to the equilibrium after a
nite amount of time. As a consequence, ergodic models are well suited for analytical estimation
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and calibration techniques [46].
In ABMs stationarity and ergodicity tests are crucial to know whether the model reaches a statistical
(unique) equilibrium state. The inherent lack of an analytical form of the data-generator process
and the diculty of dealing with unknown stochasticity requires non-parameteric statistics and
tests. For agent-based models, the standard non-parametric test used to check stationarity is an
application of the Runs Test (or Wald-Wolfowitz test) developed by Wald and Wolfowitz in 1940
[as cited in 45]. It tests the hypothesis that a given set of observations are mutually independent
and randomly distributed. On the other hand, while ergodicity is crucial for understanding the
long-term behaviour, literature surveying tests for ergodicity is scarce. [45] describe a modied
Runs Test algorithm which considers the invariance of the moment of order k between dierent
time-series produced by the same data-generator process, but with dierent random seeds. A full
detailed survey of stationarity tests can be found in Phillips and Xiao [47] and Grazzini [45].
2.5 Application to Disease Dynamics
The use of ABM in the eld of mathematical epidemiology has been rapidly growing, with the
development of comprehensive models that incorporate various databases to address public health
challenges [48, 49, 50, 51], in particular for emerging infectious diseases [52, 53, 54]. In this
section, we detail an application of ABM to disease dynamics. We illustrate the construction and
calibration of an ABM that describes the dynamics of disease transmission in a simple linear
cascade of infection and recovery.
The model we consider here was originally developed by Kermack and McKendrick in the 1920s
[18], and is referred to as the classical SIR (Susceptible-Infected-Recovered) model. In this model,
the population is stratied into three dierent compartments (or health states) of susceptible (S),
infected (I), and recovered (R). A susceptible individual leaves the S-compartment when infected
and enters the I-compartment. Similarly, an infected individual leaves the I-compartment and
enters the R-compartment upon recovery. An individual who recovers is assumed to have perfect
immunity to the disease thereafter. When the rate of infection is proportional to the total number
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of individuals in the population, the model can be represented by a set of dierential equations:
dS
dt
= −βSI
N
dI
dt
= β
SI
N
− γI
dR
dt
= γI
(2.9)
where β is the rate of disease transmission, γ is the recovery rate, and N = S + I +R. Although
Equation (2.9) is written in deterministic form, it is clear that a disease transmission process
involves stochasticity as contacts between individuals occur randomly, even when stochastic
nature of other behavioural, host, and biological factors are omitted. Thus, the classical SIR model
is built on the assumption of homogeneous mixing in the population where all individuals have
equal chance to interact with others. On average, each infected individual generates βS new
infected individuals per unit time.
Here, we develop an agent-based model to replicate the dynamics of the SIR model. The general
framework of the model includes two main entities: (i) an in-silico two-dimensional lattice envi-
ronment and (ii) a set of unique agents situated (xed) in the lattice. We set the size of the lattice
to 20× 20 resulting in an environment with a total of 400 agents. Each agent is fully characterized
by their health status of Susceptible, Infected, or Recovered which are programmatically codied as
integer values of 0 = SUS, 1 = INF, and 2 = REC, respectively. Therefore, an agent a is fully
described by its associated internal state variable xa ∈ {0, 1, 2}.
Running the agent-based model simply amounts to instantiating a fully susceptible agent pop-
ulation, introducing an infected agent as the initial condition, and iteratively letting the agents
interact by executing their associated PDA cycles. The iterative process operates over a discrete
time-step structure where the simulator engine advances the virtual clock by a single unit, in
which the PDA cycle of each agent is carried out sequentially. The perception stage of each agent
determines all possible interactions of the agent, modelled through contacts with up to 8 random
agents on the lattice that are situated in neighbouring cells. The perception function returns the
number of infected contacts k out of the eight random contacts of each agent at any time-step. In
the decision stage, decision functions encapsulating the logic of the interactions are executed. If a
susceptible agent meets an infected agent, successful disease transmission is determined using
a rejection sampling-based (Bernoulli) trial where the chance of success is dened by a suitable
probability distribution. Letting xa,t denote the internal state of an agent a at time t, the one-step
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transition probability (in the Markov process) is given by:
Pr[xa,t+1 = INF | xa,t = SUSC] = 1− (1− b)k (2.10)
where k is the number of simultaneous contacts with infectious individuals (assuming that
transmission events are independent per contact) and b is the baseline transmission probability. If
the trial is successful, a susceptible individual becomes infected. In a similar way, the one-step
transition from INF → REC is given by:
Pr
[
xa,t+1 = REC | xa,t = INF
]
=
1 if t > tU0 otherwise (2.11)
where tU is an empirically derived parameter representing the period of infectiousness, which in
this context is sampled from a Uniform distribution between 3 to 6 time units. Finally the action
stage updates the internal state of each agent as well as the global state of the model and broadcasts
it to the entire lattice for the next iteration of the PDA cycle to continue. The computational
implementation of the associated update function is described in Algorithm 1.
A key parameter in our model is the unknown transmission probability b. Typically the value of b
is calibrated to a stylized fact of the underlying system such as the basic reproduction number
(denoted byR0 as described in Section §2.3.3) or incidence rate (i.e., new infections per unit time).
By running Monte Carlo simulations, the value of b could be estimated to match, for example,
R0 obtained from simulation data with a given R0. It is worth noting that this process can be
computationally demanding depending on the complexity of the model. One must sweep through
a parameter space (which could be arbitrarily large), running Monte Carlo simulations for each
value. Reduction of the parameter space to a suitable subset requires an educated initial guess.
In our example, we calibrated b to yieldR0 = 1.6 indicating that, at the beginning of an epidemic,
an infected person can infect 1.6 individuals (on average). The calibration procedure requires
an initial value of b, and counting the number of secondary cases caused by the initial infected
agent. If the model predictedR0 is not acceptable, the value of b is changed accordingly, and the
process is repeated. Of course, multiple realisations are necessary for each value of b to address the
rst- and second-order uncertainties. Using 500 Monte-Carlo simulations, the calibration process
provided an estimated value of b = 0.047 for which the average of realisations givesR0 ≈ 1.6.
After calibration, we ran 500 Monte-Carlo simulation for 120 units of time to illustrate the behaviour
of the system, corresponding to the spread of disease in the population. The global dynamics are
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Algorithm 1: Pseudocode implementation of an agent’s PDA cycle and the associated
update function.
Input :agent a, time t
// when the agent is susceptible
1 if xa,t = SUS then
2 n← Discrete Uniform [1, 8] // sample a number of agents to contact
3 k = 0 // total contacts with infectious agents
4 for 1 to n do
5 xˆ← AgentState(Discrete Uniform [1, 400]) // contact agent’s state variable
6 if xˆ = INF then
7 k = k + 1
8 end
9 P = 1− (1− b)k
10 if rand() < P then
11 a.tU ← Discrete Uniform [3, 6] // sample length of infection tU
12 xa,t = INF // update agent state variable
13 end
14 end
15 end
// when the agent is infected
16 if xa,t = INF then
17 if t > a.tU then
// if infection duration is over, update to recovered
18 xa,t = REC
19 end
20 end
represented by the changes in the number of individuals in dierent health states of the model.
Figure 2.6A shows the outputs for the state variable I (i.e., the number of infections at any point
in time) for each realisation. As is evident, each realisation produces a dierent infection curve
as a result of stochasticity. It is also interesting to note that the average of realisations has a
lower magnitude compared to many realisations. This is due to the fact that in many simulations,
the initial infected case recovers without infecting any susceptible individuals and therefore the
epidemic dies out. Figure 2.6B shows the average of realisations for all state variables.
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Figure 2.6: Monte-Carlo simulations of the SIR computational model: (A) independent realisations of the
state variable I ; (B) average of realisations for all state variables.
2.6 Concluding Remarks
The current surge of interest in ABM has gradually built up over the last twenty years [14],
especially with emerging technologies in computational power and big data collection platforms
that bring a higher realism to such models for simulating the real-world phenomena. The use of
agent-based models has provided an additional tool for advancing quantitative science, especially
in research areas (e.g., public health domain [55]) in which decision to intervene in the system
dynamics may be subject to substantial heterogeneity and variability. While the capability of
these models to address practical questions and inform decision-making in the face of uncertainty
has been exemplied, there remain limitations to their systematic application. In particular, a
more directed research is needed for expanding the theoretical aspects of ABM, by taking into
account the objectives of reliability, eciency, and adaptability which underlie the exibility of
agent-based models.
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Chapter 3
Cost-Eectiveness Analysis
3.1 Introduction
Health economics (i.e., the application of economic theory to health16) aims to enhance and
optimize the use of healthcare resources and public health policies and interventions on the basis
of modern micro- and macro-economic theory. A branch of health economics is the comparison
of costs and benets of new healthcare interventions, technologies, or medications against an
alternative through formal socio-economic evaluations. In the context of a health care system
with limited resources and budgetary constraints, the eectiveness of a healthcare intervention is
a necessary (though not always sucient) for provision of that intervention. The costs of health
care must also be considered in order to achieve maximum health gain from limited resources.
There is vast health economics literature on formal, utility-maximizing evaluation techniques
which oers policy-makers a means to allocate limited resources based on costs and benets [56,
57]. Some of these techniques include cost–benet analysis (CBA), cost-eectiveness analysis
(CEA), and cost-utility analysis (CUA) [56, 57]. CBA, founded on economic welfare theory, requires
all costs and benets of interventions that are being investigated to be converted into monetary
units. An intervention is considered to be economically viable if the benets B exceeds that of the
costs C (i.e., B > C) known as the cost–benet criterion. While the basic use of the cost–benet
criterion is easy for the decision-maker, it presents challenges due to the ethical and logistical
diculties of associating monetary units with health outcomes such as mental illness-free years
or additional years of life, making CBA less suitable for economic evaluations. In comparison, a
CEA aims to evaluate eects of an intervention without assigning any monetary value. Instead,
a CEA expresses eects using a more descriptive unit on a one-dimensional scale such as years
of life saved, or increase in median survival, or survival rates. For example, a summary measure
16This eld consists of the economics of health and the economics of healthcare, two distinct, but closely related,
disciplines.
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used in comparison of two interventions is the average cost-eectiveness ratio
ACER = costs in units of moneyeects in natural units (e.g., life years gained)
Another more commonly used measure is the incremental cost-eectiveness ratio (ICER) which is
the ratio of incremental costs to incremental benets compared to the next most eective, dened
as
ICER = dierence in costsdierence in eects in natural units (3.1)
Multiple interventions can now be ranked by their ICER values, which provides an easy inter-
pretation of the results. Nevertheless, CEA comes with its own set of limitations. While CEA
provides a rank order of measures, it does not decide up to which ratio an intervention should
be accepted. Although this is easily addressed in the presence of a xed budget, it is dicult
under a constraint-based open budget. Another limitation is that the use of a one-dimensional
measure is not suitable for comparing interventions that provide more than one eect e.g., there
is no specic way to combine information about a treatment that reduces high blood pressure
but also gains years of life lived, since their units are neither additive nor multiplicative. This
limitation is addressed by CUA, a special case of CEA. CUA enables comparisons across dierent
interventions and multiple eects by utilizing a common measure which encapsulates the impact
of an intervention on a patient’s length of life, but also the impact on their health-related quality
of life. It so does this by measuring all eects of an intervention on morbidity and mortality on
a multi-dimensional utility scale, through the use of appropriate weights. The best-known and
most commonly used measure is called the quality-adjusted life year (QALY) followed by a related
measure called the disability-adjusted life year (DALY), which can be used in the denominator
of Equation (3.1). In addition, compared to CEA, CUA has the advantage of being applicable
to dierent interventions (and even beyond health-care interventions) because it maps all the
eects into a single utility number, and is often the preferred economic evaluation method by
health care professionals and national agencies. For these reasons, CEA and CUA are sometimes
not distinguished from each other in the literature and that the term cost-eectiveness analysis
is commonly used to refer to both family of techniques. A summary of methods is presented in
Table 3.1 with a formal review of CEA in §3.2.
Regardless of the economic methodology selected, any systematic evaluation requires a suitable
parameterization with relevant evidence and data in order to develop policies and guidelines of
new interventions and technologies. Randomized controlled trials (RCTs) provide an empirical
distribution of individual patient data to allow for head-to-head comparisons of treatments in
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Table 3.1: A comparison of the three types of economic evaluation frameworks. Health outcomes are a
single dimensional measure such as the number of lives saved or the number of deaths averted. A utility
measure is a multi-dimensional index such as the quality-adjusted life year or the disability-adjusted life
year. Table adapted from Baio [57].
Evaluation type Costs included Type of outcome
Direct Indirect
Cost-benet X X $
Cost-eectiveness X often Health outcome
Cost-utility X rarely Utility measure
controlled environments. While RCTs have been a crucial component in economic evaluations,
there are inherent limitations in their utilization to inform policy [58]. RCT sample sizes are often
too small and do not reect standard care available to the general population. Patients are also not
followed up long enough to capture the full impact of the intervention. In some scenarios RCTs can
be completely ineective in informing policy, e.g., in evaluating a potential vaccination program
against aimed at reducing long-term severe sequelae caused by a disease. This inadequacy of
RCTs have lead agencies such as the National Advisory Committee on Immunization (NACI) in
Canada and the National Institute for Health and Clinical Excellence (NICE) in the UK to call for
systematic, evidence-based methods to inform public health policies and program delivery [59,
60].
Mathematical models, as decision analytic tools, are being increasingly used within economic
evaluation studies to provide an alternative approach to RCTs. The ability of mathematical models
to synthesize evidence and integrate information from dierent sources have made them useful in
situations where RCTs are not applicable or where data from RCTs is insucient. As such they can
help to inform decisions about clinical practices and health-care resource allocations. In the last
ten years, with the rapid increase in the volume and heterogeneity of data, mathematical models
concerning health economic evaluations have integrated several disciplines, including medical
research, epidemiology, statistics, and economics. To date, the most frequently used modelling
techniques have been deterministic, aggregate level models which are relatively straightforward
to develop, but are limited by their homogeneity and inability to capture adaptive dynamics and
possible randomness in system phenomena. For instance, in an assessment of a new vaccination
programme, such models may not capture indirect benets of an intervention such as herd
immunity eects or interactions between stratied populations (e.g., dierent age-groups). These
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models are usually complemented by dynamic transmission models (such as dierential equation-
based models) or stochastic aggregate models, which overcome some of the limitations, but are
often intractable because of uncertain parameters and still display a high degree of homogeneity.
In Chapter 2, we argued that ABM computational systems are extremely exible and capable of
capturing (in principle) arbitrary level of heterogeneities. An ABM can incorporate the complex
nature of disease transmission (e.g., co-infection by multiple pathogens) and human behaviour
(e.g., sexual partnerships and contact patterns). In this chapter, we review existing methodology
for CEA and present a mathematically rigorous integration of ABM within the CEA framework.
3.2 Cost-Eectiveness Analysis (CEA)
In CEA, results are characterized by the extra cost necessary to produce additional units of
health benet, i.e., cost-per-benet gained. The methodology involves estimating costs, modelling
intervention eects, and making an inference from the estimated costs to eects ratio. Eects of an
intervention, such as illness prevention, symptoms relief, decreased medical resource utilization,
and reduced loss of productivity are usually obtained from clinical trials, observational studies,
academic and medical literature, and even patient interviews. However, how these eects are
quantied is important. For instance, eects that can be measured in a continuum, such as life
expectancy and survival time, may be estimated using survival functions [61]. We summarize the
basic analysis of any CEA in four major steps:
1. The target population and the time horizon in which the analysis takes place should be
clearly dened.
2. The necessary data, including quantied health outcomes, weights, and potential costs,
should be collected through a systematic review of peer-reviewed literature and various other
sources including government agencies and private organizations. In addition, potential
data biases should be critically considered and addressed.
3. A functional disease model (e.g., Markov models or ABM computational system) that
characterizes the transmission dynamics of a disease and identies the dierent health states
(e.g., acute or chronic, short-term or long-term sequelae) associated with disease burden
should be applied with and without the intervention under study. Relevant epidemiological
parameters should be sought, and whenever possible through the data collection process.
This step is often the most dicult and time-consuming one, while it is also the most crucial
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one.
4. Summarize the model output (i.e. relevant eects of the intervention) in a suitable, quantied
measure such as the number of years gained, quality adjusted life years, or disability adjusted
life years.
3.2.1 Types of Cost Variables
The cost of resources consumed by an intervention can be of two types of direct and indirect,
which dene the viewpoint or the perspective of the analysis. Direct costs include the value of all
goods and services consumed in the provision of an intervention or in dealing with the immediate
eects of the disease or any future consequences linked to it [62]. Common contributors to direct
costs include the cost of physicians and nurses, medical testing and hospitalization, and drugs.
Indirect costs are associated with societal care or impaired ability to work or engage in leisure
activities [62]. Indirect costs also include loss of economic productivity due to pre-mature death
caused by the disease. The extent to which indirect costs should be considered is still a matter of
debate and the arguments to include them are complex [62]. Costs can further be classied as
xed or variable. Fixed costs are those that remain the same regardless of the type of disease or
the intervention, e.g., the cost of buying specialised equipment for delivery of an intervention.
Variable costs are those that change in the short term, e.g., increasing nursing sta because of an
outbreak.
3.2.2 Quality-Adjusted and Disability-Adjusted Life Years
Quality-adjusted life year The quality-adjusted life year (QALY) is a commonly used summary
measure (or an outcome measure) to quantify the eects of an intervention, incorporating the
impact on both the quantity and quality of life through the use of generic utility weights. QALYs
provide a high degree of standardization for the comparison of interventions, insomuch that the
use of QALYs is now required by the National Institute for Health and Clinical Excellence (NICE)
in the UK for health intervention assessment [60]. Today, QALY calculation methodologies have
advanced from the qualitative analysis as originally introduced by Klarman, Francis, and Rosenthal
[63], Torrance, Thomas, and Sackett [64], and Fanshel and Bush [65] to utilizing statistical models
deeply rooted in expected utility analysis. For instance, Miyamoto [66] formulates six classes of
QALY utility models and axiomatizes these models under expected utility (EU) and rank-dependent
utility (RDU) assumptions. In general, QALY utility models are now widely used in the EU analysis
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of health interventions because they capture quantitatively concrete outcomes such as death, but
also specic improvements in the state of health, such as reduced pain or improved ability to walk.
Specic states of health are often associated with utility weights, where a more desirable health
state will receive greater utility and will be favoured in the analysis. Derivations of utility weights
are discussed later in this chapter.
By considering utility weights as a single index of morbidity and mortality, the basic calculation of
QALY is quite simple. Consider an individual who is burdened with some health state H that does
not change up to time t (in years). Let the utility of spending t years in health state H be denoted
by u(H, t), which, under an expected utility framework [56], must have the from u(H, t) = tv(H)
where v(H) is the utility weight assigned to state H . The function v(·) is cardinal and is unique
up to positive ane transformations and can be chosen such that 0 ≤ v(·) ≤ 1. This leads to
a quite intuitive interpretation of QALY: A year of life lived in perfect health is worth 1 QALY
while death is assigned 0 QALYs. A year of life live in all other health states is worth less than
1 QALY. States worse than death can exist and they would have a negative value and subtract
from the number of QALYs [67]. QALYs are calculated by simply multiplying the duration of time
spent in a health state by the associated utility of that state, For instance, if an individual is in a
health state H∗ for 10 years with v(H∗) = 0.6, this would generate six non-discounted QALYs (i.e.
0.6 multiplied by 10 years). In most cost-eectiveness analysis, future QALYs are discounted17 to
present values, incorporating the idea of positive time preference, i.e., that individuals prefer to
receive health benets now rather than in the future. The standard time discounting expression is
e−r(x−a) where r is the discount rate. The quality-adjusted life expectancy (QALE) of an individual
in health state H at age a is then given by
QALE =
∫ a+L
x=a
v(H)e−r(x−a) = v(H)
1− e−rL
r
(3.2)
where L is the life expectancy (relative to age a) and a the year in which the weight will be applied.
However, the direct use of Equation 3.2 to calculate QALYs is rare. The main use of QALYs in a
cost-eectiveness analysis is to assess the improvement in QALE obtained through an intervention
relative to a situation in which either no intervention or a standard alternative intervention is
provided. Suppose an intervention improves an individual’s quality of life from health state H1 to
17Discounting is a mathematical procedure for adjusting future costs and outcomes to present value.
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Figure 3.1: Visual interpretation of quality-adjusted life years (QALYs) and disability adjusted life years
(DALYs). In the left gure, the total number of QALYs with and without intervention are the areas under
the relevant polygons. The right gure shows the relationship between QALYs and DALYs.
H2. The outcome of interest is, then, the number of QALYs gained, determined by
QALYs gained =
∫ a+L2
x=a
v(H2)e
−r(x−a) −
∫ a+L1
x=a
v(H1)e
−r(x−a)
= v(H2)
1− e−rL2
r
− v(H1)1− e
−rL1
r
(3.3)
where L2 is the period over which an intervention aects an individual’s quality of life and v(H2)
is the associated utility weight of quality of life with intervention, while L1 and v(H1) are the
corresponding parameters without intervention. However Equation 3.3 is based on the unrealistic
assumption that quality of life remains constant throughout an individual’s life. A more general
formula, given by [68], is
QALE =
N∑
m=1
Qm
e−r(tm−a) − e−r(tm−1−a)
r
(3.4)
In this formula, an individual’s life expectancy is divided into N time periods tm (with 1 ≤ m ≤,
t0 = a, tN = a + L) with possible dierent durations, each aected by quality of life Qm. The
number of QALYs gained follows immediately,
QALYs gained =
p∑
p=1
Qip
e−r(t
′
p−a) − e−r(tip−1−a)
r
−
N∑
m=1
Qm
e−r(tm−a) − e−r(tm−1−a)
r
(3.5)
Although we have presented a simplistic framework here, a decision-theoretic analysis based on
expected utility theory including risk aversion and uncertainties can be found in [56].
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In the context of the above framework, measurements of utility weights, across dierent studies,
must ensure the same units for all possible health states. Several methods have been established
to accomplish this including direct methods such as Rating Scale, Time Trade-o, and Standard
Gamble and indirect methods also known as generic preference-based measures (see Figure 3.2) [56,
57, 69]. The rating scale method is the simplest direct approach and consists of a line with clearly
dened end points describing the best and worst health states. Respondents are asked to evaluate
a certain disease or health state by indicating where on the scale they consider the health state to
be. The corresponding QALY weight of the health state is then read, after normalization, from
the [0, 1] scale. This method is not very popular due to the inherent end-of-scale and spacing-out
bias. The Time Trade-O procedure presents respondents with two alternative scenarios and ask
which they prefer. The choice is between choosing to live x number of years in a impaired health
state or giving up years of life to live for a shorter y period in full health18. The time spent in
full health y is varied until the respondent is indierent between the alternatives. The standard
gamble procedure is similar. Here, the choice is between the certainty of remaining in a particular
health state or taking a gamble (say with probability p) on a treatment/intervention that may
award perfect health or lead to immediate death. The probability p is varied until the individual is
indierent between the certainty and the gamble. Generally, these methods are time consuming
and, in some cases, unethical. As a result, indirect methods for measuring health outcomes have
also been developed, often “o-the-shelf” questionnaires such as the Short Form 36 (SF-36), the
Nottingham Health Prole, and the Sickness Impact Prole [70].
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Figure 3.2: Methods of measuring health utility weights including The Standard Gamble (A), Rating Scale
(B), Time Trade-O (C), and the SQ-5D form (D).
Disability-adjusted life year The disability-adjusted life year (DALY) measure is an alternative
to the QALY framework developed in the early 90s, as a means of estimating the global burden of
18It is assumed that the only possible treatment is free and would cure perfectly.
38
disease [71, 72]. DALYs have been the key measure in four Global Burden of Disease (GBD) studies,
each assessing the worldwide impact of disease and injury [73, 74]. DALYs are a two-dimensional,
time-based measure that combines years of lifetime lost through premature mortality and the
number of years lived with any mental or physical disability caused by a disease or injury. One
DALY has the intuitive interpretation of losing one year of perfect health. The burden of disease,
dened by disability weights, can be thought of a measurement of the gap between an impaired
health state and the ideal situation where everyone lives into old age, free of disease and disability.
Disability weights (and their correct elicitation) are a crucial component of DALY calculations as
they enable comparison of morbidity and mortality using a common unit. Although DALYs can be
considered as a variant of QALYs, the disability weights used in DALY calculations dier from the
health-related utility weights used in QALY calculations that often rely on preference-based utility
measures usually elicited from surveys and questionnaires. DALY weights, on the other hand, are
based on a universal set of standard weights based on expert valuations and judgements. Another
signicant dierence is that, although measured on similar scales, disability weights represent
levels of loss of functioning caused by a disease or injury whereas QALYs represent the levels
of quality of life in particular health states. That is, QALY weights are normally measured on a
scale in which 1 represents full health and 0 represents death; while DALY weights are measured
on a scale in which 0 represents no disability. DALYs are therefore a measure of something lost
rather than gained, and unlike QALYS, they are not desired themselves, but what is sought is their
reduction. An advantage of DALY models is that they incorporate age-weighting function, as
opposed to QALY models which assume one QALY has always the same interpretation, regardless
of the age. Another advantage is that DALY calculations are essentially used in an aggregated
context, where the aggregation is carried out by summing each incidence of the disease or injury.
DALY calculations are composed of the morbidity component, i.e., years lived with disability (YLD)
and the mortality component years lost due to premature death (YLL). The morbidity component
for a single individual is calculated by
YLD = duration till perfect health (or death)× disability weight
The mortality component for a single individual is the dierence of life expectancy and age at time
of death. A DALY is simply the sum of YLDs and YLLs, i.e., DALY = YLD + YLL. The expressions
for YLD and YLL can be extended by applying social weighting expression such as age weighting
Cx−βx and time discounting e−r(x−a) where r is the discount rate. Thus, the general formula for
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the DALY measure due to sequelae j at time t for the person i is:
∆ti,j =
∫ ati+L(ai)
ati
KδjCxe
−βxe−r(x−a
t
i)dx (3.6)
where x is the time, ai is the age of disease onset, δj is the disability weight of sequelae j, β and
K are the age-weighting parameter and the age-weighting modulation factor, respectively, and
L(a) is the duration of condition in the case of disabilities or average life expectancy in the case
of death. The aggregate DALY at time t for a given sample of the population with size Nt due to
total disease burden is then
∆t =
Nt∑
i=0
∆ti (3.7)
Summing over the relevant time period T (with time discounting), the total number of DALYs
attributable to a disease or injury is
∆ =
∫ T
0
∆te
−rtdt (3.8)
The eectiveness of some intervention is then assessed by the reduction in DALYs in the presence
and absence of the intervention, i.e.,
eectiveness = ∆Without intervention −∆With intervention
Although QALYs and DALYs share the same conceptual framework, they are not interchangeable
as they are based on dierent assumptions and methodologies, for example, elicitation of utility
weights for quality of life as compared to the expert valuation of disability weights. Moreover,
while considered to be the cornerstone of economic evaluations, exemplied throughout literature,
both methodologies have been under debate in recent years. Concerns relating to QALYs range
from the theoretical foundations of the framework [56, 75] to problems in the multiplicative model
which underlies the generation of QALY values [76, 77]. Similarly, the idea of DALY as expressing
burden of disease in a single index is tempting; however, several studies have questioned both the
validity of the results as well as the underlying value-judgements [78, 79, 80]. For instance, Anand
and Hanson [80] exposes the inherent inequities: discounting future health gains and losses is
disadvantageous for future generations, age-weighting disfavours children and seniors, and the
chosen estimates for life expectancy tend to disfavour women.
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3.2.3 Incremental Cost-Eectiveness Ratio
The results of a cost-eectiveness analysis are usually summarized by several available measures
including the cost-eectiveness ratio, cost-eectiveness acceptability curves, and net benet ratio.
The most common, incremental cost-eectiveness ratio (ICER), is dened by Equation (3.1), where
the dierence in costs appear in the numerator and dierence in eects of interventions (usually
measured by QALYs or DALYs) are in the denominator. ICER values are more commonly used when
the interventions are mutually exclusive, e.g., in a scenario with two incompatible medications
of dierent costs for the same health condition, one needs to consider the rate at which higher
expenses brings additional benets. In other words, the ICER of an intervention is dened as the
ratio of incremental costs and incremental benets relative to the next best available alternative
or “nothing”. Most common ICER calculation frameworks take a “population” level perspective as
opposed to individual level.
Let i1 = (e1, c1) denote the eectiveness and cost of a new intervention t1 that is compared with
the alternative i0 = (e0, c0). For example, (ei, ci) could represent sample statistics of the eect
measure such as average number of QALYs. This data is usually obtained from randomized control
trials or observational studies. Then we have the following scenarios:
1. e1 > e0 and c1 < c0. The new intervention is more eective and costs less, in which case it
is said to be dominant.
2. e1 > e0 and c1 > c0. The new intervention is more eective and costs more.
3. e1 < e0 and c1 < c0. The new intervention is less eective and costs less.
4. e1 < e0 and c1 > c0. The new intervention is less eective but costs more, in which case it
can discarded.
If e1 = e0 or c1 = c0, we accept the intervention that minimizes costs or maximizes benets,
respectively. It is clear that in scenarios 1 and 4, the choice between the two interventions is
simple. For scenarios 2 and 3, an intervention has higher cost but also yields a greater benet or a
lower eectiveness but is also cheaper to implement. In this case, decisions can be made in light
of the ICER value, i.e., the additional cost for each unit of benet gained by the new intervention
over its alternative. The ICER value in the comparison of t0, t1 is dened as
ICER = ∆c
∆e
(3.9)
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where ∆c = c1− c0 and ∆e = e1− e0, provided that the denominator is not zero. An intervention
is considered acceptable by comparing the ICER value against some threshold, often based on
willingness-to-pay (WTP) criteria. In a societal perspective that accounts for the total costs to all
payers for all subjects, and the World Health Organization suggests using the per-capita gross
domestic product (GDP) as a WTP threshold [81]. ICER values up to the per-capita GDP are
considered very cost-eective, and for a WTP up to 3 times the per-capita GDP as cost-eective.
For a WTP greater than 3 times the per-capita GDP, the intervention is considered to be not
cost-eective [81]19. Other thresholds include individual WTP (2 times of salary) [83] and value of
a statistical life [84].
While the measures of interest constructed so far (i.e. QALYs, DALYs, and ICER) are seemingly
straightforward, estimates of the cost-eectiveness of healthcare interventions are subject to un-
certainty, which should be taken into account during the decision-making process [85]. Essentially,
such analysis relies on statistical models and assumptions on the underlying distributions of costs
and eects [61, 85, 86, 87, 88]. The choice of distributions used in practice is often determined by
convenience, for example, on the basis of familiarity or ease of computation. Usually, the choice of
normality is commonly assumed for describing cost and benet data [86, 87, 88], or at least a large
enough sample size for the sample means to be normally distributed; in addition, most approaches
to estimation of cost-eectiveness adopt essentially a frequentist approach. Such assumptions are
rarely realistic. For instance, data obtained from individual-level datasets (such as those collected
in RCTs) trials are unlikely to be normally distributed; clinical outcomes are often measured on a
binary scale, such as the eradication of a symptom, or on a ordinal scale, such as questionnaires.
Similarly, cost data will often have a large presence of structural zeros [89], and are typically
positively skewed (or even bimodal) [90, 91]. In such cases even the use of Lognormal or Gamma
models becomes impractical, since these distributions are dened for strictly positive parameters.
Assumptions on normality have also lead to several troubling problems in the interpretation and
estimation of the ICER, in addition to the statistical diculties with estimation of a ratio parameter
[87, 88].
In order to address these concerns, several authors have now established a general framework
19Although there is widespread acceptance of using threshold values to assess cost-eectiveness, it is argued
that thresholds based on per capita GDP have major shortcomings as guides for policy-makers [82]. An alternative
approach which avoids the limitations and focuses instead on getting the largest health impact for the budget
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for CEA that can incorporate arbitrary distributions and employ a Bayesian approach20 which
treats model parameters as random quantities while accounting for patient level data available (as
produced by RCTs or observational studies) [57, 85, 92, 93, 94, 95]. In the next section, within the
purview of this thesis, we extend this Bayesian statistical framework of [57] and [96] to integrate
an alternative source of data, mainly the data-generation process of an ABM computational system.
3.3 Integration of CEA in the ABM Framework
Consider an ABM computational system of which the data-generating process (i.e. Equation 2.1)
produces the set of observables Di = {xij | j = 1, 2, . . . , ni} where each xij is, possibly mul-
tivariate, an observation of subject j (of the in-silico population) receiving intervention i ∈ I ,
with I = (0, 1, 2, . . .) a set of interventions to be evaluated and ni is the number of individuals
given intervention i. Typically xij will be represented by two numbers: the eectiveness of a
suitable clinical outcome e (e.g., e measured in terms of QALYs or DALYs), and the measure of the
individual specic costs c, including the cost of intervention. We can then formally write xij as a
vector of two elements, xij = (eij, cij). Without loss of generality, we consider the comparison of
two interventions I = (0, 1) where i = 0 represents the status quo, standard programme that is
already available, and intervention i = 1 is suggested to replace it or implemented simultaneously,
either to the entire population or to a specic sub-group of individuals. The entire observable
dataset is then referred to as D = D0 ∪ D1. Denote by ei, ci the sample means of eectiveness
and costs, respectively, of intervention i. Dene the increment in mean eectiveness and costs as
∆e = e1 − e0
∆c = c1 − c0
(3.10)
then the ICER statistic Rˆ is
Rˆ =
∆c
∆e
(3.11)
If Rˆ < λ and ∆e > 0, or if Rˆ > λ and ∆e < 0, where λ represents some willingness-to-pay
parameter for an additional health benet, then the intervention is said to be cost-eective. That is,
the criteria of acceptability not only depends on the cost-eectiveness ratio being less than λ but
also depends on the sign of ∆e. This point is illustrated by the cost-eectiveness plane (Figure 3.3)
20O’Hagan, Stevens, and Montmartin [92] points out that the construction of the proposed cost-eectiveness
acceptability curves by van Hout et al. [86] which plots the probability of net benet against the threshold willingness-
to-pay parameters is essentially Bayesian.
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Figure 3.3: The cost-eectiveness plane. The dotted line with slope λ divides the plane into two regions,
cost-eective (grey region, lower right) and not cost-eective (white region, upper left) regions. Points a1
and a2 have ICER values less than λ, but a1 falls in the rejection region and a2 in the acceptance region.
which plots possible (∆c,∆e) pairs with a threshold line of slope λ passing through the origin.
The shaded area below this threshold line indicates the region of acceptability. Inference for the Rˆ
is limited to constructing condence intervals, however generating condence intervals of such a
ratio statistic is not straightforward since the variance of a ratio can not be obtained in closed form
and the sampling distribution of a ratio is often unknown. For instance, Wakker and Klaassen
[87] note that, under the assumption of normality for ∆e and ∆c, the sampling distribution of Rˆ
is Cauchy distributed and thus standard statistical techniques of inference are not applicable21.
These concerns can be addressed by an alternative, but equivalent, formulation. The region of
acceptability of an intervention in the cost-eectiveness plane can be expressed as the region in
which
β(λ) := λ∆e −∆c > 0 (3.12)
21Several studies have established methods for constructing statistically rigorous condence intervals including
parametric methods (normal theory methods), nonparametric methods (e.g. standard bootstrap, bootstrap percentile),
and Bayesian methods [88, 97].
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where β(λ) is referred to as the Monetary Net Benet, which expresses the cost-eectiveness
criterion on a single, monetary scale by converting the ∆e units of eectiveness into λ∆e units of
money. In practice however, the explicit value of λ is unknown and subject to uncertainty. As such,
decision makers often infer the relative cost-eectiveness by means of a Cost-eective Acceptability
Curve, introduced by van Hout et al. [86], which plots the probability of β(λ) > 0 over a range
of suitable λ values, based on available evidence. Although the CEAC was originally formulated
under a frequentist approach, unknown parameters such as λ are often better understood in
a Bayesian framework where appropriate probability distributions can be used to address the
uncertainty. That is, the probability of β(λ) > 0 is only meaningful in a Bayesian framework.
The Bayesian extension to the above framework is relatively simple. We suppose that a general
observation x = (e, c) follows a distribution from a family F = {f(· | θ)}, indexed by the
population parameter θ = {θ0, θ1} where the true parameter value for intervention i is θi. The
likelihood of observing the data is then,
p(D | θ) =
∏
i∈I
ni∏
j=1
f(xij | θi) (3.13)
The uncertainty about θ can be formally described by probability distribution by starting from
a suitable prior distribution pi(θ) that represents beliefs on θ prior to observing any data. The
posterior joint density is then given by Bayes’ theorem,
p(θ | D) ∝ p(D | θ)pi(θ) (3.14)
from which it is possible to obtain the marginal distributions p(θi | D). With a functional form for
the posterior distribution, future (i.e. yet unobserved) health responses be evaluated by drawing
independent x from p(θ | D), thereby taking into account prior information and all individual
and population variability.
In order to assess the relative cost-eectiveness of interventions i ∈ (0, 1), we consider the means
of eectiveness and costs for each intervention. Denote by α(θ) = (µ(θ),γ(θ)) the mean of
the distribution f(· | θ), where µ(θ) = (µ(θ0), µ(θ1)) is the population mean eectiveness, and
γ(θ) = (γ(θ0), γ(θ1)) is the population mean costs. Accordingly, an intervention i (say i = 1) is
cost-eective relative to intervention i = 0 if it is more eective and cost less, i.e., if µ(θ1) > µ(θ1)
and cheaper, i.e., if γ(θ) < γ(θ0). We may also consider, similar to the Equation 3.10, the increment
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in mean eectiveness and costs,
∆µ = µ1 − µ0 (3.15)
∆γ = γ1 − γ0 (3.16)
For a given WTP threshold λ, the net benet is given by β(λ) := λ∆µ−∆γ , by which intervention
i = 1 is more cost-eective than intervention i = 0 if β(λ) > 0. However since µ and γ are
inherently functions of the random variable θ with associated posterior distribution p(θ | D)
(Equation 3.14), β is also a function of θ, and its posterior distribution is derived from the posterior
distribution of θ. We are interested in the probability of positive net benet, i.e.
Q(λ) = P(β(λ) > 0 | D) (3.17)
which is evaluated with the associated posterior distribution. A plot of Q(λ) against λ is called
the cost-eectiveness acceptability curve, which provides a visual representation of the uncertainty
of the cost-eective analysis. The CEAC is particularly useful in presenting the results of a
cost-eectiveness analysis as it provides a summary of the probability of cost-eectiveness by
varying WTP values, as decision-makers are often not ready to commit to a single value of λ.
The ultimate aim of the Bayesian extension is, then, to provide a framework for computing Q(λ)
for various assumptions and scenarios, utilizing prior information to inform on the parameters
θ 22. However, while this approach provides a well-justied interpretation for a CEAC, it is not
without inherent limitations. For instance, since the calculation of a Bayesian CEAC requires the
specication of the prior distribution, there exists many CEAC plots, one for each unique prior
distribution chosen, with no “correct” one. Using a non-informative prior also creates further
potential areas of question in the analysis.
Another criterion to investigate cost-eectiveness of interventions is the expected net benet,
ENB = E[β(λ) | D] = E[λ∆µ −∆γ] = λE[∆µ]− E[∆γ] (3.18)
where the expectations are now over the distribution of θ. It is clear to see that if ENB > 0 then
22The R package BCEA developed by Baio, Berardi, and Heath [98] describes in detail and provides the relevant
algorithms on how to perform health economic evaluations from the perspective of a Bayesian statistical approach.
The package can be used present the results of a Bayesian cost-eectiveness model, producing standardised and
highly customisable outputs. I have actively started to port this code over to Julia programming language, a fresh
new approach to numerical computing.
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λ >
E[∆µ]
E[∆γ]
(3.19)
which is similar to the approach to cost-eectiveness analysis based on the incremental cost-
eectiveness ratio, except inference about ENB is more straightforward to evaluate since it is a
ratio of expectations as opposed to an expectation of a ratio.
Although the above Bayesian approach accounts for individual variations and uncertainty of
the parameters by utilizing prior information, traditional economic evaluations have resorted to
additional sensitivity analysis methods to test the robustness of the results, particularly given
the irreversibility of decisions and the large nancial commitments of health care interventions.
Various dierent methods for SA have been recognized in health-economic literature. In Scenario
Analysis, likely values are selected for the parameters and the model is evaluated under all
these dierent scenarios. Although this leads to a spectrum of results, fails to consider the
possible correlation between the parameters of interest or the underlying uncertainty and thus no
probabilistic meaning can be placed on the results. More in line with the Bayesian approach, and an
alternative to Scenario Analysis is Probabilistic Sensitivity Analysis in which all input parameters are
considered as random variables and are therefore associated with relevant probability distributions.
Probabilistic Sensitivity Analysis is often conducted using a simulation approach, such that for
each simulation s = 1 . . . S, a value θ(s) is simulated from the distribution p(θ | D) and used in
the cost-eectiveness analysis. An alternative approach to PSA is based on the value of information
analysis, in which the overall value of the decision process is compared to that obtained in the
actual evaluation [57].
Sensitivity analysis methods are often required for when the data-generating process is inadequate
for a robust analysis, e.g., using randomized clinical trial data in which censored data is present such
as time to death. In our approach of using an ABM to model epidemiological relevant scenarios,
the computational model provides a data-generating process which naturally accounts for rst-
and second- order uncertainties, both on the individual and population level, through Monte Carlo
simulations. As such, it addresses some of the limitations of traditional data-generating processes
including censored data and small sample sizes, by incorporating more realistic prior information
and hence reaching stronger conclusions.
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3.4 Discussion
The integration of ABM computational systems with Bayesian cost-eectiveness analysis, along
with rapid developments in computational power and simulation models, provides a robust
framework for approaching more intuitive and complex problems in health care systems. In
such a framework, independent individuals (“agents”) are assigned context-specic attributes
such stage and severity of disease, and move through the model experiencing events at discrete
times, induced by independent decisions and localized interactions. The eects of implementing a
health intervention, e.g. vaccination, can then aect the probabilities of experiencing these events
or even generate new events, signicantly changing the outcomes of the model. Cost-inducing
events can be categorized and averaged over the relevant time horizon. Similarly, eectiveness
of the intervention can be quantied in terms of individual QALYs or DALYs. By modelling at
the individual level, ABM provides more exibility and oers greater realism over traditional
methods. The data-generation process of ABM enhances the utility of existing methods such as
randomized clinical trials in which data may be inadequate for decision-making and capturing
important heterogeneities.
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Chapter 4
Case Study 1:
Cost-Eectiveness of a Vaccine for
Haemophilus Influenzae Serotype ‘a’
In this case study, we highlight a human-to-human infection agent-based model of Haemophilus
inuenzae serotype ‘a’ (Hia) to simulate epidemic dynamics taking into account the relevant clinical
and epidemiological outcomes of Hia disease. This approach takes into consideration the age-
dependent individual characteristics and population heterogeneities, as well as the herd immunity
generated by naturally acquired or vaccine-induced protection. The model is then utilized to
conduct cost-eectiveness analysis of a potential vaccine candidate to inform government decision-
making and program delivery. This cost-eectiveness analysis was conducted in the context of
Nunavut, Canada where pre-dominantly the aboriginal population is aected by Hia.
4.1 Background
Haemophilus inuenzae (H. inuenzae) is a Gram-negative pathogenic bacterium that normally
resides in the upper respiratory tract and is responsible for a wide range of invasive infections [99,
100, 101]. H. inuenzae is divided into typeable and nontypeable strains based on the presence or
absence of a polysaccharide capsule. Typeable strains are further classied into six serotypes (‘a’
to ‘f’) based on their ability to react with antisera against recognized polysaccharide capsules [99,
100]. Typeable strains tend to cause invasive diseases such as meningitis, bacteremic pneumonia
and septic arthritis, while nontypeable strains generally cause non-invasive infections.
Among encapsulated serotypes, the serotype b (Hib) was one of the leading causes of invasive
disease with severe long-term sequelae in paediatric population and immunocompromised adults
worldwide prior to the introduction of universal infant immunization in the late 1980s [99, 102, 103].
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Since the introduction of Hib conjugate vaccines, the incidence of Hib has dramatically decreased
[104, 105], although it has not been eliminated and instances of resurgence have occurred [106,
107, 108]. However, surveillance programs, and clinical and epidemiological studies indicate that
serotype a (Hia) has now emerged as a signicant cause of invasive disease in some populations
and geographic regions, especially among indigenous communities of the North American Arctic,
including Alaska and northern Canada [109, 110, 111, 112, 113, 114, 115, 116]. A recent study
shows that in Northwestern Ontario, Canada, with a relatively high (82%) indigenous population,
the incidence of invasive Hia disease exceeds that of Hib in the pre-Hib vaccine era [117]. The
severity and outcomes of Hia infections are reminiscent to those of invasive Hib disease [118, 119].
The reasons for increased susceptibility of these specic populations to Haemophilus inuenzae
infections are still unknown [118, 120].
The global success of Hib immunization programs over the past 20 years suggests that a protein-
polysaccharide conjugated vaccine may be a solution to prevent Hia disease before it can open the
niche to spread in the general population [120, 121, 122]. In 2016, the National Research Council,
Public Health Agency of Canada, and the Canadian Institutes of Health Research organized a
workshop to examine the current state of Hia disease epidemiology, summarize immunology
and vaccine research, and identify potential vaccine solutions [121, 122]. The meeting included
representatives from academia, government public health agencies, hospital laboratories, and
federal departments involved in Aboriginal health. It concluded with a list of recommendations
and identied the key components to focus on in the development of an Hia vaccine including
completing pre-clinical studies (i.e. choice of protein carrier, obtaining regulatory approvals) and
policy to demonstrate value of a Hia vaccine [121]. As such, recent research eorts have now
established the pre-clinical proof of concept for a glycoconjugate vaccine against Hia; in a rst
study by Cox et al. [123], they show that antibodies to encapsulated Hia can be generated via
a conjugation strategy and that these antibodies can facilitate bactericidal killing of Hia strains.
However, the cost-eectiveness and economic impact of a potential vaccine candidate is a major
factor in decisions regarding vaccine production and implementation of immunization programs.
To address this knowledge gap, we developed an ABM to conduct a cost-eectiveness analysis
from a government perspective. In this chapter, we detail the modelling process and its analysis,
and present the results.
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4.2 Model Details and Parameterization
The general structure of the model is a single-agent, discrete-time ABM in which an agent
represents an individual human, characterized by a time-dependent vector of variables, including
their demographic information, health status, and immunity levels. The key characteristics of
each agent is illustrated in Algorithm 2.
Algorithm 2: The agent structure for human in HIA.
1 agent structure {
2 basic variables {
3 id ; // ID of the human
4 health ; // current health status
5 age ; // age in days - 365 days per year
6 expectancy ; // life expectancy
7 expectancyreduced ; // expectancy can be reduced due to invasive disease
8 agegroup
9 gender
10 };
11 model specic variables {
12 invtype ; // invasive sequelae
13 invdeath ; // death due to invasive disease
14 plvl ; // immunity level following vaccination or recovery
15 meetcnt ; // total no. of interactions
16 pvaccine ; // if primary vaccine series is received
17 bvaccine ; // if booster vaccine is received
18 dosesgiven ; // no. of doses given
19 vaccineexpirytime ; // duration of vaccine and naturally acquired protection
20 };
21 associated functions {
22 func initialize()
23 func interact()
24 func update()
25 };
26 } end;
4.2.1 Disease Model, States, and Outcomes
The disease model is based on the natural history of Haemophilus inuenzae infection, which
includes the states of latent (infected but not yet infectious), carriage (infectious without symptoms),
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Figure 4.1: Schematic diagram for transitions and natural history between epidemiological states in the
disease component of the ABM framework. The model does not include recurrent episodes of invasive
disease. We structured the health status of the individuals in the model based on the epidemiological and
clinical characteristics of Hia disease reported in previous studies [107, 124, 125].
symptomatic non-invasive disease, and symptomatic invasive disease. This infection stage of
each agent is stored as a dynamic attribute. Recovery from infection provides a high level of
protection, although there is a possibility of reinfection. Similar to vaccine-induced immunity,
naturally acquired immune protection is assumed to wane over time. The model does not include
the recurrence of invasive disease after the rst episode or during partial protection following
recovery from infection or vaccination. A schematic diagram for the model for infection dynamics
is illustrated in Figure 4.1. Clinical presentations of invasive Hia disease are analogous to those
caused by Hib, including meningitis, bacteraemic pneumonia, septic arthritis, and osteomyelitis
[118]. Bacterial meningitis is often associated with long-term sequelae even after full recovery
from the disease. Survivors of bacterial meningitis are at risk of developing life-long neurological
and behavioural decits leading to an impaired quality of life. These factors have been considered
in the cost-eectiveness analysis of an Hia vaccine.
All parameters governing the dynamics of the model are drawn from previously published literature.
Their descriptions are provided below and their relevant sources are provided in Table 4.3 and
Table 4.4.
4.2.2 Population and Demographics
An in-silico population of 100 000 agents (“individuals”) was generated, with a demographic
distribution identical to Nunavut, Canada, considering that Hia was the predominant serotype
causing invasive disease in the region during 2000 – 2012. Nunavut spans over 1,750,000 km2 of the
Canadian Arctic Archipelago, with a population of approximately 36,000 primarily inhabited with
Indigenous Inuit. We used the sero-epidemiological data reported for Nunavut to parameterize
and calibrate the model to the incidence of invasive Hia disease in dierent age groups [111, 114,
116]. During a 13-year period from 2000 to 2012, a total of 89 cases were serotyped, of which 43
were Hia with an overall rate of 13.7 per 100,000 population for the incidence of Hia disease [111].
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Age specic annual incidence rates were 274.8 per 100 000 for < 1 year old, and 61.2 per 100 000
for 1–4 years of age [111]. Taking this into account, we stratied our population into ve age
groups of <1, 1–5, 6–10, 11–59, and 60+ years of age to match the age-specic incidence rates and
other population characteristics used for model parameterization. In the simulation model, all
natural or disease-induced deaths were replaced by newborns to maintain a constant population
size.
4.2.3 Transmission and Infection Dynamics
Disease transmission (infection) occurs through contacts between susceptible and infectious
individuals in the state of carriage or symptomatic (but non-invasive) disease. Since invasive
disease often requires hospitalization, we assume that this state of disease is not a signicant
contributing factor to disease transmission.
In order to determine the contact structure between individuals, the population was stratied to
four age groups (0 to <2 years of age; 2 to <5 years of age; 5 to <10 years of age; and 10+ years of
age). The population contact structure was then derived by converting a relevant Who Acquires
Infection From Whom (WAIFW) matrix [107] for Alaska Native populations, whose elements
correspond to the product of the annual rate at which persons of age group i encounter persons
of age group j and the probability of transmission between a susceptible contact in age group i
and infectious contact in age group j, into a probability distribution of individuals in age group i
encountering individuals in age group j. See Table 4.1. Disease transmission occurred as a result of
Table 4.1: (a) Who Aquired Infection From Who matrix adapted from [107]. The elements correspond to the
product of the yearly rate at which individuals of age group i encounter persons of age group j and the
probability of transmission given contact between susceptible in age group i and infectious in age group j.
(b) Cumulative probability distribution for individuals in age group i encountering individuals in age group
j.
age group of
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0-2 2.11 0.15 0.53 0.03
2-5 0.55 0.40 0.50 0.12
5-10 0.56 3.68 3.61 0.13
>10 0.55 0.55 0.81 1.43
age group of
person j
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i
0-2 0.75 0.80 0.98 1.0
2-5 0.35 0.60 0.92 1.0
5-10 0.07 0.53 0.98 1.0
>10 0.17 0.33 0.57 1.0
rejection sampling-based (Bernoulli) trials where the chance of success is dened by a probability
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distribution. Given a contact between a susceptible (or recovered person) i and infectious person
j, the probability transmission of disease between this susceptible-infectious pair was calculated
by
Ptransmission(j → i) = Cβag(1− ρi) (4.1)
where βag is the age-specic transmission rate of person j calibrated by tting the model to
reported incidence rates (see Table 4.3), C is the reduction in transmission for individuals in
carriage state that assumed to be 50% less infectious compared to those in symptomatic state [126],
and ρi is the eect of naturally-acquired or vaccine-induced protection acting as a reduction factor
in the baseline transmission depending on the level of immune protection at the time of contact
(Table 4.3).
Upon successful transmission of the bacteria, infected individuals move to the latent state. The
latent period for an infected individual (following exposure and colonization) was sampled from
a truncated log-normal distribution with shape and scale parameters of 0.588 and 0.458, with
the mean of 2 days [127]. After the latent period has elapsed, individuals become infectious and
experience one of the clinical states of carriage, symptomatic, or invasive disease. The transition
to carriage or symptomatic (and invasive) states is determined through a probability distribution
dened by decision tree analysis, taking into account their infection stage, age, natural immunity
levels, and vaccination status. The decision tree paths are illustrated in Figure 4.2. For example,
a susceptible individual who has previously experienced infection has a 60%–90% chance of
transitioning to a carriage state. The duration of carriage varies in reported estimates, but it
can last from several days to several months [107, 128]. We sampled the carriage period from
a uniform distribution in the range of 14–70 days. The period for symptomatic infection was
sampled from a Poisson distribution with a mean of 2 days post symptoms onset. The symptomatic
(non-invasive) infection was considered non-communicable 2 days after the start of eective
antibiotic treatment [129]. Individuals who further progressed to invasive disease (manifested as
meningitis, pneumonia, or non-meningitis-non-pneumonia) were assumed to receive critical care
(i.e., hospitalization).
The length of hospital stay, obtained from the Canadian Institute of Health Information databases
[130], varies by age and depends on the type of invasive disease (Table 4.2). About 25% of deaths
caused by invasive disease due to bacterial meningitis occur within 2 days of hospitalization
[131]. To corroborate this estimate for individuals with fatal outcomes, the time spent in the
hospital before death was sampled from a truncated Poisson distribution with an average of 4
days and maximum of 10 days. The case fatality ratio was set to 9.1% for invasive disease [111].
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Figure 4.2: Progression through the Hia disease model by an infected agent.
Table 4.2: The length of hospital stay estimates for meningitis, pneumonia, and non-meningitis-non-
pneumonia (NMNP) outcomes of invasive disease due to Hia.
Parameter Description Baseline value (range) Source
Length of hospital stay (days) for invasive disease
Age Group Meningitis Pneumonia NMNP
<1 years 11.8 (10-14) 5 (3-7) 9.1 (7-11)
[130]
1-7 years 9.3 (7-11) 4 (2-6) 5.6 (5-7)
8-17 years 4.9 (3-7) 5.6 (4-7) 6.7 (5-9)
18-59 years 6.9 (5-9) 8.1 (6-10) 9.5 (8-11)
60-70 years 11.2 (9-13) 8.8 (7-11) 11.7 (10-14)
80+ years 19 (17-21) 8.4 (6-10) 12.2 (10-14)
Clearance of infection upon recovery was assumed to confer a transient immune protection of
95% that wanes over time between 2 and 5 years, thereby increasing the level of susceptibility to
re-colonization [107, 126, 127]. This protection level was considered adequate to prevent invasive
disease if infection occurred.
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4.2.4 Vaccination Schedules and Dynamics
Prevention of infection and invasive disease following vaccination was implemented based on the
number of vaccine doses and induced protection levels. In the context of Hib, clinical studies have
shown that a high level of protection requires at least two doses of conjugate vaccines [132, 133],
followed by a booster. In the absence of Hia vaccine data, we assumed that an Hia vaccine will
be rolled out in a similar schedule to the routine infant immunization programs against Hib in
Canada23 [134]. We therefore implemented vaccination in primary series with 3 doses scheduled
at 2, 4, and 6 months, followed by a booster dose at 18 months of age. Furthermore, considering
the similarity between Hia and Hib immune dynamics, vaccine ecacy was estimated based on
Hib conjugate vaccines against colonization and invasive disease. Vaccine specic parameters are
summarized in Table 4.3.
The durations of high protection following primary series (1–3 years) and booster vaccination
(6–10 years) were also sampled from estimates reported for vaccination against Hib [107]. For
the coverage of infant immunization, we used estimates of Hib vaccine coverage in Canada for
primary series (77%) and booster vaccination (93.5% of primary vaccinated infants) [135], though
recognizing that this coverage is even lower in remote regions like Nunavut. Since bacteria
with identical or similar polysaccharides to Haemophilus inuenzae can induce cross-protective
antibodies [136, 137], the accumulated exposure to such bacteria may raise some level of pre-
existing immunity. We therefore assumed a 50% protection against colonization for individuals
older than 5 years of age.
4.2.5 Model Calibration
The model was calibrated by tting baseline age-specic transmission probabilities β1, β2, β3, β4
to reported incidence rates (Table 4.3), by running simulations over a 30-year period in a no-
vaccine scenario corresponding to the period of 1991–2020. In particular, we ran simulations for
the rst 10 years as a warm-up period to reach a stationary state in the model. In the next 13
years, transmission probabilities β1, β2, β3, β4 were systematically adjusted over a 4-dimensional
parameter space to generated results that match incidence rates reported for dierent age-group,
with an overall rate of 13.2 per 100,000 population. All calculations were based on the average of
500 Monte-Carlo independent realizations. Each simulation was seeded independently with an
23The schedule for a routine Hib vaccination varies in dierent countries depending on the type of vaccine and the
region’s public health recommendations. For example, vaccination schedules for individual EU countries and specic
age groups can be found in https://vaccine-schedule.ecdc.europa.eu/.
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Table 4.3: Description of Haemophilus Inuenzae serotype ‘a’ model parameters and associated ranges.
Model parameters were largely derived from published literature.
Parameter description Baseline value (range) Source
Transmission rates for infection β
<1 year β1 = 0.0793
calibrated to
age-specic
incidence rates
1 – 5 years β2 = 0.0545
6 – 10 years β3 = 0.0491
10 – 60 years β4 = 0.0799
60+ years β5 = 0.0491
Relative transmission
of carriage 0.5 (0.3 - 0.7) [127]
Infection Parameters
Latent period
following colonization
Mean: 2 days
(Lognormal) [127]
Period of
communicability following
the start of treatment for
(non-invasive) symptomatic
2 days [129]
Infectious period for carriage 14 – 70 days [107, 128]
Disease Outcomes
Case fatality ratio 9.1% [111]
Probability of carriage Depends on ageand immunity [132, 138]
Probability of
invasive disease
Depends on age
and immunity [138]
Length of hospital stay Depends on ageand immunity [130]
Time spent in
hospital before death Mean: 4 days (Poisson) [131]
Immune Protection levels Against colonization Against Invasive
After 1st dose 50% 60%
[132, 133]
After 2nd dose 80% 90%
After 3rd dose 85% 93%
After booster dose (85%-95%) 97%
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Table 4.3: Description of Haemophilus Inuenzae serotype ‘a’ model parameters and associated ranges.
Model parameters were largely derived from published literature.
Parameter description Baseline value (range) Source
After recovery
from infection 95% 100%
Duration of immune protection against colonization
Naturally acquired 2 - 5 years
[107, 126]After completing primary series 1 - 3 years
After receiving a booster dose 6 - 10 years
Vaccine Coverage
Primary Series <1 year 77% [135]
Booster Dose <2 years 93% of primaryvaccinated individuals
individual in the latent state of the infection, and the events and outcomes were recorded over
time.
4.2.6 Cost-Eectiveness Analysis
For the cost-eectiveness analysis, we considered sequelae for individuals who develop invasive
disease through short and long-term nancial burden together with associated disabilities, and
possible reduction of life expectancy [139].
Direct costs borne by government were considered for the cost-eectiveness analysis, including
physician visits, immediate hospitalization for invasive disease, and long-term care for patients
with neurological sequelae. In addition, infants with invasive disease can’t be treated in their
home community due to the general lack of medical resources, expertise, equipment, and facilities
in the Canadian North and have to be medically evacuated to hospitals by the Medivac program
[140]. As these transportation costs can be signicant (upwards of $55,000 CAD), our analysis
takes considers the associated costs of the Medivac program. For minor sequelae, we considered
costs associated with special programs in pre-school (0-5), school years (6-18), and adult training
programs up to 22 years of age [141]. Bacterial meningitis is often associated with major sequelae
even after full recovery from the disease. Survivors of bacterial meningitis are at risk of developing
life-long neurological and behavioural decits leading to an impaired quality of life, and often
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require lifetime care [141] which carries a signicant nancial burden.
Costs of vaccine doses and administration were estimated based on a monovalent Hib conjugate
vaccine in Canada. Indirect costs associated with lost productivity and those incurred by house-
holds were not included in the cost-eectiveness analysis. All costs were converted to year 2017
Canadian dollars using the health and personal care component of the Canadian Consumer Price
Index [142] and future costs and health outcomes were discounted at 3% [143]. All cost parameters
and values are presented in Table 4.4.
Table 4.4: Cost parameters of Haemophilus Inuenzae treatments and interventions used in the cost-
eectiveness analysis.
Parameter description Estimated Costs Source
Medivac per evacuation $55,000 [121]
Physician visit $ 60 [130]
Hospitalization per night Meningitis Pneumonia NPNM
<1 years $11,076 $8,739 $10,237
[130]
1 – 7 years $8,856 $7,554 $7,088
8 – 17 years $6,833 $9,649 $7,508
18 – 59 years $9,994 $13,278 $11,696
60 – 79 years $16,088 $13,093 $13,645
80+ years $24,479 $9,983 $12,866
Long-term sequelae
Major (lifetime) $109,664/year
[141]
Minor (up to age 22)
Pre-school $21,434/year
School years $26,917/year
Adult training $13,957/year
Vaccination
Vaccine dose $20 [144]
Administration $8 [144]
Wastage 3% Assumed
Our model measures eectiveness in disability-adjusted life years (DALYs) averted, which was
estimated using the method recommended in the 1996 global burden of disease study [72]. Although
there is no data comparing the long-term disability rates of Hia and Hib, we considered existing
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weights (as measures of impairment of quality of life) for major and minor sequelae used for Hib,
corresponding to standard global burden of disease categories. These include cognitive decit,
hearing loss, motor decit, seizures, visual impairment, and multiple impairments [145, 146, 147].
For the scenarios with years of life lost due to bacterial meningitis, we assumed a reduction
of lifetime in the range 2–10 years [139]. The disability weights for minor and major sequelae
due to invasive Hia disease are presented in Table 4.5, along with their sources. To determine
cost-eective scenarios for vaccination, we calculated ICER values and condence intervals over
a 10-year period following the start of vaccination. Since the ICER is neither a sucient nor
an unbiased statistic, the uncertainty around the point estimates was assessed by applying a
non-parametric bootstrap method [87, 97]. A cost-eectiveness plane was then utilized to oer a
visual representation of the joint distribution and uncertainty along with 95% condence intervals.
Table 4.5: Disability weights for long-term major and minor sequelae of bacterial meningitis due to invasive
Haemophilus Inuenzae disease.
Parameter Description Parameter value (range) Source
Long-term sequelae Disability weights Major Sequelae Minor Sequelae
Cognitive diculties 0.469 0.01 0.024
[145, 146]
Seizure disorder 0.099 0.015 0
Hearing loss 0.223 0.032 0.006
Motor decit 0.388 0.012 0.013
Visual disturbance 0.223 0.01 0.001
Clinical impairments 0.359 0.07 0.008
Multiple impairments 0.627 0.019 0.008
4.3 Results
We implemented two vaccination strategies for infants during the warm-up period in the model
simulations, with primary vaccination coverages of 77% and 90%. For booster doses, we considered
coverages of 90% and 93%, and this coverage applied to those who have completed the primary
series. We also considered scenarios in which the expected individual lifetime was reduced due to
invasive disease outcomes [139]. Individuals who suer from invasive disease with major sequelae
can die prematurely before reaching expected life expectancy. This was modelled by a uniform
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Table 4.6: Summary of Hia simulation scenarios and their associated gures.
Scenario PrimaryCoverage
Booster
Coverage
Life-time
Reduction
Associated
Figures
I 77% 90% No 4.3, 4.4, 4.5, 4.6
II 90% 93% No 4.7, 4.8, 4.9, 4.10
III 77% 90% Yes 4.11, 4.12, 4.13, 4.14
IV 90% 93% Yes 4.15, 4.16, 4.17, 4.18
distribution with minimum of 2 years and a maximum of 10 years of life lost. These scenarios are
summarized in Table 4.6.
No lifetime reduction The results of the scenario with 77% coverage of primary series and 90%
coverage of booster dose and without any lifetime reduction due to invasive disease are illustrated
in Figure 4.3. In this gure, the overall and age-specic incidence rates are shown over a 40-year
time horizon. Years 10 to 22 correspond to a calibration period tting the model to Nunavut
incidence rates between 2000 and 2012. At year 30, the model diverged to two alternative settings.
The rst setting was in the absence of vaccination. The second setting included a routine infant
vaccination schedule. The results show that the vaccination program reduced the overall incidence
of invasive disease by 63.8% on average after 10 years of vaccination from 9.97 to 3.61 cases per
100 000 population. While there is a steady decline in the incidence of invasive disease in infants
following the start of vaccination, we observed an initial increase in the incidence of disease in
other age groups. This is explained by the eect of partial protection conferred by primary series
in infants, who are more likely to experience carriage if infected. Because the carriage period
is signicantly longer than symptomatic period, it can lead to more opportunities for infection
transmission in the population. With continuous vaccination and the rise of herd immunity, the
initial increase in the incidence of other age groups is followed by a sharp decline several years
after the onset of the vaccination program. The cost-eectiveness analysis was performed over
the course of 10 years post vaccination. Our results show that a routine vaccination program
with 77% primary coverage reduces the overall costs of disease management by 53.4% on average
by the tenth year, from CDN $1.863 million (95% CI: $1.229–$2.519) to CDN $0.868 million (95%
CI: $0.627–$1.120) (Figure 4.4). The cost categories included in the analysis were hospitalization,
MediVac, physician visits, and long-term disability care caused by major and minor sequelae
(Figure 4.5). The largest costs are associated with hospitalization and long-term care of major
sequelae. The distribution of costs in the presence and absence of vaccine were signicantly
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Figure 4.3: Scenario I. Overall (A) and age-specic (B) incidence rates over a 40-year simulation time period.
Years 10 to 22 correspond to a calibration period tting the model to Nunavut incidence rates between 2000
and 2012. At year 30, two alternative scenarios were run in the absence of vaccination (solid curves), and
with routine infant vaccination schedules (dashed curves).
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Figure 4.4: Scenario I. Overall average annual costs without vaccination (red) and with vaccination (blue)
over a 10-year period. Average costs and associated 95% condence intervals were computed by performing
nonparametric bootstrapping method over 500 independent simulations. Direct costs included physician
visits, hospitalization, MediVac, major and minor disability, and vaccination costs of doses per individual,
administration, and wastage. All costs are in 2017 Canadian dollars.
dierent (Mann-Whitney U test, p-value < 0.001).
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Figure 4.5: Scenario I. Distribution of dierent cost categories with their 95% condence intervals, obtained
using nonparametric bootstrap over 500 independent simulations without vaccination (A), and with routine
infant vaccination schedule (B). All costs are in 2017 Canadian dollars.
The associated cost-eectiveness plane, constructed using 5000 bootstrap replicates, of the net
costs and net eects (measured by DALYs) is illustrated in Figure 4.6. This gure, based on a
$30 vaccine cost per individual (including vaccine dose, administration and wastage) derived
from current Hib vaccine prices, shows the cost-eectiveness results with the inclusion and
exclusion of the MediVac program. All ICER values are clustered in the dominant region of the
cost-eectiveness plane, suggesting that a routine infant immunization program is expected to
be very cost-eective in both scenarios. Further interpretation of these results suggests that in
populations with similar incidence rates, vaccination would still be very cost-eective even when
critical care resources for management of invasive disease are available and exorbitant costs of
MediVac are averted.
Since an Hia vaccine has not yet been developed (and licensed), vaccination costs per individual
are undetermined. We therefore performed the same analysis for a plausible range of vaccine costs
per individual from $10 to $50 per dose. The results of ICER values, illustrated in Figure 4.6, show
that our conclusions of vaccine cost-eectiveness for a routine infant immunization program
remain intact.
Increasing the coverage of primary series to 90% did not alter the conclusion obtained for 77%
coverage of primary vaccine. Figure 4.7 shows the rapid decline in incidence by the tenth year
of vaccination and Figures 4.8 and 4.9 illustrate the cost savings associated with the vaccination
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Figure 4.6: Scenario I. (Left) Boxplots for ICER values with the inclusion (black) and exclusion (red) of
Medivac costs, as functions of vaccine costs per individual. Each box contains 50% of data points for ICER
values between the rst and third quartiles of the bootstrap sampling distribution. Whiskers represent
the remaining 50% data points. (Right) Cost-eectiveness plane using average costs (y-axis) and average
DALYs averted (x-axis) calculated on daily bases for two scenarios in the presence and absence of MediVac
program. The dashed lines indicate 95% condence intervals for the ICER values. The ICER values, clustered
in the southeast quadrant of the cost-eectiveness plane, indicate that the vaccination program is very
cost-eective.
programs. In Figure 4.10, ICER values are clustered in the dominant region of the cost-eectiveness
plane, suggesting that a routine infant immunization program is expected to be very cost-eective
with or without MediVac programs. Figure 4.10 describes the results of cost-eectiveness analysis
for a plausible range of vaccine costs.
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Figure 4.7: Scenario II. Overall (A) and age-specic (B) incidence rates over a 40-year simulation time
period. Years 10 to 22 correspond to a calibration period tting the model to Nunavut incidence rates
between 2000 and 2012. At year 30, two alternative scenarios were run in the absence of vaccination (solid
curves), and with routine infant vaccination schedules (dashed curves).
With lifetime reduction Similar results for incidence and vaccine cost-eectiveness were
obtained by considering a reduction in lifetime expectancy due to major sequelae. The reduction
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Figure 4.8: Scenario II. Overall average annual costs without vaccination (red) and with vaccination (blue)
over a 10-year period. Average costs and associated 95% condence intervals were computed by performing
nonparametric bootstrapping method over 500 independent simulations. Direct costs included physician
visits, hospitalization, MediVac, major and minor disability, and vaccination costs of doses, administration,
and wastage. All costs are in 2017 Canadian dollars.
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Figure 4.9: Scenario II.Distribution of dierent cost categories with their 95% condence intervals, obtained
using nonparametric bootstrap over 500 independent simulations without vaccination (A), and with routine
infant vaccination schedule (B). All costs are in 2017 Canadian dollars.
Figure 4.10: Scenario II. (A) Boxplots for ICER values with the inclusion (black) and exclusion (red) of
Medivac costs, as functions of vaccine costs per individual. Each box contains 50% of data points for ICER
values between the rst and third quartiles of the bootstrap sampling distribution. Whiskers represent
the remaining 50% data points. (B) Cost-eectiveness plane using average costs (y-axis) and average
DALYs averted (x-axis) calculated on daily bases for two scenarios in the presence and absence of MediVac
program. The dashed lines indicate 95% condence intervals for the ICER values. The ICER values, clustered
in the southeast quadrant of the cost-eectiveness plane, indicate that the vaccination program is very
cost-eective.
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Figure 4.11: Scenario III. Overall (A) and age-specic (B) incidence rates over a 40-year simulation time
period. Years 10 to 22 correspond to a calibration period tting the model to Nunavut incidence rates
between 2000 and 2012. At year 30, two alternative scenarios were run in the absence of vaccination (solid
curves), and with routine infant vaccination schedules (dashed curves).
in lifetime was modelled by a uniform distribution with minimum of 2 years and a maximum of
10 years. The results for vaccination coverages of 77% plus a 93% booster coverage are shown in
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Figure 4.12: Scenario III. Overall average annual costs without vaccination (red) and with vaccination
(blue) over a 10-year period. Average costs and associated 95% condence intervals were computed by
performing nonparametric bootstrapping method over 500 independent simulations. Direct costs included
physician visits, hospitalization, MediVac, major and minor disability, and vaccination costs of doses,
administration, and wastage. All costs are in 2017 Canadian dollars.
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Figure 4.11, Figure 4.12, Figure 4.13. Cost-eectiveness results of these scenarios are shown in
Figure 4.14. The results for vaccination coverages of 90% plus a 93% booster coverage are shown
in Figure 4.15, Figure 4.16, Figure 4.17. Cost-eectiveness results of these scenarios are shown in
Figure 4.18.
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Figure 4.13: Scenario III. Distribution of dierent cost categories with their 95% condence intervals,
obtained using nonparametric bootstrap over 500 independent simulations without vaccination (A), and
with routine infant vaccination schedule (B). All costs are in 2017 Canadian dollars.
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Figure 4.14: Scenario III.(A) Boxplots for ICER values with the inclusion (black) and exclusion (red) of
Medivac costs, as functions of vaccine costs per individual. Each box contains 50% of data points for ICER
values between the rst and third quartiles of the bootstrap sampling distribution. Whiskers represent
the remaining 50% data points. (B) Cost-eectiveness plane using average costs (y-axis) and average
DALYs averted (x-axis) calculated on daily bases for two scenarios in the presence and absence of MediVac
program. The dashed lines indicate 95% condence intervals for the ICER values. The ICER values, clustered
in the southeast quadrant of the cost-eectiveness plane, indicate that the vaccination program is very
cost-eective.
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Figure 4.15: Scenario IV. Overall (A) and age-specic (B) incidence rates over a 40-year simulation time
period. Years 10 to 22 correspond to a calibration period tting the model to Nunavut incidence rates
between 2000 and 2012. At year 30, two alternative scenarios were run in the absence of vaccination (solid
curves), and with routine infant vaccination schedules (dashed curves).
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Figure 4.16: Scenario IV. Overall average annual costs without vaccination (red) and with vaccination (blue)
over a 10-year period. Average costs and associated 95% condence intervals were computed by performing
nonparametric bootstrapping method over 500 independent simulations. Direct costs included physician
visits, hospitalization, MediVac, major and minor disability, and vaccination costs of doses, administration,
and wastage. All costs are in 2017 Canadian dollars.
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Figure 4.17: Scenario IV. Distribution of dierent cost categories with their 95% condence intervals,
obtained using nonparametric bootstrap over 500 independent simulations without vaccination (A), and
with routine infant vaccination schedule (B). All costs are in 2017 Canadian dollars.
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Figure 4.18: Scenario IV. (A) Boxplots for ICER values with the inclusion (black) and exclusion (red) of
Medivac costs, as functions of vaccine costs per individual. Each box contains 50% of data points for ICER
values between the rst and third quartiles of the bootstrap sampling distribution. Whiskers represent
the remaining 50% data points. (B) Cost-eectiveness plane using average costs (y-axis) and average
DALYs averted (x-axis) calculated on daily bases for two scenarios in the presence and absence of MediVac
program. The dashed lines indicate 95% condence intervals for the ICER values. The ICER values, clustered
in the southeast quadrant of the cost-eectiveness plane, indicate that the vaccination program is very
cost-eective.
4.4 Discussion
In this chapter, we sought to investigate the cost-eectiveness analysis of a potential Hia vaccine
candidate. Our motivation stems from a number of studies which have reported the emergence
and increasing rates of invasive Hia in the northern regions of Canada and Alaska [109, 110, 111,
112, 113, 114, 115]. It is now established that Hia is a signicant health burden in northern Canada,
particularly among aboriginal communities in Nunavut, with over 90% of cases being less than
two years of age. Surveillance of IMPACT (Canada’s Immunization Monitoring Program ACTive)
study between 2007 and 2015 reports a number of invasive Hia cases in major urban centres [121],
indicating that the disease is not just a risk to indigenous or northern populations. Immunization
with Hib conjugate vaccine confers no cross-protection against Hia, and therefore timely treatment
is essential to alleviate disease outcomes [99, 123]. The incidence rates of invasive Hia disease now
underscore the urgent need to prevent primary infection, especially among pediatric population.
The experience with Hib vaccines demonstrate that even highly vulnerable populations can be
successfully protected using immunization with protein-polysaccharide conjugated vaccines.
71
To this end, we developed an ABM system, which implements a population-based probabilistic ap-
proach, taking into account the herd immunity eects, in addition to encapsulating heterogeneities
in mixing patterns and transmission rates. We used the simulation results at the individual level
to calculate disability adjusted life years and calculate ICER values to quantify the benets of a
vaccination program. We employed a nonparametric bootstrap method to infer statistical prop-
erties of ICER measuring the sensitivity of the model outcomes to parameter variations, which
indicates the robustness of our results.
Using the cost estimates associated with treatment, vaccine administration, and long-term sequelae
of Hia, our results show that the introduction of a 3-dose primary series plus a booster dose
vaccination program is (dominantly) cost-eective. The total costs of such immunization program
is signicantly less than the costs required to provide life-time care of severely debilitated survivors
of invasive Hia. Our analysis suggests an overall 53.4% reduction in costs by the tenth year of the
vaccination program, with signicant decreases across all cost categories, including immediate
hospitalization and long-term disability. We assumed incremental increase in vaccine ecacy
with 50% (rst dose), 80% (second dose), and 85% (third dose) protection against infection in
primary series, and 85%-95% protection following a booster dose. These protection levels are
conservative compared to estimates reported in previous studies, indicating that vaccine ecacy
against invasive Hib disease after one, two or three doses of vaccine was 59%, 92% and 93%,
respectively [133].
The immunization coverage for Hia vaccine in our model is based on the estimates of Hib vaccine
coverage of 77% in Canada [135]. This coverage is even lower in northern populations with an
estimate of 68% in Nunavut [135]. These relatively low rates may be explained by the rising
prevalence of vaccine hesitancy in Canada [148]. The perceived (but untrue) lack of safety in the
Diphtheria, Tetanus, Pertussis, Hepatitis B, Polio, and Haemophilus inuenzae type b (DTaP-HB-
IPV-Hib) combination vaccine might be a contributing factor to reduced vaccination coverage [149]
There is also evidence of reduced immunogenicity of Hib in the DTaP-HB-IPV-Hib combination
vaccine compared to the monovalent Hib vaccine [150, 151, 152]. Thus, a possible solution to
increasing coverage and conserve immunogenicity would be to decouple the Hib vaccine from
other antigens and oer a conjugate bivalent Hib/Hia vaccine with an appropriate composition of
carrier proteins [120, 153]. In our study, increasing Hia vaccine coverage to 90% did not alter our
conclusion, and the vaccine remains dominantly cost-eective.
Despite the strengths of the ABM approach for cost-eectiveness analysis, this particular study
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has several limitations which the model did not account for, but warrant further investigation.
Currently, there is a clear lack of literature detailing the risks and nancial burdens of long-term
sequelae caused by Hia invasive disease. Furthermore, epidemiological and clinical databases
are mainly established for invasive cases, and therefore rates of non-invasive symptomatic or
carriage remain undetermined. For missing information on Hia, we parameterized our model
with available estimates pertinent to Hib infection. There is also evidence that young children,
especially infants may experience repeated invasive episodes after the initial one [154]. Our
model does not include recurrence of invasive disease, but considers the possibility of recurrent
symptomatic infection or carriage. We expect that repeated invasive disease would argue in
favor of an Hia vaccine being cost-eective. Our analysis was carried out in the context of the
Canadian healthcare system with publicly funded immunization programs. We conducted this
analysis from a governmental perspective, and not a societal perspective; yet we understand
that invasive disease and its outcomes can lead to signicant socioeconomic burden (e.g., loss of
productivity). We also did not consider the costs associated with research and development of
a vaccine candidate prior to its availability and use in immunization programs. Moreover, our
model did not include possible costs associated with potential adverse side-eects of vaccination.
However, based on low adverse rates of Hib and other conjugate vaccines [155], we do not expect
the inclusion of these costs in the model to change the conclusion of our cost-eectiveness analysis.
Despite these limitations, our results highlight the importance of vaccination against Hia, and
indicate that a routine infant immunization program will be highly cost-eective. While informing
decision-making on vaccination policies, this study provides a modelling framework for future
eorts in vaccine cost-eectiveness analysis. Given our results [50], we believe research and
development of an Hia vaccine candidate is an important public health investment.
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Chapter 5
Case Study 2 (Part I):
Dynamics of Zika Infection
In this chapter, we detail the construction of a multi-agent model in which two distinct types
of agents interact to generate the overall dynamics of the system. We present a case study for
Zika virus (ZIKV) infection (vector-borne disease), which employs populations of humans and
mosquitoes as agents in the chain of disease transmission. The model is utilized to uncover
important characteristics of ZIKV epidemics and transmission dynamics.
5.1 Background
ZIKV, an arbovirus from Flaviviridae family, is a mosquito-borne virus that is phylogenetically
similar to other important mosquito-borne aviviruses such as West Nile, dengue, and yellow
fever viruses [156, 157, 158]. In most cases, the infection presents no symptoms or only mild
symptoms, including mild fever, rash, arthralgia, arthritis, myalgia, headache, conjunctivitis, and
edema [156, 157]. However, prenatal ZIKV infection has been linked to adverse pregnancy and
birth outcomes, most notably microcephaly and other serious neurological disorders [159, 160,
161, 162]. ZIKV is transmitted to humans primarily through the bites of infectious mosquitoes
in the subgenus Stegomyia, particularly Aedes aegypti [163]. However, a number of cases have
been reported as a result of sexual contacts [164, 165, 166, 167] and blood transfusion [168] which
highlights the potential signicance of human-to-human transmission, especially when clinical
symptoms of ZIKV infection are absent.
In 2013-2014, the largest documented outbreak of ZIKV occurred in French Polynesia with an
approximated 11% of the population seeking medical attention for ZIKV related complications
[158]. Following this initial outbreak, ZIKV spread to 69 countries and territories worldwide
[158, 169], causing the World Health Organization (WHO) to declare a public health emergency
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of international concern [170]. Ideal climate conditions and the lack of countermeasures such
as vaccination or treatment intensied the ZIKV outbreaks, especially in regions such as Latin
America where the primary transmitting vector (i.e., Aedes aegypti mosquito) is endemic [171]. The
outbreaks spread to more northern latitudes, including several southern parts of the United States
[172, 173] and Canada [174]. Although ZIKV outbreaks have diminished in aected countries and
the WHO has ended its declaration, the risk of future outbreaks cannot be discounted. Sporadic
cases of ZIKV infection have occurred [175] and the threat of large outbreaks continues to exist
in the absence of countermeasures such as vaccination or prophylactic drugs. Although vector-
control programs can mitigate the impact of disease, ZIKV still remains an important public health
concern due to its potential to cause severe outcomes and long-term sequelae, especially in the
absence of estimates for the levels of herd immunity generated during the 2015-2016 outbreaks
and unknown transmissibility of asymptomatic compared to symptomatic ZIKV infection.
A signicant portion (up to 80%) of ZIKV infection is estimated to be asymptomatic without
presenting any clinical symptoms of illness [162, 176]. However, the extent to which asymptomatic
infection contributes to the overall disease incidence and its impact on the size of outbreaks has
not been quantied, which introduces substantial uncertainty into modeling studies of ZIKV
transmission dynamics and control interventions. For instance, this quantication is required
in understanding the levels of herd immunity in the population, which can prevent large-scale
outbreaks if it is suciently high.
To understand the eect of asymptomatic transmission to the overall ZIKV dynamics, a comprehen-
sive multi-agent ABM was constructed which encapsulates age-dependent individual attributes,
population heterogeneities, and the eect of herd immunity to simulates disease spread in hu-
mans through vector (i.e., mosquitoes) and sexual encounters. In particular, using a scaled-down
population with demographic characteristics resembling those of Colombia, one of the most
Zika-aected countries in South America, we generated simulations of the daily incidence of
ZIKV infection over a 2-year period. We also investigated the likelihood of observing a second
wave of ZIKV infection, estimated the cumulative attack rates for dierence levels of the relative
transmissibility of asymptomatic infection (compared to symptomatic infection), and calculated
the eective reproduction number of ZIKV infection at the end of rst wave. We demonstrate
that the occurrence of a second wave of ZIKV depends heavily on the relative transmissibility of
asymptomatic infection.
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5.2 Model Structure and Parameterization
The general structure of our model is a multi-ABM consisting of an in-silico population of human
and mosquito populations, characterized by a time-dependent vector of relevant variables and
parameters including their infection stage, demographic information, and disease outcomes. The
functional structure of the agents as implemented programatically are illustrated in Algorithm 3.
Each of the populations resides on a one-dimensional in-silico lattice. Due to the lack of individual
movement data, our model does not include mobility patterns (which may inuence the level of
exposure to the vector), but we did consider individual interactions only for the implementation
of sexual transmission (to be described later). The number of human and mosquito agents in each
population was determined based on a range of estimated basic reproduction numbersR0 of ZIKV
reported in previous studies [177, 178]. Particularly, using daily counts of conrmed ZIKV cases
obtained from the Secretary of Health of Antioquia, Colombia during January-April 2016, [177]
estimates the basic reproduction number in the range 1.9 to 2.8 with a mean of 2.216. Thus, the
abundance of mosquito, considered as the ratio of mosquito population to human population,
was varied between 2, 5 and 10 corresponding to scenarios ofR0 = 1.9,R0 = 2.2 andR0 = 2.8.
Given the short simulation time horizon, we ignored the individual births and deaths in the
populations, and therefore the population size remained constant.
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Figure 5.1: Schematic model diagram and natural history ZIKV infection.
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Algorithm 3: The dynamic variables and functions that characterize both types of agents
(human and mosquito) in the model.
1 human agent structure {
2 basic variables {
3 ID ; // ID of the human
4 health ; // infection stage of human
5 gender
6 };
7 model specic variables {
8 partner ; // monogamous partner of human
9 sexfrequency ; // total frequency of sex
10 sexprobability ; // probability of weekly sex
11 cumulativesex
12 };
13 associated functions {
14 func initialize()
15 func interact()
16 func update()
17 };
18 };
19 mosquito agent structure {
20 basic variables {
21 health ; // infection stage of mosquito
22 age
23 ageofdeath ; // lifespan
24 };
25 model specic variables {
26 numofbites ; // number of bites over lifespan
27 bitedistribution ; // how the bites are distributed
28 };
29 associated functions {
30 func initialize()
31 func interact()
32 func update()
33 };
34 } end;
The model is initialized by the corresponding functions which set up the one-dimensional lattice
environments, apply relevant demographics and sexual interaction rules, and mosquito-human
bite interactions. The evolution of time was in discrete time steps, representing a single day of
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the real-world system. This pattern was repeated over a 2-year time horizon, with 2000 Monte
Carlo iterations for each scenario. All simulations started at day “0” in a high-temperature season.
In the next few sections, we describe the general components of our model. All baseline values
of the model parameters are based on published estimates and are summarized in Table 5.1. A
schematic diagram describing the multi-agent model is illustrated in Figure 5.1.
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Figure 5.2: Population age and sex distributions of Colombia derived from census data [179].
Human Demographics For the human population, individual age and sex attributes were
sampled from relevant distributions of population demographics of Colombia (Figure 5.2). Natural
death for the human population was not implemented given the relatively short time-span of
the epidemic dynamics. An epidemiological report from the US Center for Disease Control and
Prevention indicates that about 1% of Zika cases resulted from sexual contact with travellers
to aected areas [180]. Previous studies [52, 181] have omitted this route of transmission for
ZIKV infection dynamics due to its low risk [182]. Here, we include the possibility of ZIKV
transmission through sexual contact in the model, and consider the range of 1–5% for the risk
of transmission to account for its variability. To implement ZIKV sexual transmission dynamics
in the model, we considered individuals above age of 15, and created partners in a monogamous
context. The frequency of sexual encounters per week for partnered individuals was sampled
from their associated distributions corresponding to sex and age of the individuals. Figure 5.3
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Figure 5.3: Age-dependent probability distributions of weekly frequency of sexual encounters among adult
men and women [183, 184].
represents weekly frequency of sexual encounters derived from a national probability sample
among adult men and women in the United States [183, 184]. For an individual of age ai years,
the partner was selected with an age in the range ai ± 5. We assumed the same risk of ZIKV
sexual transmission for infectious individuals to their susceptible partners. Demographic related
variables were static and did not change during the simulation.
Mosquito Lifespans and Biting Process Due to similarities between ZIKV and dengue infec-
tions, being primarily transmitted through the bites of infectious Aedes aegypti mosquitoes, we
relied on parameter estimates reported in the literature for dengue infection. We assumed that
mosquitoes have a lifespan [185] determined by a hazard function given by [185]
H(t) =
aebt
1 + as
b
(ebt − 1) (5.1)
Using Equation (5.1), we generated discretized distributions for sampling lifetime of mosquitoes
shown in Figure 5.4. For the season with a high temperature, the lifetime of mosquitoes was
sampled with a = 0.0018, b = 0.3228, and s = 2.146, having the mean of 19.6 days [185]. The
longevity of mosquitoes for the season with a low temperature was sampled from the distribution
generated using a = 0.0018, b = 0.8496, and s = 4.2920, with the mean of 11.2 days. After 180
days of simulations, mosquito lifespans were sampled from the distribution corresponding to the
low temperature season. All deaths in the mosquito population were replaced, thus maintaining a
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Figure 5.4: Distributions of mosquitos lifespan during seasons with: (A) high temperature (a=0.0018,
b=0.3228, s=2.1460) and (B) low temperature (a=0.0018, b=0.8496, s=4.2920).
constant population size.
The mosquito bites were implemented as a Poisson process, with a biting rate of 0.5 per day within
the reported range 0.33–1 in previous studies [186, 187, 188]. This corresponds to an average of
1 bite every 2 days. We considered the half-life of a single mosquito as the mean of a Poisson
distribution, from which the number of bites was sampled. Bites for each mosquito were randomly
distributed over the mosquito lifetime, with a maximum of 1 bite per day. We assumed that a single
bite corresponds to a full blood meal for a mosquito and has the potential for disease transmission.
Infection Stages The human population was constructed to encapsulate several epidemiological
statuses of susceptible, exposed and incubating, infectious (i.e., symptomatic and asymptomatic),
and recovered. The infection stages of vector population included compartments of susceptible,
infected and incubating, and infectious. We assumed that recovered individuals are fully protected
against ZIKV re-infection (at least for 3 years).
Transmission Dynamics ZIKV transmission from humans to mosquitoes occurred as a result
of Bernoulli trials where the chance of success is dened by a transmission probability distribution.
This probability was calculated at the time of bite from a susceptible mosquito to an infectious
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human (or vice versa) by
P [M→ H] = P [H→ M] = 1− (1− βvec)N
where βvec is the baseline probability of transmission for symptomatic cases and N is the number
of bites of a single mosquito to an infectious individual. This baseline probability of transmission
was determined by calibration of the model to the given basic reproduction number in the range
1.9 to 2.8 as estimated in [177]. Recent studies suggest that symptomatic cases reached levels
of molecular viral load that were signicantly higher than asymptomatic cases [189]. Although
this level depends on the time of sampling, it may be an indication of lower transmissibility of
asymptomatic infection. We therefore considered scenarios in which the reduction factor in the
transmissibility of asymptomatic infection compared with symptomatic infection was in the range
0.1 to 0.9. This was implemented as a reduction factor in transmission parameter βvec. Similarly,
any potential interventions to blunt transmission such as reducing the number of mosquitoes or
use of condoms was also included in the model as a reduction factor in βvec. Transmission values
βvec ranged from 0.2851 to 0.3947 (obtained from calibration, §5.2.1) depending on the assumed
relative transmissibility of asymptomatic infection compared to symptomatic infection from 0.9
to 0.1.
For sexual transmission of ZIKV, we considered the probability
P [H→ H] = 1− (1− βsex)
where βsex is the risk of sexual transmission per encounter. If an infectious individual was at
least 15 years old and had a sexual partner, we used Bernoulli trials for each sexual contact
where the weekly frequency of contacts with the susceptible partner was sampled from age and
sex-dependent distributions with a maximum of one encounter per day. We assumed the risk
of sexual transmission was included only during the infectious period. Although this risk may
continue for several days or weeks following recovery [190, 191], our assumption is justied
due to uncertainty in the duration of sexual transmission at the individual level. The associated
pseudocode describing the transmission dynamics is illustrated in Algorithm 4.
Upon successful transfer of ZIKV, individuals experience an intrinsic incubation period (IIP) before
becoming infectious [192, 193]. We sampled the IIP for an infected individual from a log-normal
distribution with the shape and scale parameters of 1.72 and 0.21, and mean of 5.7 days (95% CI:
4–8), as estimated for dengue infection [192]. In the infectious stage, individuals are classied as
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Algorithm 4: Pseudocode implementation of ZIKV transmission dynamics.
input :βvec = calibrated transmission probability
input :H = humans with an assigned partner
1 for each mosquito m do
2 if m will bite then
3 h = random(non-isolated humans) ;
4 if h.health = SUSC and m.health = INF then
5 r = rand()
6 r ≤ β =⇒ h.health = INF
7 end
8 if h.health = SYMP and m.health = SUSC then
9 r = rand()
10 r ≤ β =⇒ h.health = INF
11 end
12 if h.health = ASYMP and m.health = SUSC then
13 r = rand()
14 α = reduction factor
15 r ≤ α · β =⇒ h.health = INF
16 end
17 end
18 end
19 for each human h ∈ H do
20 p = partner ;
21 if h.health = INF and p.health = SUSC then
22 βsex = calculate probability(h)
23 if P = true then
24 βe = h.sexprobability · (1− p.condom reduction)
25 end
26 end
27 end
either symptomatic or asymptomatic, with (40–80%, sampled uniformly) of infected individuals
experiencing asymptomatic infection without developing clinical symptoms [162, 176, 193]. The
infectious period was sampled from a log-normal distribution with the shape and scale parameters
of 1.54 and 0.12, and mean of 4.7 days (95% CI: 3.8–5.7) [194]. For a bite through which a mosquito
was infected, the extrinsic incubation period (EIP) was sampled from a log-normal distribution
with the shape and scale parameters of 2.28 and 0.21, and mean of 10 days (95% CI: 7–14) [195].
Once this period elapsed, the mosquito became infectious for its remaining lifespan.
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Table 5.1: Zika model parameters values and their associated ranges. Transmissibility values ranged
depending on the assumed relative transmissibility of asymptomatic infection compared to symptomatic
infection from 0.1 to 0.9. Risk of infection through sexual encounter was assumed to be low [182].
Parameter Description Baseline value (range) Source
Transmission rates for infection
Human to mosquito 0.2851 to 0.3947 based calibration process
Mosquito to human on relative transmission
Relative transmissibility of
asymptomatic infection
0.1 to 0.9 assumed
Human infection parameters
Intrinsic incubation period Lognormal(µ = 1.72, σ = 0.2) [178, 193]
Infectious period Lognormal(µ = 1.54, σ = 0.12) [196]
Risk of infection through sexual
encounter
1% - 5% assumed
Fraction of infected cases
experiencing asymptomatic
infection
40% - 80% [162, 176]
Mosquito lifespan and infection parameters
Lifespan (high temperature) mean: 19.6 days [185]
Lifespan (low temperature) mean: 11.2 days [185]
Extrinsic incubation period Lognormal(µ = 2.28, σ = 0.21) [195]
Number of mosquito bites Poisson(λ = mosquito half-life) [187, 188]
5.2.1 Calibration
The baseline transmission probability βvec was determined by calibrating the model to estimated
basic reproduction numbers of Antioquia, Colombia. These estimates were in the range 1.9–
2.8 with the mean of 2.2 [177, 178], determined using daily counts of conrmed ZIKV cases.
Accordingly, we calibrated for three scenarios of basic reproduction numbersR0 = 1.9,R0 = 2.2
andR0 = 2.8. For eachR0 scenario, we considered a reduction factor in the transmissibility of
asymptomatic infection compared with symptomatic infection in the range 0.1 to 0.9.
Calibration simulations were started by seeding the simulation with 1 infected human in the IIP
stage and a fully susceptible mosquito population. To obtain the average R0, each simulation
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Figure 5.5: Calibrated probabilities of ZIKV transmission based on the reproduction number and ratio of
mosquito to human populations.
was run until this initial infected person recovered. The basic reproduction number R0 was
then calculated by counting the average number of secondary infections over 1000 Monte Carlo
simulations, generated by the initial case either through mosquito bites or sexual transmission.
This was repeated while sweeping over a range of transmission values and relative transmissions
of asymptomatic infection. A linear regression was applied to the resulting data in order to
determine βvec values, illustrated in Figure 5.5.
5.3 Results: The Role of Asymptomatic Infection
Disease outcomes and cumulative daily incidence throughout each simulation were recorded and
averaged for each scenario to estimate attack rates during an outbreak. We dened an outbreak if
the cumulative incidence of infection during the third disease generation was greater thanR0,
which implies a sustained transmission within the rst two disease generation intervals with
R0 exceeding 1. Simulations in which there was no more transmission of ZIKV after the third
generation interval were excluded in estimating the attack rate. We assumed a gamma distribution
for the generation interval with the mean of 14 days and standard deviation of 2 days [197]. The
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eective reproduction number Re at the end of an outbreak was estimated using the formula
Re =
(
number of susceptibles at the end of outbreak
number of susceptibles at the start of outbreak
)
R0
In addition, the probability of a second wave was calculated by considering the fraction of
simulations that resulted in an outbreak in the second year following the outbreak in the rst year.
Simulations were run to obtain the daily case incidence of ZIKV infection for calibrated scenarios,
corresponding to basic reproduction numbers R0 of 1.9, 2.2 and 2.8. For each scenario, we
further considered disease spread when the contribution of symptomatic ZIKV infection to
disease transmission through mosquitoes was reduced by 10%, 30% and 50%. This reduction was
implemented probabilistically for each mosquito bite when the infectious case was symptomatic.
For R0 = 2.2, Figure 5.6 shows the daily incidence of symptomatic infection over a two year
period for various levels of the relative transmissibility of asymptomatic infection and dierent
reduction levels of Zika transmission from symptomatic cases to mosquitoes. As the contribution
of symptomatic infection to disease spread reduced (e.g., due to vector control interventions), the
occurrence of a second wave of outbreak required a higher level of the relative transmissibility of
asymptomatic infection. The probability of a second wave of infection occurring as a function of
the relative transmissibility of asymptomatic infection is illustrated in Figure 5.7.
With 10% reduction of transmission from symptomatic cases, the probability of a second wave
occurring increased from 0.19 to 0.48 when the relative transmissibility of asymptomatic infection
increased from 10% to 90%. We observed the same increasing trend (with lower probabilities) for
higher levels of transmission reduction.
We also estimated the eective reproduction numbersRe and the cumulative attack rates at the
end of the rst wave of ZIKV outbreak. Figure 5.9 shows boxplots for the range ofRe estimates
as a function of the relative transmissibility of asymptomatic infection when R0 = 2.2 at the
onset of the outbreak. With a 10% reduction of ZIKV transmission from symptomatic cases,
the median Re was estimated at 2.04 (95% CI: 1.64–2.18) for 10% relative transmissibility of
asymptomatic infection. The mean attack rate for this scenario (Figure 5.10) was estimated at 9%
(95% CI: 8.4%–9.4%). When the relative transmissibility increases to 90%, the medianRe was
1.99 (95% CI: 1.50, 2.18) with an average attack rate of 11% (95% CI: 10.5%–11.3%). As the level
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Figure 5.6: Incidence of symptomatic ZIKV infection over a two year period for the rst and second waves,
when the contribution of symptomatic ZIKV infection to disease transmission through mosquitoes was
reduced by 10% (A1–E1), 30% (A2–E2), and 50% (A3–E3). The relative transmissibility of asymptomatic
infection is 10% (A1,A2,A3), 30% (B1,B2,B3), 50% (C1,C2,C3), 70% (D1,D2,D3) and 90% (E1,E2,E3). The red
curve represents the average of sample realizations for incidence curves. Figure corresponds to model
scenario calibrated to basic reproduction numberR0 = 2.2.
of ZIKV transmission from symptomatic cases decreased, the medianRe declined towardsR0
(Figure 5.9), giving lower attack rates for the rst wave (Figure 5.10). Overall, we estimated attack
rates to range from 2.2% to 11% for the scenarios simulated here withR0 = 2.2. These estimates
are consistent with those reported for Colombia during outbreaks through February 2017 [52].
We also estimated the cumulative number of Zika infection resulted from the virus transmission
through sexual encounter. Figure 5.8 shows the range of these estimates for dierent relative
transmissibility of asymptomatic infection in the absence of any control measure. For a low
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Figure 5.7: The probability of a second wave of ZIKV outbreak occurring as a function of the relative trans-
missibility of asymptomatic infection. Color bars correspond to scenarios in which infection transmission
from symptomatic cases to mosquitoes was reduced by 10% (dark blue), 30% (light blue), and 50% (grey).
Figure corresponds to model scenario calibrated to basic reproduction numberR0 = 2.2.
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Figure 5.8: Estimated range of cumulative incidence of sexual transmission during the rst wave of ZIKV
infection as a function of the relative transmissibility of asymptomatic infection, in the absence of condom
use (blue) and 50% condom use during symptomatic infection (red). Figure corresponds to model scenario
calibrated to basic reproduction numberR0 = 2.2.
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Figure 5.9: Eective reproduction number Re at the end of the rst wave as a function of the relative
transmissibility of asymptomatic infection. The contribution of symptomatic ZIKV infection to disease
transmission through mosquitoes was reduced by 10%, 30%, and 50%. Figure corresponds to model scenario
calibrated to basic reproduction numberR0 = 2.2.
relative transmissibility (10%), the median number of sexual transmission is 10.6 (95% CI: 0, 31.5),
which accounts for 1.16% of the cumulative incidence (95% CI: 0, 2.29%). When the relative
transmissibility increased to 90%, the median number of sexual transmission increased to 23 (95%
CI: 0, 77). This corresponds to 2.4% of the cumulative incidence (95% CI: 1.02, 3.88%). These
results suggest that the previous work in a deterministic context [198] may have overestimated
the upper bound of the fraction of cases due to sexual transmission.
We observed similar results for scenarios ofR0 = 1.9 andR0 = 2.8. Incidence of symptomatic
ZIKV infection over a two year period are shown in Figure 5.11 and Figure 5.12. The probability
of a second wave of ZIKV outbreak and eective reproduction numbers at the end of the rst
wave are shown in Figure 5.13 and Figure 5.14. Attack rates (cumulative incidence per 10,000) of
ZIKV infection over a 2-year period are shown in Figure 5.15 and Figure 5.16. Estimated range of
cumulative incidence of sexual transmission during the rst wave is shown in Figure 5.17. These
results suggest that the relative transmissibility of asymptomatic infection is a key parameter in
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Figure 5.10: Attack rates (cumulative incidence per 10,000) of ZIKV infection over a 2-year period for the rst
and second waves, when the contribution of symptomatic ZIKV infection to disease transmission through
mosquitoes was reduced by 10% (A1–E1), 30% (A2–E2), and 50% (A3–E3). The relative transmissibility
of asymptomatic infection is 10% (A1,A2,A3), 30% (B1,B2,B3), 50% (C1,C2,C3), 70% (D1,D2,D3) and 90%
(E1,E2,E3). The red curve represents the mean attack rate in each scenario within its 95% condence interval.
Figure corresponds to model scenario calibrated to basic reproduction numberR0 = 2.2.
estimating the burden of disease through dierent modes of transmission (i.e., mosquito bites and
sexual interactions) and evaluating the probability of a second wave of ZIKV infection.
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Figure 5.11: Incidence of symptomatic ZIKV infection over a two year period for the rst and second waves,
when the contribution of symptomatic ZIKV infection to disease transmission through mosquitoes was
reduced by 10% (A1–E1), 30% (A2–E2), and 50% (A3–E3). The relative transmissibility of asymptomatic
infection is 10% (A1,A2,A3), 30% (B1,B2,B3), 50% (C1,C2,C3), 70% (D1,D2,D3) and 90% (E1,E2,E3). The red
curve represents the average of sample realizations for incidence curves. Figure corresponds to model
scenario calibrated to basic reproduction numberR0 = 2.8.
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Figure 5.12: Incidence of symptomatic ZIKV infection over a two year period for the rst and second waves,
when the contribution of symptomatic ZIKV infection to disease transmission through mosquitoes was
reduced by 10% (A1–E1), 30% (A2–E2), and 50% (A3–E3). The relative transmissibility of asymptomatic
infection is 10% (A1,A2,A3), 30% (B1,B2,B3), 50% (C1,C2,C3), 70% (D1,D2,D3) and 90% (E1,E2,E3). The red
curve represents the average of sample realizations for incidence curves. Figure corresponds to model
scenario calibrated to basic reproduction numberR0 = 1.9.
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Figure 5.13: The probability of a second wave of ZIKV outbreak occurring as a function of the relative trans-
missibility of asymptomatic infection. Color bars correspond to scenarios in which infection transmission
from symptomatic cases to mosquitoes was reduced by 10% (dark blue), 30% (light blue), and 50% (grey).
Top and bottom gures correspond to model scenario calibrated to basic reproduction numbersR0 = 2.8
andR0 = 1.9, respectively.
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Figure 5.14: Eective reproduction number at the end of the rst wave as a function of the relative
transmissibility of asymptomatic infection. The contribution of symptomatic ZIKV infection to disease
transmission through mosquitoes was reduced by 10%, 30% , and 50%. Top and bottom gures correspond
to model scenario calibrated to basic reproduction numbersR0 = 2.8 andR0 = 1.9, respectively.
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Figure 5.15: Attack rates (cumulative incidence per 10,000) of ZIKV infection over a 2-year period for the rst
and second waves, when the contribution of symptomatic ZIKV infection to disease transmission through
mosquitoes was reduced by 10% (A1–E1), 30% (A2–E2), and 50% (A3–E3). The relative transmissibility
of asymptomatic infection is 10% (A1,A2,A3), 30% (B1,B2,B3), 50% (C1,C2,C3), 70% (D1,D2,D3) and 90%
(E1,E2,E3). The red curve represents the mean attack rate in each scenario within its 95% condence interval.
Figure corresponds to model scenario calibrated to basic reproduction numberR0 = 2.8.
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Figure 5.16: Attack rates (cumulative incidence per 10,000) of ZIKV infection over a 2-year period for the rst
and second waves, when the contribution of symptomatic ZIKV infection to disease transmission through
mosquitoes was reduced by 10% (A1–E1), 30% (A2–E2), and 50% (A3–E3). The relative transmissibility
of asymptomatic infection is 10% (A1,A2,A3), 30% (B1,B2,B3), 50% (C1,C2,C3), 70% (D1,D2,D3) and 90%
(E1,E2,E3). The red curve represents the mean attack rate in each scenario within its 95% condence interval.
Figure corresponds to model scenario calibrated to basic reproduction numberR0 = 1.9.
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Figure 5.17: Estimated range of cumulative incidence of sexual transmission during the rst wave of ZIKV
infection as a function of the relative transmissibility of asymptomatic infection, in the absence of condom
use (blue) and 50% condom use during symptomatic infection (red). Top and bottom gures correspond to
model scenario calibrated to basic reproduction numbersR0 = 2.8 andR0 = 1.9, respectively.
5.4 Discussion
The results above show that the relative transmissibility of asymptomatic infection is a key
epidemiological parameter that can signicantly inuence disease dynamics, especially in the
context of intervention strategies. We considered scenarios in which the contribution of ZIKV
transmission from symptomatic cases is reduced as a result of isolation via hospitalization, self-
isolation, or through disease interventions. For instance, interventions to reduce exposure to
infectious bites may include mosquito avoidance through full clothing, mosquito repellents, and
spraying and larviciding. Similarly, condom use was considered as an eective intervention to
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prevent sexual transmission of the Zika virus. In an exploratory analysis, we found that the
use of condoms could signicantly reduce the risk of sexual transmission (Figure 5.8, red bars);
however, this reduction depends on the level of condom use. We observed that when interventions
are absent or their eectiveness is very low in blunting the contribution of symptomatic cases
to ZIKV transmission, a second wave is more likely to occur as the relative transmissibility of
asymptomatic infection increases (Figures 5.6, 5.12, 5.11). Furthermore, the occurrence of a second
wave of ZIKV infection requires higher values of the relative transmissibility as the eectiveness
of interventions increases.
The relative transmissibility of asymptomatic infection has also important implications for the use
of the eective basic reproduction numberRe in determining the potential for a second wave. For
example, the probability of a second wave occurring is over 26% for a relative transmissibility of 0.5
when the transmission of ZIKV from symptomatic cases is reduced by 10% on average (Figure 5.6,
E1). In this case, the estimatedRe has the median of 2.05 (95% CI: 1.71, 2.18), suggesting that the
herd immunity is relatively low to prevent a second wave (Figure 5.6, C1). In fact, the median attack
rate is estimated at 6.6% (95% CI: 6.2%, 6.9%). However, for the same relative transmissibility, the
corresponding probability for the scenario in which the transmission of ZIKV from symptomatic
cases is reduced by 30% remains below 9%. In this case, whileRe is above 1 (median: 2.11) due
to the eectiveness of interventions and low attack rates of the rst wave, the second wave is
unlikely to occur (Figure 5.6, C2). Increasing the relative transmissibility leads to higher attack
rates of the rst wave (Figure 5.6), but may also increase the probability of a second wave unfolding
(Figure 5.7). These results indicate that the level of herd immunity in the population cannot be
accurately measured without quantitative estimates of the contribution of asymptomatic infection.
In the context of the 2015–2016 ZIKV outbreaks in the Americas, previous work suggests that Zika
spread may have contributed to the generation of herd immunity, which prevented the occurrence
of a second wave of widespread ZIKV infection in the presence of sustained control eorts [199].
A recent stochastic model of ZIKV spread through the Americas estimates reporting and detection
rates of 1–2% [52]. Without considering the eect of interventions or behavioural changes due
to increased awareness, the model in [52] projects a signicant variation amongst attack rates
in dierent countries, and illustrates the importance of seasonal factors in the introduction
and occurrence of multiple waves of ZIKV infections. As expected [52, 200] and shown in
our simulations, these epidemic waves coincide with the seasonal pattern of mosquito lifetime.
However, our results also indicate that the occurrence of a second wave depends on other factors,
such as transmission reduction measures that largely inuence the contribution of symptomatic
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infection to disease spread, and more importantly, the silent transmission of the Zika virus from
asymptomatic infection. Quantifying asymptomatic transmission requires specic data on the
magnitude and duration of infectiousness in infected individuals, combined with measures of
exposure to biting mosquitoes during the course of infection [201]. While we do not address the
contribution of asymptomatic infection to herd immunity, our study highlights its importance in
understanding the disease dynamics and the epidemiological trends observed in countries aected
by the Zika virus. In a recent study [202], the authors highlight the potential for large errors that
can arise in quantifying the contribution of asymptomatic infection to the overall cumulative
incidence in an infectious disease outbreak These considerations call for further biological, clinical,
and epidemiological studies to provide estimates of the relative transmissibility of asymptomatic
infection, given its central role in determining the levels of herd immunity.
The importance of asymptomatic transmission has also been recognized in other vector-borne
diseases including dengue and malaria [203, 204]. While infectiousness and severity of the
disease are strongly correlated with viremia, outbreaks of dengue associated with low viremia
have been reported [205, 206, 207]. It has been shown that, at a given level of dengue viremia,
infected individuals with no symptoms or prior to the onset of symptoms are more infectious to
mosquitoes than those with symptoms [203]. In the case of Zika, asymptomatic cases with low
viremia may also play a role in silent transmission of infection through sexual contacts and blood
transfusion. Within the context of previous studies [52, 181, 199, 200], our results underscore the
need to characterize and quantify the transmission potential for asymptomatic ZIKV infection.
Quantitative modelling can be used to predict the risk of infection more accurately, identify
eective public health measures, and suggest strategies to counter vector-borne diseases with
similar characteristics.
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Chapter 6
Case Study 2 (Part II):
Cost-Eectiveness of a Zika Vaccine
In this chapter, we extend the previously developed ZIKV transmission model in Chapter 5 to
include vaccination dynamics and Zika-associated sequelae during pregnancy. We utilize the
extended model to inform on the socio-economic impact of a vaccination program in 18 countries
in the Americas aected by the 2015-2017 ZIKV outbreaks, with a particular focus on Colombia
which was one of the most ZIKV aected country. We perform this analysis using country-specic
parameter estimates extracted from published studies with a plausible range of costs of vaccine
administration.
6.1 Background
Several studies have shown the potential for ZIKV to cause severe outcomes and long-term
sequelae, including microcephaly with brain abnormalities and neurological disorders in infants,
and Guillain-Barré syndrome (GBS) in adults [160, 161, 162]. Furthermore, congenital ZIKV
syndrome has been reported to occur in the same proportion of women with asymptomatic
infection as symptomatic ZIKV infection during pregnancy [208]. These outcomes have instigated
global eorts for the development of a safe and eective Zika vaccine. A prophylactic vaccine has
the potential to reduce disease incidence and eliminate birth defects of prenatal ZIKV infection in
future outbreaks.
At its rst consultation in March 2016, the World Health Organization and United Nations Inter-
national Children’s Emergency Fund set out a framework to facilitate the development of a safe
and eective ZIKV vaccine, and its strategic implementation [169, 209]. They proposed a Target
Product Prole (TPP) for vaccination as a response measure for future ZIKV outbreaks [210]. The
TPP recommends vaccinating women of reproductive age and childbearing women to minimize
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the incidence of microcephaly and related neurological disorders in infants. In addition to women
of reproductive age, vaccination of males is also recommended, provided vaccine supply and
resources are available. The TPP describes two scenarios:
• Outbreak Response: A mass vaccination campaign of the target group to prevent ZIKV
infection and associated complications for an ongoing epidemic or an imminent outbreak.
• Routine/Endemic use: A routine immunization program for the general population.
The TPP is more oriented towards addressing the rst scenario.
Since the development of the TPP, there are a number of vaccine candidates being investigated
using a variety of vaccine platforms [211], including puried inactivated, live attenuated, viral-
vectored, virus-like particles, recombinant subunit, DNA, self-replicating RNA, and mRNA [211,
212]. Experience with the development of other avivirus vaccines suggests that generating a
preventive Zika vaccine should be feasible [213, 214]. Indeed, several vaccine candidates have
now advanced to clinical trials and shown to be safe and well-tolerated in generating humoral
immune responses [215, 216]. However, the economic impact of a vaccine candidate will be a
major factor in decisions regarding implementation and strategic use of vaccines in immunization
programs. We sought to investigate the cost-eectiveness of a potential Zika vaccine candidate in
18 aected countries in the Americas, where the estimated attack rates (i.e., the proportion of the
population infected) during the 2015-2017 outbreaks exceeded 2% [52, 217]. We considered the
World Health Organization’s recommendation of vaccine prioritization of women of reproductive
age including pregnant women, and assessed the vaccination’s impact on prenatal ZIKV infection
and microcephaly as well as other severe brain anomalies [210].
6.2 Model Details and Parameterization
The basic agent structure from Chapter 5 was expanded to account for vaccination dynamics,
pregnancy, and microcephaly disease outcomes (Algorithm 5). We briey describe the model again.
For infection dynamics, human population remained stratied into susceptible, exposed and incu-
bating, infectious (i.e., symptomatic and asymptomatic), and recovered compartments. Similarly,
mosquito population remained divided into susceptible, exposed and incubating, and infectious
groups. The model simulated disease spread via two main modes of transmission, including vector
bites and sexual interactions. Human to mosquito transmission (or vice versa) occurred as a result
of rejection sampling-based (Bernoulli) trials, where the chance of successful transmission is given
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Algorithm 5: The extended human agent from algorithm 3 with elds relevant to
vaccination and pregnancy dynamics.
1 human agent structure {
2 basic variables {
3 ID ; // ID of the human
4 health ; // infection stage of human
5 gender
6 };
7 model specic variables {
8 partner ; // monogamous partner of human
9 sexfrequency ; // total frequency of sex
10 sexprobability ; // probability of weekly sex
11 cumulativesex
12 ispregnant ; // is agent pregnant?
13 timeinpregnancy ; // total time in pregnancy
14 isvaccinated ; // is agent vaccinated?
15 protectionlvl ; // efficacy of vaccine
16 };
17 };
by P [M→ H] = P [H→ M] = 1− (1− βvec)N where βvec is the calibrated baseline probability
of transmission for symptomatic cases and N is the number of bites of a single mosquito to an
infectious individual. The number of bites for each mosquito was individually sampled from a
Poisson distribution with the half-life of the mosquito as the mean of the distribution. The bites
over the lifespan of a mosquito were also implemented as a Poisson process with an average of
one bite every two days, and a maximum of 1 bite per day. Sexual transmission of ZIKV was im-
plemented for individuals older than 15 years of age and in a monogamous context. The frequency
of sexual encounters for partnered individuals was sampled from age-dependent distributions.
Upon successful ZIKV transmission, susceptible individuals entered an intrinsic incubation period
(IIP), sampled for each individual from the associated distribution. After the IIP elapsed, a fraction
(sampled between 40% to 80%) of infected individuals entered asymptomatic infection without
developing clinical symptoms. A schematic diagram of the model for transmission dynamics,
natural history of ZIKV infection, and disease outcomes are provided in Figure 5.1
The model was parameterized with country-specic demographics (i.e., age and sex distributions
and fertility rates). Each simulation was seeded with a single case of Zika in the incubating stage
and run for a time horizon of 1 year (360 days), beginning with a high temperature season. We ran
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2000 Monte Carlo simulations of ZIKV infection dynamics with a scaled-down population of 10 000
individuals and 50 000 mosquitos. Given the short (one-year) simulation timelines, we ignored
the individual births and deaths in the populations, and therefore the population size remained
constant. However, births following pregnancy were considered in the model implicitly for the
eect of microcephaly if Zika infection occurred. Disease and vaccination outcomes were recorded
throughout each simulation and used to calculate ICER values and cost-eectiveness acceptability
probabilities. Only epidemic curves that had at least one secondary case by the end simulations
were considered in cost-eectiveness analysis. Infection and disease transmission parameters
were as described previously in Table 5.1. Vaccination, disease outcomes, and cost-eectiveness
parameters are summarized in Table 6.1 and Table 6.4.
Calibration and Transmissibility
Based on the calibration process in the previous chapter, we initially present cost-eectiveness
results of a ZIKV vaccine in Colombia. This calibration was based on the estimates of the re-
production number of R0 = 2.2 and R0 = 2.8 for Antioquia, Colombia with the mean attack
rate of 8% (95% CI: 4% and 26%) [177, 178]. Given that relative transmissibility of asymptomatic
infection is a key epidemiological parameter, we therefore considered two scenarios with reduction
factors of 0.1 (low) and 0.9 (high) to quantify this relative transmissibility. We also considered
two scenarios with reduction factors of 0.1 and 0.5 for symptomatic transmission to account
for decreased mobility and lower exposure to mosquito bites through full clothing, mosquito
repellents, or possible isolation during symptomatic infection.
Later studies [52, 217] provided ZIKV burden in countries aected by the disease, and estimated
attack rates for these countries. We therefore expanded our cost-eectiveness analysis for 18
countries in the Americas, where the estimated attack rates (i.e., the proportion of the popula-
tion infected) during the 2015-2017 outbreaks exceeded 2%, by calibrating the model to these
estimated attack rates (considering both symptomatic and asymptomatic infections). Here we
assumed the same transmissibility for both asymptomatic and symptomatic infection, with any
transmission reduction in asymptomatic infection accounted for in the calibration process. In the
main simulations, these attack rates were considered as the proportion of the population immune
(i.e., representing the level of herd immunity) at the start of simulations for each country in the
evaluation of vaccination scenarios.
Calibration was performed to determine the transmissibility of the disease corresponding to
country-specic attack rates in the absence of any control measures. We seeded the calibration
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Table 6.1: Zika model parameters values and their associated ranges.
Parameter Description Baseline value (range) Source
Risk of microcephaly
First trimester (97 days) 5% - 14% [159, 208, 218]
Second and third trimester 3% - 5% [159, 208, 218]
Risk of Guillain-Barre Syndrome 0.025% - 0.06% [219]
Life expectancy
Without microcephaly 70 years [220]
With microcephaly 35 years [220]
Probability of survival past rst year
of life for infants with microcephaly
0.798 [221]
Pre-existing level of herd immunity
From previous outbreaks 8% (2.2% - 11%) [52]
Vaccination coverage and ecacy
Non-pregnant women of 15 to 49
years of age
60%
Pregnant women 80% assumed
Other individuals from 9 to 60 years
of age
10%
Preventing infection 60% - 90%
Cost-eectiveness rates
Disability weight for microcephaly 0.16 [147]
Annual discount rate 3% assumed
for an appropriate initial value of the transmissibility, and ran 2000 Monte-Carlo simulations. The
simulations were averaged after a 2-year time horizon to estimate the attack rate. This process was
iterated over a range of transmission values so that estimated attack rates were covered for each
country. We then performed curve tting to the simulated data to determine the transmission
values that correspond to the country-specic attack rates for simulation scenarios. A general
formula of transmission values as a function of attack rates was found using Matlab’s curve tting
toolbox. These attack rates and calibrated transmission values are shown in Table 6.2.
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Table 6.2: Estimated attack rates for the 2015-2017 ZIKV outbreaks [52, 217], and corresponding transmissi-
bility values via model calibration.
Country Attack Rate Estimated Transmissibility
Belize 21% 0.2884
Bolivia 10% 0.2761
Brazil 18% 0.2859
Colombia 12% 0.2792
Costa Rica 2% 0.2476
Ecuador 8% 0.2723
El Salvador 16% 0.2839
French Guiana 18% 0.2859
Guatemala 14% 0.2817
Guyana 15% 0.2829
Honduras 14% 0.2817
Mexico 5% 0.2641
Nicaragua 17% 0.2849
Panama 15% 0.2829
Paraguay 17% 0.2849
Peru 4% 0.2602
Suriname 22% 0.2891
Venezuela 19% 0.2868
6.2.1 Disease Outcomes and Microcephaly
There is evidence that associates the risk of microcephaly in infants to ZIKV infection in all
trimesters of pregnancy, although the risk is signicantly higher in the rst and second trimesters
[208, 218]. Previous studies, considering possible over-reporting, have quantied the risk of
developing microcephaly in both symptomatic and asymptomatic pregnant women [159, 222].
We considered the associated risks in a probabilistic approach to determine the microcephaly
outcome in pregnant women at the time of infection. The risk of microcephaly was highest in the
range 5% to 14% during the rst trimester (which ends at 97 days of pregnancy), and reduced to
3% to 5% during the second and third trimesters [159, 208, 218]. We set a probability of 0.798 for
survival past rst year of life for infants with microcephaly [221]. Infants with microcephaly who
survived their rst year of life were assumed to have signicantly lower life expectancy [220, 221],
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Table 6.3: Age-specic fertility rates per 10,000 women of reproductive age [224].
Country Age Groups
15-19 20-24 25-29 30-34 35-39 40-44 45-49
Belize 69.7 150.9 142 98.5 49.3 16.2 1.3
Bolivia 72.6 146.9 148.6 115 80.9 36.5 8
Brazil 68.4 107.6 90.6 55.8 29.2 10.2 1.9
Colombia 57.7 112.3 96.8 65 37.7 14.7 2.7
Costa Rica 59.1 101.1 87.2 70.3 40.5 10.7 1.3
Ecuador 77.3 139.3 124.6 90.9 55.1 24.4 5.7
El Salvador 66.8 108.1 97.6 70.5 37.2 12.6 1.7
French Guiana 82.6 156.2 182.5 151.3 88.7 33 2.6
Guatemala 84 173.2 159.4 124.2 80.1 32.8 6.4
Guyana 90.1 156.3 118.7 87.2 49.7 13.1 4.7
Honduras 68.4 134.8 113.7 87.3 56.2 28.2 5.3
Mexico 66 126.4 127.5 83 44 9.2 1.8
Nicaragua 92.8 122.5 108.7 76.1 42.8 16.1 4.6
Panama 78.5 149.1 132.2 87.9 38 9.1 0.9
Paraguay 60.2 129.8 130.3 102.9 65.3 26.1 5.1
Peru 68 110 113 104 73 25 3
Suriname 48.1 117 128.6 101.1 59 24.3 1.9
and reduced by 50% from 70 years to 35 years on average [220]. In addition to microcephaly, we
considered the risk of developing GBS in ZIKV-infected individuals [219]. The risk of GBS in adults
was sampled in the range 0.025%–0.06% [219]. We also considered the eect of neurological
and behavioural decits due to microcephaly, leading to an impaired quality of life, quantied
by disability weights provided in the Global Burden of Disease study [223]. The total number of
pregnant women was calculated based on the country-specic fertility rate of population in each
simulation (Table 6.3). Ignoring fatal complications, the number of pregnant women at any point
in time for each simulation was calculated by
number of pregnant women =
(
nWRA
1000
)
(fertility rate× 0.75 + abortion rate× 0.167) (6.1)
where nWRA is the number of women of reproductive age. We used an estimated abortion rate of
12% for WRA [225]. The probability of birth for 9 months was assumed 0.75, and the probability
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of abortion for 2 months was assumed 0.167.
Given the exibility of an ABM, we considered trimesters to implement risk of microcephaly in
the model. At the onset of each simulation, the trimester for each pregnant woman was randomly
selected according to the respective distributions [226]. The beginning of the rst trimester was
set for newly pregnant women during simulations. Microcephaly occurred according to the risk
associated with infection in each trimester, which was implemented at the time of infection.
6.2.2 Vaccination Dynamics
Based on the recommendations outlined in the WHO/UNICEF ZIKV Vaccine Target Product
Prole (TPP) for vaccine prioritization [210], we implemented vaccination in the model for women
between 15 and 49 years of age. The vaccination coverage was set to 60% for this group at the
onset of simulations. For pregnant women in the same age group, the vaccination coverage was
set to 80% throughout the simulations. We also considered a vaccination coverage of 10% for
other individuals in the population between 9 and 60 years of age, in order to reduce the risk
of disease transmission to pregnant women. This implementation strategy corresponds to the
outbreak response strategy in the TPP document [210], prioritizing women of reproductive age
(WRA).
While some ZIKV vaccine candidates have entered clinical trials, there is currently no data available
to indicate the level of vaccine-induced protection and number of vaccine doses required. We
therefore assumed that a single vaccine dose provides a protection ecacy in the range 60% –
90% against infection, which was sampled for each vaccinated individual and implemented as a
reduction factor in disease transmission. We assumed that ZIKV infection following vaccination (if
occurred) was asymptomatic without clinical manifestation and that vaccination has no eect on
the risk of microcephaly in pregnant women if infection occurred. Naturally acquired immunity
was assumed to provide full protection for suciently long period of time, so that the risk of
re-infection within the same epidemic season was eliminated.
6.3 Cost-Eectiveness
We conducted the cost-eectiveness analysis from a government (or a public-payer) perspective
and considered both short- and long-term medical costs specic to each country, summarized in
Table 6.4. Short-term costs included physician visits and diagnostic tests for symptomatic ZIKV
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infection in pregnant women. For microcephaly in infants and GBS in adults, we considered
lifetime direct medical costs related to hospitalization, treatment, and other associated outcomes.
Based on the estimates for other avivirus vaccines, we considered a range of US$2 to US$100
for vaccination costs per individual (VCPI) [228], including vaccine dose, administration, and 3%
wastage.
The health impact of microcephaly and GBS on an individual’s quality of life was captured by
disability-adjusted life years (DALYs) with disability weights extracted from the Global Burden of
Disease [223]. We used disability weights associated with i.e., severe intellectual disability, which
was considered a good proxy for microcephaly, also used in previous work [220]. We understand
that the disability weights may be subject to uncertainty, such uncertainty is not quantied, and
Table 6.4: Direct medical costs, and GDP per capita for aected countries in the Americas. Physician visits
only applied to symptomatic individuals. Data obtained from [227].
Country Cost Categories
Microcephaly GBS Physician Visit GDP per capita
Belize $103,586 $32,709 $61 $4,955
Bolivia $80,974 $25,569 $57 $3,097
Brazil $100,068 $31,599 $57 $8,694
Colombia $78,990 $24,943 $68 $5,900
Costa Rica $124,203 $39,220 $63 $11,563
Ecuador $98,759 $31,185 $60 $6,084
El Salvador $124,203 $39,220 $63 $3,719
French Guiana $91,925 $29,027 $65 $18,036
Guatemala $91,173 $28,790 $59 $4,032
Guyana $98,974 $31,253 $57 $4,325
Honduras $88,351 $27,899 $57 $2,358
Mexico $93,867 $29,640 $67 $8,867
Nicaragua $72,383 $22,856 $56 $2,109
Panama $107,620 $33,983 $63 $14,009
Paraguay $81,542 $25,749 $58 $4,094
Peru $88,850 $28,056 $61 $6,042
Suriname $95,294 $30,091 $63 $7,298
Venezuela $120,582 $38,076 $69 $7,766
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we therefore relied on established values used in previous work. For given vaccination costs
per individual (VCPI), we calculated incremental cost-eectiveness ratios (ICER) averaged over
simulations. Negative ICER values are always considered to be cost-saving since the intervention
provides additional benet over the alternative while costs less than the alternative. For positive
ICER values, we considered the World Health Organization standards of using the per-capita
gross domestic product (GDP) as a threshold of Willingness to Pay (WTP) [81]. The vaccination
program was considered very cost-eective and cost-eective for ICER values up to the per-capita
GDP and 3 times the per capita GDP, respectively. We also considered a range of WTP values to
inform decisions on vaccine cost-eectiveness in settings where the per-capita GDP threshold
may not be applicable. We calculated the average incremental cost-eectiveness ratio (ICER)
and the associated 95% condence interval using a non-parametric bootstrap method of 2000
replicates, and constructed the cost-eectiveness plane and acceptability probabilities to oer a
visual representation of the joint distribution of costs and benets. A discount rate of 3% was
applied to both the costs and DALY calculations to consider preference for present value.
6.4 Results
We considered a plausible range of $2 to $100 for VCPI to account for vaccine dose, administration,
and wastage based on the estimates for other avivirus vaccines [228]. Our results show that for a
suciently low VCPI, a single-dose vaccination program is cost-saving for all countries studied
here. We describe our results below.
6.4.1 Vaccination in Colombia
We rst present the results for Colombia since it is one of the most Zika-aected countries in
the northwest of South America. We considered the scenarios ofR0 = 2.2 andR0 = 2.8, taking
into consideration pre-existing herd immunity in the population. Figure 6.1 and Figure 6.2 show
disease incidence of 2000 independent realizations for a time horizon of one year. Each gure
shows simulation-level incidence (blue curves) with and without vaccination, and in the absence
and presence of herd immunity in the population. Subgures correspond to dierent relative
transmissibility of asymptomatic infection. In the next few sections, we describe the results of the
cost-eectiveness analysis however one may nd a succinct summary of the analysis in Table 6.5
which summarizes simulation outcomes for VCPI in each scenario.
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Disease incidence without vaccination
Disease incidence with vaccination
Figure 6.1: Incidence of infection for 5000 independent realizations without (top) and with (bottom)
vaccination in the absence of herd immunity (A1-A4) and in the presence of 8% herd immunity (B1-B4) in
the population. Simulations were run considering the relative transmissibility of asymptomatic infection
and the reduction of transmission by symptomatic infection to be respectively: 0.1 and 0.1 (A1,B1); 0.1 and
0.5 (A2,B2); 0.9 and 0.1 (A3,B3); 0.9 and 0.5 (A4,B4). Figure corresponds to model scenario calibrated to basic
reproduction numberR0 = 2.2.
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Disease incidence without vaccination
Disease incidence with vaccination
Figure 6.2: Incidence of infection for 5000 independent realizations without (top) and with (bottom)
vaccination in the absence of herd immunity (A1-A4) and in the presence of 8% herd immunity (B1-B4) in
the population. Simulations were run considering the relative transmissibility of asymptomatic infection
and the reduction of transmission by symptomatic infection to be respectively: 0.1 and 0.1 (A1,B1); 0.1 and
0.5 (A2,B2); 0.9 and 0.1 (A3,B3); 0.9 and 0.5 (A4,B4). Figure corresponds to model scenario calibrated to basic
reproduction numberR0 = 2.8.
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Figure 6.3: Boxplots for ICER values obtained using bootstrap method for a range of VCPI. Subplots
correspond to the scenarios without pre-existing immunity (A,B), and with an average of 8% pre-existing
immunity (C,D) in the population. The relative transmissibility of asymptomatic infection was set to 10%
(A,C) and 90% (B,D). Solid (grey) line represents the willingness-to-pay threshold corresponding to the
average of per capita GDP of Colombia between 2013 and 2017. Figure corresponds to model scenario
calibrated to basic reproduction numberR0 = 2.2.
Vaccine cost-eectiveness Estimated ICER values (corresponding to R0 = 2.2) are shown
in Figure 6.3. In this gure, boxplots of calculated ICER values and their associated condence
intervals obtained using the non-parametric bootstrap method are shown for a range of VCPI. The
grey line corresponds to Colombia’s GDP of $6610 per DALY averted, corresponding to the average
per-capita GDP of Colombia between 2013 and 2017, which was considered as the threshold value
for cost-eectiveness. Subplots correspond to the scenarios of no pre-existing immunity and with
an average of 8% pre-existing immunity in the population. In a fully susceptible population, with
a 10% relative transmissibility of asymptomatic infection (i.e. Figure 6.3A), the ICER values and
their associated ranges remained negative for 100% of simulation results when VCPI is $6 or less,
thus suggesting that the vaccine is cost-saving regardless of the thresholds of WTP. For VCPI
with positive ICER values, the vaccine is very cost-eective with a probability of at least 90%
if VCPI is $10 or less. Increasing the threshold to $19832 (three times the average GDP) [228],
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Figure 6.4: Probabilities of vaccine being cost-eective for a range of VCPI and willingness-to-pay. Subplots
correspond to the scenarios without pre-existing immunity (A,B), and with an average of 8% pre-existing
immunity (C,D) in the population. The relative transmissibility of asymptomatic infection was set to 10%
(A,C) and 90% (B,D). Solid line represents the willingness-to-pay threshold corresponding to the average of
per capita GDP of Colombia between 2013 and 2017. Dashed line represents three times the average of per
capita GDP of Colombia. The red curve represents the 90% probability of vaccine being cost-eective for a
given VCPI. Figure corresponds to model scenario calibrated to basic reproduction numberR0 = 2.2.
our results suggest that vaccination is still cost-eective for VCPI up to $16. The probability of
cost-eectiveness is sensitive to VCPI and decreases sharply from 90% to below 10% with marginal
increase in the VCPI (Figure 6.4). When the transmissibility of asymptomatic infection is relatively
high, i.e., 90% (Figure 6.3B), then vaccination is cost-saving for VCPI up to $12, as suggested
by negative ICER values. For positive ICER values, vaccination is very cost-eective if VCPI is
$16 or less. For three times the GDP threshold of willingness-to-pay, vaccination is still cost-
eective for VCPI up to $29. We also investigated the presence of pre-existing herd immunity as a
result of previous outbreaks. We used estimates of 8% (95% CI: 4% – 26%) attack rate to account
for herd immunity in the population [52]. When the relative transmissibility of asymptomatic
infection was low (10%), the ICER values and their associated ranges are negative for VCPI up to
$4 (Figure 6.3C). In the presence of herd immunity, for positive ICER values, vaccination remains
very cost-eective (with a probability of at least 90%) at the $6610 threshold of WTP per DALY
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Figure 6.5: Boxplots for ICER values obtained using bootstrap method for a range of VCPI. Subplots
correspond to the scenarios without pre-existing immunity (A,B), and with an average of 8% pre-existing
immunity (C,D) in the population. The relative transmissibility of asymptomatic infection was set to 10%
(A,C) and 90% (B,D). Solid (grey) line represents the willingness-to-pay threshold corresponding to the
average of per capita GDP of Colombia between 2013 and 2017. Figure corresponds to model scenario
calibrated to basic reproduction numberR0 = 2.8.
averted if VCPI does not exceed $7. At the threshold of three times the average GDP, vaccination is
still cost-eective for VCPI up to $13. With the same level of herd immunity (i.e., 8%), but a higher
relative transmissibility of asymptomatic infection (90%) (Figure 6.3D), vaccination is cost-saving
(with negative ICER values) for VCPI up to $6. When ICER values are positive, vaccination is very
cost-eective if VCPI is $8 or less, and cost-eective if VCPI is $14. In Figure 6.4, the associated
probabilities of vaccine being cost-eective for a range of VCPI and WTP values forR0 = 2.2 are
presented for all scenarios. In this gure, the red curve represents the 90% probability of vaccine
being very cost-eective for a given VCPI. Solid line represents the WTP threshold corresponding
to the average of per capita GDP of Colombia. Dashed line represents three times the average of
per capita GDP of Colombia. Subplots correspond to the scenarios with and without pre-existing
immunity and with reductions of 10% and 90% relative transmissibility of asymptomatic infection.
We also evaluated the vaccine cost-eectiveness scenarios in a population setting with a higher
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Figure 6.6: Probabilities of vaccine being cost-eective for a range of VCPI and willingness-to-pay, with
R0 = 2.8. Subplots correspond to the scenarios without pre-existing immunity (A,B), and with an average
of 8% pre-existing immunity (C,D) in the population. The relative transmissibility of asymptomatic infection
was set to 10% (A,C) and 90% (B,D). Solid line represents the willingness-to-pay threshold corresponding
to the average of per capita GDP of Colombia between 2013 and 2017. Dashed line represents three times
the average of per capita GDP of Colombia. The red curve represents the 90% probability of vaccine being
cost-eective for a given VCPI. Figure corresponds to model scenario calibrated to basic reproduction
numberR0 = 2.8.
transmissibility of R0 = 2.8. The estimated ICER values and associated condence intervals
shown in Figure 6.5. Compared toR0 = 2.2, Figure 6.5 and Figure 6.6 indicate that vaccination is
very cost-eective for a larger range of VCPI, in particular, when the reduction of transmission
from ZIKV symptomatic infection is relatively low (10% on average). Figure 6.5A and Figure 6.5B
show that in the absence of pre-existing herd immunity the vaccine is cost-saving (as suggested
by negative ICER values) up to a VCPI of $29 when the relative transmissibility of asymptomatic
infection is 10%, and up to $35 when the relative transmissibility of asymptomatic infection is 90%.
Similarly, Figure 6.5C and Figure 6.5D show that in the presence of herd immunity the vaccine is
cost-saving when VCPI is $16 and $20 for low and high relative transmissibility, respectively. For
positive ICER values, vaccination remains very cost-eective (with a probability of at least 90%)
up to VCPI of $38 and $45 in the absence of herd immunity and up to VCPI of $22 and $27 in the
presence of herd immunity, for 10% and 90% relative transmissibility of asymptomatic infection.
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In Figure 6.6, the associated probabilities of vaccine being cost-eective for a range of VCPI and
willingness-to-pay forR0 = 2.8 are presented.
Eect of vaccination on microcephaly We calculated the reduction of fetal microcephaly
during pregnancy by comparing the simulation scenarios in the presence and absence of vaccina-
tion. We used cumulative number of fetal microcephaly cases following ZIKV infection during
pregnancy at the end of each simulation and calculated percentage reduction of microcephaly due
to vaccination using non-parametric bootstrap sampling. The results are presented in Figure 6.7
and Figure 6.8, in which the distribution of the percentage reduction is shown. In all scenarios
investigated for vaccine cost-eectiveness, the median percentage reduction of microcephaly
exceeded 64%, suggesting that a vaccine with protection ecacy as low as 60% could signicantly
reduce the incidence of microcephaly.
6.4.2 Vaccination in the Americas
In addition to Colombia, we applied the model to assess the cost-eectiveness of a potential
ZIKV vaccine in 18 other countries in the Americas. All estimates are based on the attack rates
reported in Table 6.2 as the level of pre-existing herd immunity in the population for each country.
Incidence and attack rates (which serve to validate the model) for dierent countries in the absence
of vaccination are illustrated in Figure 6.9 and Figure 6.10.
Our results show that for a suciently low VCPI, a single-dose vaccination program is cost-
saving for all countries studied here (Figure 6.11, green). In this gure, green curves correspond
to the upper range of VCPI for which the vaccine is cost-saving, i.e. ICER < 0. Similarly, red
and black curves correspond to the upper range of VCPI for which the vaccine is very cost-
eective and cost-eective, respectively. The lowest VCPI was estimated for Costa Rica, where
Table 6.5: Upper range of VCPI (US dollar) for a Zika vaccine candidate to be cost-saving (ICER<0), very
cost-eective (WTP of per capita GDP) or cost-eective (WTP of three times per capita GDP).
0% herd immunity 8% herd immunity
RTA 10% 90% 10% 90%
R0 <$0 $6,610 $19,832 <$0 $6,610 $19,832 <$0 $6,610 $19,832 <$0 $6,610 $19,832
2.2 $6 $10 $16 $12 $16 $29 $4 $7 $13 $6 $8 $14
2.8 $29 $38 $53 $35 $45 $66 $16 $22 $35 $20 $27 $45
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Figure 6.7: Distribution of percentage reduction of microcephaly obtained using bootstrap method. Subplots
correspond to the scenarios without pre-existing immunity (A,B), and with an average of 8% pre-existing
immunity (C,D) in the population. The relative transmissibility of asymptomatic infection was set to 10%
(A,C) and 90% (B,D). The median percentage reduction is (A) 0.739 (IQR: 0.715 – 0.759); (B) 0.723 (IQR: 0.709
– 0.736); (C) 0.687 (IQR: 0.652 – 0.717); (D) 0.711 (IQR: 0.694 – 0.728). Figure corresponds to model scenario
calibrated to basic reproduction numberR0 = 2.2.
the vaccine is cost-saving with a probability of at least 90% for VCPI up to $10, derived from
the cost-eectiveness acceptability curves (Figure 6.12). With the same probability, the highest
VCPI was estimated at $25 for Guatemala and Panama under which the vaccine is cost-saving.
The upper range of VCPI for a cost-saving scenario in other countries is estimated between $14
and $24. For positive ICER values, the vaccine is very cost-eective with a probability of at
least 90% at VCPI of $16 or less in Costa Rica (mean incremental cost of $7352/DALY averted;
95% CI: $1280–$9234) and $47 or less in French Guiana (mean incremental cost of $14475/DALY
averted; 95% CI: $10016–$16653), with other countries having an upper value of VCPI in this
range (Figure 6.11, red). For the threshold of three times the per capita GDP, the vaccine is still
cost-eective (with a probability of at least 90%) with VCPI up to $24 (mean incremental cost
of $4829/DALY averted; 95% CI: $2395–$6068) in Nicaragua and $96 (mean incremental cost of
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Figure 6.8: Distribution of percentage reduction of microcephaly obtained using bootstrap method, with
R0 = 2.8. Subplots correspond to the scenarios without pre-existing immunity (A,B), and with an average
of 8% pre-existing immunity (C,D) in the population. The relative transmissibility of asymptomatic infection
was set to 10% (A,C) and 90% (B,D). The median percentage reduction is (A) 0.699 (IQR: 0.687 – 0.712); (B)
0.695 (IQR: 0.687 – 0.704); (C) 0.666 (IQR: 0.649 – 0.683); (D) 0.670 (IQR: 0.658 – 0.682). Figure corresponds
to model scenario calibrated to basic reproduction numberR0 = 2.8.
$49934/DALY averted; 95% CI: $36523–$53661) in French Guiana, with other countries having an
upper value of VCPI in this range (Figure 6.11, black). The VCPI for scenarios of cost-saving, very
cost-eective, and cost-eective for each country are provided in Table 6.6. The corresponding
incremental cost per DALY averted with 95% condence intervals are reported in Table 6.7. The
associated cost-eectiveness acceptability curves are presented in Figure 6.12. In this gure, the
red curve represents the 90% probability of vaccine being cost-eective for a given VCPI. Solid
line represents the willingness-to-pay threshold corresponding to the average of per capita GDP
of each country between 2015 and 2017. Dashed line represents three times this average of per
capita GDP.
We also calculated the reduction of fetal microcephaly during pregnancy by comparing the
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Figure 6.9: Incidence of ZIKV infection for each country with estimated attack rates for two years in the
absence of vaccination (corresponding to the main scenario). The black curve shows the average of 2000
realizations.
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Figure 6.10: Attack rates (average of 2000 realizations) of ZIKV outbreaks for two years in the absence of
vaccination (corresponding to the main scenario).
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Figure 6.11: Upper range of VCPI (US dollar) for the scenarios of cost-saving (green), very cost-eective
(red), and cost-eective (black). All estimates are based on the level of pre-existing herd immunity in the
population for each country.
simulation scenarios in the presence and absence of vaccination. We found a marked reduction
in cases of microcephaly within the range of 74%–92% due to vaccination, with the median
percentage reduction exceeding 80% in all countries (Figure 6.13). This suggests that a ZIKV
vaccine with a prophylactic ecacy as low as 60% could signicantly reduce the incidence of
microcephaly.
Given that the attack rates in future outbreaks may be dierent from those estimated for the
2015–2017 outbreaks, we further conducted cost-eectiveness analysis for two additional scenarios
(Table 6.8). As such, we conducted cost-eectiveness analysis for two additional scenarios. In the
rst scenario, we calibrated the model to an increase of 4% to the estimated attack rate for each
country. In the second scenario, the model was calibrated to a 4% decrease in the estimated attack
rates, with a lower bound of 1%, for each country. The levels of pre-existing herd immunity at the
onset of simulations remained the same as those in Table 6.2. In the scenario with increased attack
rates, we found that vaccination is very cost-eective with a probability of at least 90% at VCPI of
$20 or less in Nicaragua (mean incremental cost of $1067/DALY averted) and $50 or less in French
Guiana (mean incremental cost of $14914/DALY averted). The upper VCPI for other countries
119
Guyana
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Honduras
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Mexico
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
0
0.2
0.4
0.6
0.8
1
Nicaragua
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Panama
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Paraguay
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
0
0.2
0.4
0.6
0.8
1
Peru
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Suriname
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Venezuela
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
0
0.2
0.4
0.6
0.8
1
Belize
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Bolivia
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Brazil
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
0
0.2
0.4
0.6
0.8
1
Colombia
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Costa Rica
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
Ecuador
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
0
0.2
0.4
0.6
0.8
1
El Salvador
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
French Guiana
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
40
50
Guatemala
2 5 10 20 30 40 50 60 70 80 90 100
1
5
10
20
30
0
0.2
0.4
0.6
0.8
1
vaccination costs per individual (VCPI)
wi
llin
gn
es
s t
o 
pa
y (
   
10
00
 U
S$
)
×
pr
ob
ab
ilit
y o
f v
ac
cin
e 
be
ing
 co
st-
ef
fe
cti
ve
Figure 6.12: Probabilities of vaccine being cost-eective in 18 Latin American countries for a range of VCPI
and willingness-to-pay. Solid line represents the willingness-to-pay threshold corresponding to the average
of per capita GDP of each country in 2015 and 2016. Dashed line represents three times the average of per
capita GDP of each country. The red curve represents the 90% probability of vaccine being cost-eective
for a given VCPI
ranged between these values (Figure 6.14). Similarly, using three times the per-capita GDP, the
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Table 6.6: Upper range of VCPI (US dollar) for a Zika vaccine candidate to be cost-saving (ICER<0), very
cost-eective (threshold of the per capita GDP) or cost-eective (threshold of 3× the per capita GDP).
Cost Saving Very Cost-Eective Cost-Eective
Country Herd immunity VCPI GDP VCPI 3×GDP VCPI
Belize 21% $18 $4955 $23 $14865 $34
Bolivia 10% $22 $3097 $27 $9291 $36
Brazil 18% $14 $8694 $21 $26082 $38
Colombia 12% $16 $5900 $23 $17700 $35
Costa Rica 2% $10 $11563 $16 $34689 $29
Ecuador 8% $24 $6084 $32 $18252 $48
El Salvador 16% $22 $3719 $26 $11157 $34
French Guiana 18% $23 $18036 $47 $54108 $96
Guatemala 14% $25 $4032 $32 $12096 $45
Guyana 15% $18 $4325 $23 $12975 $33
Honduras 14% $21 $2358 $23 $7074 $29
Mexico 5% $17 $8867 $26 $26601 $44
Nicaragua 17% $16 $2109 $18 $6327 $24
Panama 15% $25 $14009 $43 $42027 $82
Paraguay 17% $19 $4094 $23 $12282 $32
Peru 4% $16 $6042 $22 $18126 $35
Suriname 22% $14 $7298 $21 $21894 $37
Venezuela 19% $21 $7766 $29 $23298 $47
vaccine is still cost-eective for a VCPI up to $26 in Nicaragua and up to $98 in French Guiana
(Figure 6.14). In the scenario with decreased attack rates, the results show that vaccination was
very cost-eective with a VCPI of $4 or less in Mexico (mean incremental cost of $3054/DALY
averted) and $41 or less in French Guiana (mean incremental cost of $15037/DALY averted), with
other countries having an upper VCPI value in this range (Figure 6.15). The median percentage
reduction of microcephaly in these scenarios exceeded 75% with vaccination (Technical Appendix,
Figure A8). Summaries of the cost-eectiveness analysis for both scenarios of higher and lower
attack rates are provided in Table 6.9.
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Table 6.7: Mean ICER values with 95% condence intervals corresponding to VCPI values under which
vaccination program is at least 90% cost-eective in each country. The per capita GDP and three times the
per capita GDP were used as thresholds for very cost-eective and cost-eective analysis, respectively.
The dollar values in ‘()’ indicates that the 95% CI extends to negative ICER values, which is considered
cost-saving.
Very cost-eective Cost-eective
Country VCPI ICER 95% CI VCPI ICER 95% CI
Belize $23 $3,516 $144–$4,575 $34 $12,092 $7,379–$15,050
Bolivia $27 $1,827 $(872)–$2,669 $36 $7,038 $4,249–$9,745
Brazil $21 $6,356 $1,596–$7,223 $38 $21,725 $14,938–$27,441
Colombia $23 $4,184 $1,284–$5,349 $35 $14,086 $9,447–$16,736
Costa Rica $16 $7,352 $1,280–$9,234 $29 $29,061 $15,459–$30,561
Ecuador $32 $4,451 $1,343–$5,560 $48 $15,581 $10,338–$17,576
El Salvador $26 $1,379 $(1,884)–$2,826 $34 $8,177 $3,408–$9,785
French Guiana $47 $14,475 $10,016–$16,653 $96 $49,934 $36,523–$53,661
Guatemala $32 $2,544 $148–$3,944 $45 $9,786 $6,556–$11,859
Guyana $23 $2,270 $(285)–$3,717 $33 $10,034 $5,884–$12,262
Honduras $23 $892 $(1,711)–$1,705 $29 $4,992 $1,623–$6,142
Mexico $26 $6,362 $2,564–$7,445 $44 $21,652 $14,717–$24,875
Nicaragua $18 $595 $(1,465)–$1,231 $24 $4,829 $2,395–$6,068
Panama $43 $11,001 $7,016–$13,486 $82 $37,247 $29,096–$43,898
Paraguay $23 $2,348 $(305)–$3,332 $32 $9,903 $5,028–$10,670
Peru $22 $4,332 $1,087–$4,870 $35 $14,028 $9,262–$16,432
Suriname $21 $4,434 $1,505–$6,235 $37 $18,705 $12,714–$22,331
Venezuela $29 $4,697 $623–$6,590 $47 $19,170 $13,160–$23,579
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Figure 6.13: Boxplots for percentage reduction of microcephaly due to vaccination. The median is shown
by the red circle.
Table 6.8: Attack rates for additional simulation scenarios. Attack rates were increased and decreased by
4%, with a lower bound of 1%. The model was calibrated to country-specic attack rate.
Main Scenario Additional Scenarios
Country Attack rate (AR) AR+ 4% AR− 4%
Belize 21% 25% 17%
Bolivia 10% 14% 6%
Brazil 18% 22% 14%
Colombia 12% 16% 8%
Costa Rica 2% 6% 1%
Ecuador 8% 12% 4%
El Salvador 16% 20% 12%
French Guiana 18% 22% 14%
Guatemala 14% 18% 10%
Guyana 15% 19% 11%
Honduras 14% 18% 10%
Mexico 5% 9% 1%
Nicaragua 17% 21% 13%
Panama 15% 19% 11%
Paraguay 17% 21% 13%
Peru 4% 8% 1%
Suriname 22% 26% 18%
Venezuela 19% 23% 15%
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Figure 6.14: Upper range of VCPI (US dollar) for the scenarios of cost-saving (green), very cost-eective
(red), and cost-eective (black). Estimates correspond to simulations calibrated to an increase of 4% in
estimated attack rates for the 2015-2017 outbreaks.
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Figure 6.15: Upper range of VCPI (US dollar) for the scenarios of cost-saving (green), very cost-eective
(red), and cost-eective (black). Estimates correspond to simulations calibrated to an decrease of 4% in
estimated attack rates for the 2015-2017 outbreaks.
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Table 6.9: Mean ICER values with 95% condence intervals corresponding to VCPI values under which
vaccination program is at least 90% cost-eective in each country. The per capita GDP were used as
thresholds for cost-eective analysis. The dollar values in ‘()’ indicates that the 95% CI extends to negative
ICER values, which is considered cost-saving.
Simulations calibrated to an increase of 4% in estimated attack rates.
Very cost-eective Cost-eective
Country VCPI ICER 95% CI VCPI ICER 95% CI
Belize $24 $2689 $(1194)–$3773 $34 $10892 $6136–$14590
Bolivia $30 $1189 $(1334)–$2164 $40 $6920 $4089–$8997
Brazil $27 $6589 $2553–$7720 $45 $21841 $15274–$26353
Colombia $26 $4181 $1458–$5539 $38 $13721 $9371–$16483
Costa Rica $40 $9072 $4951–$12098 $70 $30013 $22287–$33976
Ecuador $39 $3618 $973–$5276 $58 $15088 $10878–$18087
El Salvador $25 $1098 $(2753)–$2733 $34 $7545 $2781–$10230
French Guiana $50 $14914 $10328–$18865 $98 $49466 $34961–$53192
Guatemala $36 $2197 $(200)–$3521 $51 $10076 $6620–$11936
Guyana $27 $2691 $(250)–$4032 $37 $9665 $5907–$11632
Honduras $30 $1078 $(1445)–$1723 $38 $5439 $2953–$6806
Mexico $43 $7099 $4304–$8866 $70 $23159 $18270–$27829
Nicaragua $20 $1067 $(757)–$1789 $26 $5069 $2673–$6063
Panama $48 $10427 $6843–$13151 $88 $34894 $27744–$42041
Paraguay $25 $2662 $5–$3705 $35 $9702 $5960–$11045
Peru $39 $4398 $1577–$5465 $60 $15565 $11540–$17911
Suriname $21 $4820 $798–$6335 $35 $17716 $11223 –$21123
Venezuela $34 $4820 $1944–$7838 $51 $19982 $11823–$21092
Simulations calibrated to an increase of 4% in estimated attack rates.
Very cost-eective Cost-eective
Country VCPI ICER 95% CI VCPI ICER 95% CI
Belize $21 $2344 $(812)–$3581 $32 $12128 $7102–$14, 544
Bolivia $16 $909 $(1459)–$2077 $23 $7207 $3196–$8, 751
Brazil $21 $6720 $2642–$8089 $36 $20704 $14484–$24808
Colombia $16 $3465 $266–$4008 $27 $14476 $9076–$17082
Costa Rica $9 $6661 $(741)–$8037 $18 $25476 $12133–$38507
Ecuador $19 $4241 $688–$5265 $29 $13608 $8413–$16282
El Salvador $20 $1183 $(1846)–$2852 $27 $8404 $3222–$9843
French Guiana $41 $15037 $10339–$17905 $84 $48232 $37689–$57894
Guatemala $25 $2445 $(447)–$3601 $35 $9639 $5399–$11411
Guyana $17 $2130 $(1099)–$3429 $25 $10149 $5292–$13610
Honduras $16 $946 $(1896)–$1676 $21 $5276 $1658–$7219
Mexico $4 $3054 $(5722)–$2798 $9 $19550 $3620–$23927
Nicaragua $14 $802 $(1638)–$1335 $19 $4798 $2246–$6295
Panama $29 $11311 $5967–$13785 $54 $34281 $24242–$41282
Paraguay $19 $2627 $(29)–$3344 $27 $8492 $5258–$10724
Peru $6 $2594 $(2114)–$2779 $11 $13487 $3063–$17903
Suriname $18 $5057 $1164–$6269 $30 $16836 $10634–$20560
Venezuela $23 $4915 $808–$6501 $39 $19481 $12735–$23902
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Figure 6.16: Boxplots for the percentage reduction of microcephaly due to vaccination for scenarios: (A)
an increase of 4%; and (B) a decrease of 4% to estimated attack rates for the 2015–2017 outbreaks. The
median is shown by the red circle.
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6.5 Discussion
In this chapter, we evaluated the cost-eectiveness of a Zika vaccine candidate from a government
perspective under a number of plausible scenarios. We utilized the comprehensive ABM developed
in Chapter 5 by extending it to include vaccination dynamics. Our analysis considered: (i) in a
Colombian population setting where the model was calibrated to estimated basic reproduction
numberR0 of Colombia, taking into account existing herd-immunity from previous outbreaks
and relative transmission of asymptomatic infection, and (ii) 17 other countries in the Americas
where the model was calibrated to attack rates estimated for the 2015-2017 outbreaks. Our analysis
determined a range of VCPI within which vaccination is cost-saving, very cost-eective, and
cost-eective for these countries. Although a number of factors (e.g., the level of pre-existing herd
immunity, attack rate, costs associated with the management of Zika infection and its outcomes,
and the WTP) are critical in determining VCPI for cost-eectiveness, our results show that targeted
vaccination of women of reproductive age would be cost-eective, and even cost-saving, in all
countries studied here if VCPI is suciently low. Furthermore, vaccination with a protection
ecacy in the range 60% – 90% signicantly reduces the incidence of microcephaly, with a median
percentage reduction that exceeds 75% in simulated scenarios.
Cost-eectiveness analysis was based on using direct medical cost estimates associated with
the treatment of symptomatic Zika infection, GBS cases, and long-term neurological sequelae
caused by microcephaly condition. Although the likelihood of cost-eectiveness was shown
to be sensitive to willingness-to-pay and vaccination costs, the largest range of VCPI for cost-
eectiveness corresponded to scenarios in which the population is fully susceptible or the eect
of other interventions to blunt ZIKV transmission is relatively low. However, non-pharmaceutical
measures (including vector control programs), increased access to contraception [229], and pre-
existing herd eects as a result of naturally acquired immunity in previous outbreaks could decrease
the range of VCPI for cost-eectiveness, requiring a signicantly higher willingness-to-pay for
vaccination to prove cost-eective. Previous work suggests that a prophylactic vaccine with a
protection ecacy of 75% reduces the incidence of prenatal infections by at least 94% if 90% of
women of reproductive age are vaccinated [224] These estimates are higher than what our model
predicts (with a median percentage reduction between 75% and 88%) in similar scenarios, which is
expected given the deterministic nature of model used in the previous study [224]. Nevertheless,
the ndings indicate that targeted vaccination is an important preventive measure for mitigating
the impact of ZIKV infection in future outbreaks.
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The strength of our study relies on the evaluation of cost-eectiveness for countries aected by
Zika with estimated attack rates exceeding 2% within a single modelling framework. Our analysis
was based on an individual-level stochastic approach, accounting for parameter uncertainty and
heterogeneities in disease transmission. Due to its dynamic nature, the simulation model also
takes into account the accruing herd immunity during the epidemic that results from the indirect
protection eects of naturally acquired immunity in the population.
The results presented in this chapter should be considered within the context of study limitations.
First, we note that our analysis was based on estimates of attack rates during the 2015-2017 ZIKV
outbreaks in the Latin and South American countries [52, 217, 227], which were regarded as the
level of pre-existing herd immunity in the simulations. Should this level fall at the time of vaccine
availability in future outbreaks, the expected changes in the VCPI range for cost-eectiveness
require further analysis. Second, although the initial phase of clinical trials indicates high levels
of neutralizing antibodies [215, 216], the range of vaccine ecacy is not ascertained, and our
estimates relied on the assumption that a single dose of vaccine would provide a protection
ecacy of 60% to 90%. The ecacy data can also provide information on the number of vaccine
doses required, which would aect the vaccination costs per individual. We also assumed that
the risk of microcephaly is independent of vaccine-induced immunity in a vaccinated pregnant
woman if infection occurred. In the absence of pre-existing immunity, clinical and epidemiological
studies indicate that a signicant portion (up to 80%) of ZIKV-infected individuals experience
asymptomatic infection without presenting clinical symptoms. We assumed that vaccine-induced
immunity further reduces the chance of clinical manifestation (if infection occurred), and therefore
considered infection following vaccination to be asymptomatic.
We assumed that during the epidemic, pregnant women are vaccinated (with a coverage of
80%) early in their rst trimester that is associated with the highest risk of microcephaly. Yet,
we understand that due to various factors, including access to healthcare resources and late
recognition of pregnancy, vaccination may not occur prior to any potential ZIKV infection during
pregnancy. The risk of microcephaly following vaccination was not altered if infection occurred
but the disease was considered to be asymptomatic. However, in terms of costs associated with
microcephaly (which dominate), we expect the results of cost-eectiveness analysis to hold because
we did not alter the risk of microcephaly in the presence of vaccine-induced immunity in pregnant
women. Without the outcomes of clinical trials, our model did not consider the possible adverse
side eects of vaccination and their associated costs. Although, other neurological disorders have
been reported in association with ZIKV infection (including encephalitis, meningoencephalitis,
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myelitis, and optical neuritis), we considered only microcephaly and GBS outcomes. Finally, in
the context of cost-eectiveness analysis from a government perspective, our analysis excluded
indirect costs such as loss of productivity and earnings in families inicted by microcephaly
and GBS, yet we understand that the lifetime indirect costs related to the care of children with
microcephaly could be substantial. The validation of the above assumptions requires ecacy data
from clinical trials, which are currently lacking.
Despite these limitations that merit further investigation as relevant information and data become
available, we have provided estimates for Zika vaccine cost-eectiveness to inform decision makers
for the implementation of a targeted vaccination program. The ndings suggest that a vaccine has
the potential to signicantly reduce the health and economic burden of ZIKV infection in at-risk
populations.
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Chapter 7
Closing Remarks and Future Directions
Cost-eective analysis, as part of health economics, is widely used in many settings across the
world to evaluate the potential impact of healthcare interventions and technologies, often in the
face of budget constraints, scarce resources, and even ethical considerations. Traditional economic
evaluations often utilize clinical trials and observational studies which are inadequate in many
aspects to support decision-making processes, largely because of limited follow-up time-horizon
and small sample sizes. In order to address these limitations for the long-term consequences of
health intervention strategies, mathematical and computational models are needed to extrapolate
results to a larger scale and a longer timeframe. The choice on the type of model, including
explicit and implicit assumptions on system dynamics and parameters, depends on the context
of the intervention or technology [230]. Incorrect assumptions or an inappropriate choice of
model can lead to suboptimal decisions at best, with potential negative consequences in the
quality of life or wasted resources. We found that most economic evaluations are conducted using
aggregate frameworks such as state-transition (Markov) models or compartmental models with
dierential equations [231]. While these approaches span a vast literature, they often impose
restrictive limitations such as homogeneous populations and linear interactions, which hinders
their application to communicable disease dynamics. Moreover, aggregate models often adopt
assumptions that are inaccurate or inadequate to faithfully represent the underlying system
dynamics and may generate spurious results.
In this thesis, we described a more comprehensive modelling framework in which traditional cost-
eectiveness analysis is integrated with an ABM computational system to overcome the limitations
of other methodologies. ABM can adopt less stringent assumptions and have a “bottom-up”
approach in which system dynamics are generated as a result of modelling at the individual level.
For example, ABM can capture indirect eects such as herd immunity without explicitly having to
model them. This is an important characteristic that is overlooked in many Markov models with
cohort structure for evaluating vaccination eects. As a result, the data-generating process of an
ABM captures non-linear interactions among agents and feedback loops. In our framework, we
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integrate this data-generating process into cost-eectiveness analysis, thus avoiding the inherent
diculties of traditional methods, such as censored data and homogeneity.
In order to test the robustness of our framework, we considered two case studies: (i) a human-to-
human infection transmission (i.e., Haemophilus infuenzae) model and (ii) a vector-borne disease
(i.e., Zika) model. In each case, we developed a disease-specic agent-based model to determine
how a potential vaccine candidate may aect the epidemic dynamics, but also present their rst
cost-eectiveness analysis and implications for vaccination strategies in dierent population
settings. For a routine vaccination against Haemophilus infuenzae serotype ‘a’, our analysis
suggests a signicant reduction in costs by the tenth year of the vaccination program, with
signicant decreases across all cost categories, including immediate hospitalization and long-term
disability. The total costs of the immunization program are signicantly lower than the costs
required to provide life-time care of severely debilitated survivors of invasive Hia disease. Similarly,
for a potential vaccination against Zika virus, our analysis shows that targeted vaccination of
women of reproductive age would be cost-eective (and even cost-saving) for suciently low
vaccine costs per individual in many countries in the Americas aected by previous Zika outbreaks.
We also found that a Zika vaccine can provide substantial benets by reducing the incidence of
microcephaly, which leads to life-long sequelae with reduced quality of life.
Given the results of our case studies, we believe this framework advances the research eorts in
understating the mechanisms of disease processes and evaluating the potential impact of health
intervention strategies in a more systematic manner, and with a higher level of realism and
exibility. Our results show that the empirical reliability generated by our model can be far more
informative than traditional aggregate models. As part of further studies in near-term research
eorts, this framework can be extended to include a number of other important investigations in
health economics of interventions or technologies, such as:
• Cost-benet analysis, which examines both costs and consequences in monetary terms.
• Cost-utility analysis, which examines costs and a single consequence in the form of a
health-related quality of life measure.
• Cost-minimization analysis, which examines the least costly consequence among alternatives
with equivalent consequences.
• Cost-consequence analysis, which examines the costs and multiple consequences in their
natural units without aggregation into a single consequence.
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• Input cost analysis, which examines the costs of all alternatives but not their consequences.
• Cost-related outcome analysis, which examines the consequences of all alternatives in
monetary terms but not the input costs incurred.
Despite the growing application of ABM in various elds of research beyond health economics,
a number of limitations exists that need to be addressed in future work. For example, while the
computational aspects of ABM have been detailed in existing literature, the underlying theoretical
basis has rarely been used in its construction. As a consequence, the advantage of ABM to capture
realistic features of real-world phenomena is undermined by the lack of dynamical systems tools
for their analysis. In §2.4, we introduced a brief mathematical formalism in terms of recursive
functions, but little is gained in terms of analytical power without methods like bifurcation and
stability analyses that are well-established for investigating dierential equation-based models.
Recently, however, it has been established that the basic mathematical nature of many agent-based
models can be derived from a sequential dynamical system. This characterization makes ABM
amenable to powerful symbolic analysis, in which the language and tools of mathematical theory
are used to examine the system. Although it is beyond the scope of this thesis, the theory of
sequential dynamical systems and their application to ABM will be a subject of future studies
within the framework proposed here.
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